Psychological, perinatal, lifestyle and health-economic aspects of the polycystic ovary syndrome : what really matters for the patient, her family and the society by De Frène, Veerle
   
Psychological, perinatal, lifestyle and health-economic aspects of the 
polycystic ovary syndrome 
What really matters for the patient, her family and the society 
  
The picture on the cover is drawn by my best friend, Griet Huysentruyt. 
The polycystic ovary syndrome is often compared with a chameleon; an animal that 
changes color according to different circumstances. Similarly, the “color” of the 
polycystic ovary syndrome differs from person to person and changes over time. 
The tail of the chameleon on the picture symbolizes the polycystic ovarian morphology. 
 
 
 
 
 
 
 
 
 
 
 
This dissertation received an educational grant from Merck Serono from November 2006 till October 
2008, and was financially supported for operating costs by the Artevelde University College Ghent 
from January 2007 till December 2008. The author of this dissertation was holder of a Special PhD 
Fellowship by the Flemish Foundation for Scientific Research from September 2013 till August 2014. 
 
University Press, Leegstraat 15, 9060 Zelzate, Belgium 
info@universitypress.be – www.universitypress.be 
 
 
 
 
© Veerle De Frène, Ghent 2015 
All rights reserved. No parts of this book may be reproduced or transmitted in any form or by any 
means, electronic, mechanical, photocopying, recording or otherwise, without the prior written 
permission of the author. 
   
 
 
 
 
 
 
Psychological, perinatal, lifestyle and health-economic aspects of the 
polycystic ovary syndrome 
What really matters for the patient, her family and the society 
 
 
 
 
Dissertation submitted by Veerle De Frène to obtain the degree of “Doctor in Medical Sciences” at 
the Ghent University 
 
 
 
 
 
 
  
Promotor 
Professor dr. Petra De Sutter 
 
Co-promotor 
Professor dr. Lieven Annemans 
 
Guidance committee 
Professor dr. Ann Buysse 
Professor dr. Jan Gerris 
Professor dr. Guy T‘Sjoen 
 
Reading and examination committee 
Prof. dr. Dirk De Bacquer (president) 
dr. Annick Bogaerts 
Prof. dr. Liesbet Goubert 
Prof. dr. Cornelis B. Lambalk 
Prof. dr. Kristien Roelens 
Prof. dr. Johannes Ruige 
  
   
Table of contents 
 
List of abbreviations ............................................................................................................................7 
 INTRODUCTION ...............................................................................................................9 
1.1 Definition and prevalence .................................................................................................. 11 
1.2 Pathogenesis and pathophysiology .................................................................................... 12 
1.3 Symptomatology ............................................................................................................... 15 
1.4 PCOS and obesity............................................................................................................... 20 
1.5 PCOS and psychological wellbeing ..................................................................................... 22 
1.6 Treatment of anovulatory subfertility in PCOS ................................................................... 26 
1.7 PCOS and pregnancy, delivery and neonatal outcome ....................................................... 33 
1.8 Aim of this dissertation and methodology.......................................................................... 35 
 SEXUAL AND RELATIONAL SATISFACTION IN COUPLES WHERE THE WOMAN HAS 
POLYCYSTIC OVARY SYNDROME: A DYADIC ANALYSIS .................................................... 49 
 A RETROSPECTIVE STUDY OF THE PREGNANCY, DELIVERY AND NEONATAL OUTCOME IN 
OVERWEIGHT VERSUS NORMAL WEIGHT WOMEN WITH POLYCYSTIC OVARY SYNDROME 
 ...................................................................................................................................... 71 
 QUALITY OF LIFE AND BODY MASS INDEX IN OVERWEIGHT ADULT WOMEN WITH 
POLYCYSTIC OVARY SYNDROME DURING A LIFESTYLE MODIFICATION PROGRAM .......... 89 
 GONADOTROPIN THERAPY VERSUS LAPAROSCOPIC OVARIAN DRILLING IN CLOMIPHENE 
CITRATE RESISTANT POLYCYSTIC OVARY SYNDROME PATIENTS: A RETROSPECTIVE COST-
EFFECTIVENESS ANALYSIS. ........................................................................................... 117 
 GENERAL DISCUSSION and PERSPECTIVES FOR FUTURE RESEARCH .............................. 135 
 CONTRIBUTIONS OF THIS DISSERTATION and IMPLICATIONS FOR CLINICAL PRACTICE . 163 
 SUMMARY ................................................................................................................... 167 
 SAMENVATTING .......................................................................................................... 171 
 LIST OF PUBLICATIONS ................................................................................................. 177 
 DANKWOORD .............................................................................................................. 181 
 CURRICULUM VITAE..................................................................................................... 187 
 
 
   7 
List of abbreviations 
 
AMH Antimüllerian hormone 
ASRM American Society for Reproductive Medicine 
BMI Body mass index 
BSRM Belgian Society for Reproductive Medicine 
CBT Cognitive-behavioral therapy 
CC Clomiphene citrate 
CEA Cost-effectiveness analysis 
CS Caesarean section 
E2 Estradiol 
ESHRE European Society of Human Reproduction and Embryology 
FSH Follicle stimulating hormone 
FSHR Follicle stimulating hormone receptor 
fT Free testosterone 
GnRH Gonadotropin-releasing hormone 
GDM Gestational diabetes mellitus 
GWG Gestational weight gain 
HIV Human immunodeficiency virus 
hMG Human menopausal gonadotropin 
HRQoL Health-related quality of life 
ICSI Intracytoplasmatic sperm injection 
IR Insulin resistance 
IVF In vitro fertilization 
LBR Live birth rate 
LOD Laparoscopic ovarian drilling 
LMP Lifestyle modification program 
LH Luteinizing hormone 
mFG modified Ferriman-Gallwey 
MMQ Maudsley Marital Questionnaire 
NICE National Institute for Clinical Excellence 
NICU Neonatal intensive care unit 
OD Ovarian drilling 
OHSS Ovarian hyperstimulation syndrome 
 8 
OI Ovulation induction 
PCOM Polycystic ovarian morphology 
PCOS Polycystic ovary syndrome 
PCOSQ PolyCystic Ovary Syndrome Questionnaire 
PE Pre-eclampsia 
PR Pregnancy rate  
rFSH Recombinant follicle stimulating hormone 
Ser Serine 
SHBG Sex hormone-binding globulin 
THLOD Transvaginal hydrolaparoscopic ovarian drilling 
uFSH Urinary follicle stimulating hormone 
WHO World Health Organization 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 INTRODUCTION 
  
  
 
INTRODUCTION 
  11 
1.1 Definition and prevalence 
The polycystic ovary syndrome (PCOS) was first described in 1935 by Stein and Leventhal (Stein and 
Leventhal, 1935). At that time, the so-called Stein-Leventhal syndrome was characterized by the 
presence of enlarged sclerocystic ovaries, menstrual irregularity, infertility, hirsutism and obesity 
(Chamberlain and Wood, 1964; Geisthövel, 2003). Ever since there has been an evolution in the 
diagnostic criteria of PCOS. The criteria that were captured during the Rotterdam consensus meeting 
in 2003, enclose most of the PCOS phenotypes and are nowadays internationally applied by 
gynecologists. Using these criteria, PCOS is diagnosed in the presence of two out of the following three 
criteria: (1) oligo- or anovulation, (2) clinical and/or biochemical signs of hyperandrogenism, and (3) 
polycystic aspect of one or both ovaries on ultrasound. Pathologies which present or imitate the same 
characteristics as PCOS, must be excluded (The Rotterdam ESHRE/ASRM-sponsored PCOS consensus 
workshop group, 2004). The Rotterdam criteria result in four PCOS phenotypes (Figure 1). According 
to these criteria, the prevalence of PCOS is estimated as high as 10%, making this syndrome one of the 
most common endocrine disorders in women at reproductive age in the developed world (Broekmans, 
et al., 2006). 
 
Figure 1: PCOS phenotypes according to the 2003 Rotterdam consensus criteria. Type A = Full-blown 
PCOS; PCOM = Polycystic ovarian morphology. 
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1.2 Pathogenesis and pathophysiology 
1.2.1 Pathogenesis 
The cause of PCOS is still unknown. It is even doubtful if ever one single cause will be found since the 
pathogenesis is thought to be multifactorial. Endogeneous (e.g., genetic) as well as exogeneous (e.g., 
life style) factors play an important role in the development and progress of this syndrome (Pasquali 
et al., 2006; Setji and Brown, 2007). Some believe that a dysfunction in the ovarian steroidogenesis, 
resulting in androgen excess, is the axis on which the wheel of the vicious PCOS circle turns (Escobar-
Morreale and San Millán, 2007; Setji and Brown, 2007; Hirschberg, 2009), while others mention an 
altered endocrine feedback system or insulin resistance (IR) as the primary defects causing the 
syndrome (Ching et al., 2007; Hirschberg, 2009). 
 
1.2.2 Pathophysiology 
The pathophysiology is not fully understood as well. The involvement of many factors make the 
pathophysiology quite complex (see Figure 2). 
At the level of the hypothalamic-pituitary axis, an abnormal secretion of gonadotropin-releasing 
hormone (GnRH) results in an increased secretion of luteinizing hormone (LH) and a relative deficiency 
of follicle stimulating hormone (FSH) (Hirschberg, 2009). As such, elevated LH:FSH ratios of ≥ 2 are 
detected in ~50% of the women with PCOS (Banaszewska et al., 2003). These elevated LH:FSH ratios 
cause an impaired follicle development in one or both ovaries which is characterized by (a) an excessive 
follicular growth in combination with (b) a poor follicle maturation, (c) a disturbed selection of a 
dominant follicle, so called “follicular arrest”, and (d) an increased follicular atresia (Jonard and 
Dewailly, 2004; Hirschberg, 2009). Follicular atresia is characterized by apoptosis of granulosa cells 
which results in an increased amount of ovarian stroma (Balen et al., 2005; Hirschberg, 2009). 
Hyperandrogenism is also associated with the impaired LH and FSH secretion. More specifically, the 
production of androgens (i.e., androstenedione) by the theca cells is increased due to the elevated LH 
stimulation and an increased amount of ovarian stroma, which is laden by interstitial cells and is 
responsive to LH, leads to an increased androgen production as well (Balen et al., 2005). On the other 
hand, androgen excess promotes the process of follicular atresia (Balen et al., 2005). In the mural 
granulosa cells androstenedione is converted into estradiol (E2) through a process of aromatization 
(Balen et al., 2005). The rising E2 level, in combination with the higher potency of polycystic ovaries to 
produce inhibin may be responsible for the impaired endocrine feedback system (Tanabe et al., 1990).  
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An increased prevalence of IR and compensatory hyperinsulinemia is observed in women with PCOS. 
Insulin functions as a co-gonadotropin and hence has an influence on the folliculogenesis (Diamanti-
Kandarakis and Dunaif, 2012). In women with PCOS the ovarian theca cells seem also more responsive 
to androgen-stimulating insulin-actions resulting in increased androgen levels (Diamanti-Kandarakis 
and Dunaif, 2012). Additionally, hyperinsulinemia leads to a decrease of the level of sex hormone-
binding globulin (SHBG) which results in an increased level of free testosterone (fT) (Snyder, 2006; 
Hirschberg, 2009). Taken together, hyperinsulinemia has hence a strengthening effect on the 
development of hyperandrogenism.  
The influence of obesity on the pathophysiology of PCOS is further discussed in Chapter 1.4. 
  
Chapter 1 
14 
 
  
INTRODUCTION 
  15 
1.3 Symptomatology 
The pathophysiology results in a very heterogeneous palette of symptoms which differs from person 
to person and changes over time in terms of type, number and severity of symptoms (Balen et al., 2005; 
Snyder, 2006; Diamanti-Kandarakis, 2007). Therefore PCOS is often compared to a chameleon which 
frequently changes color. The first signs of PCOS arise during or just after adolescence and stay until 
postmenopausal age (Pasquali and Gambineri, 2006; Snyder, 2006; Mani et al., 2014). 
The clinical manifestation of PCOS is characterized by polycystic ovaries, menstrual cycle disturbances, 
hirsutism, alopecia androgenetica, acne, and acanthosis nigricans. Biochemically, elevated levels of LH, 
(free) testosterone and insulin can be detected. Women with PCOS also often present with obesity 
(see Chapter 1.4). 
 
1.3.1 Polycystic ovarian morphology 
The polycystic ovarian morphology (PCOM) is the result of the impaired follicle development leading 
to an excessive amount of small follicles and ovarian stroma (Hirschberg, 2009). PCOM, as visualized 
on transvaginal ultrasound, is diagnosed in the presence of ≥ 12 follicles measuring 2-9 mm in diameter 
and/or an ovarian volume > 10 cm³ in at least one ovary (The Rotterdam ESHRE/ASRM-sponsored PCOS 
consensus workshop group, 2004) (Figure 3). Although PCOM is prevalent in 20% to 30% of the general 
female population, not all women present with other features of PCOS (Azziz et al., 2009). In the group 
of PCOS women, PCOM is estimated to be present in more than 80% of them (Azziz et al., 2009). 
 
Figure 3: Polycystic ovarian morphology on transvaginal ultrasound. 
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1.3.2 Ovulatory disorder and/or menstrual cycle disturbances 
The polycystic ovary syndrome is classified in the World Health Organization (WHO) Group II-category 
of ovulation disorders which are caused by a dysfunction in the hypothalamic-pituitary-ovarian axis 
(Brown et al., 2009; National Collaborating Centre for Women’s and Children’s Health, 2013). 
Moreover, this syndrome is the most common cause of ovulatory disorders. The absence of ovulation 
is specifically due to the lack of growth of a dominant follicle which in turn results in no LH surge. The 
disturbed LH:FSH ratio also leads to an impaired proliferation and secretion of the endometrium. The 
latter clinically manifests as menstrual cycle disturbances which are defined as less than six to eight 
menstrual bleedings per year with irregular intervals between 35 days and six months (i.e., 
oligomenorrhea) or intervals of more than or equal to six months (i.e., amenorrhea) (Balen et al., 2005; 
Macut et al., 2013). Menstrual cycle disturbances are present in 75% to 85% of women with PCOS 
(Azziz et al., 2009). The menstrual cycle disturbances in women with PCOS often occur after at least 
one menstrual cycle and are so-called secondary menstrual problems. 
The presence of < 10 menstrual cycles per year is mostly used as a criterion to diagnose ovulatory 
dysfunction (i.e., oligo- or anovulatory) (Macut et al., 2013). Still, irregular cycles are not per se 
anovulatory and regular cycles are also not per se ovulatory (Azziz et al., 2009). So, one has to keep in 
mind that using this criterion may lead to a number of false negative and false positive diagnoses 
(Macut  et al., 2013). 
Anovulatory subfertility is an important consequence of the ovulatory disorder and is present in 55 to 
90% of women with PCOS (Balen et al., 2005; Badawy et al., 2009). The pathophysiologic mechanism 
that causes oligo- and/or anovulation is explained in Chapter 1.2.2 and 1.3.2. The treatment of 
anovulatory subfertility is discussed in Chapter 1.6. 
 
1.3.3 Antimüllerian hormone 
The antimüllerian hormone (AMH) is a protein that is produced by granulosa cells of small antral 
follicles (≤ 4 mm) among others (Weenen et al., 2004; Bhide et al., 2015). It serves as a molecular 
biomarker for the relative size of the ovarian reserve (Weenen et al., 2004). PCOS is associated with 
an increased concentration of serum AMH (Homburg et al., 2014; Bhide et al., 2015). This can partially 
be explained by the increased number of small antral follicles. Besides, Bhide et al. (2015) has proven 
that the AMH production per antral follicle is significantly higher in subfertile women with PCOS when 
compared with women with PCOM only, and when compared with women without PCOM or PCOS. 
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AMH is thought to play a role in the pathophysiologic mechanism of anovulation in women with PCOS 
due to an inhibitory effect of AMH on the actions of FSH (Homburg et al., 2014; Bhide et al., 2015). 
 
1.3.4 Biochemical and clinical hyperandrogenism 
1.3.4.1 Biochemical hyperandrogenism 
Hyperandrogenemia is the biochemical expression of androgen excess. The causal pathway is 
explained in Chapter 1.2.2. Free testosterone appears to be the single most predictive marker with 
~60% of PCOS women demonstrating supra-normal levels (Huang et al., 2010). The increased bio-
availability of androgens to peripheral tissues leads to the well-known clinical signs of androgen excess. 
1.3.4.2 Clinical hyperandrogenism 
Androgens influence the functioning of the pilosebaceous unit from which both hair follicles and 
sebaceous glands develop (Balen et al., 2005). Hence, androgens – and especially high levels of 
androgens - may on the one hand stimulate, and on the other hand inhibit the growth of hair follicles 
of the sexual type, as well as they may stimulate the development of seborrhea. These mechanisms 
result in hirsutism, alopecia androgenetica and acne, respectively. 
Hirsutism is present in 60-70% of the women with PCOS, making this the most common clinical sign of 
hyperandrogenemia (Macut et al., 2013). It is defined as the presence of excessive terminal hair growth 
according to a male-like pattern which is typified by hair on the chin, face, chest, abdomen, back, thighs, 
and upper arms (Azziz et al., 2009; Yildiz et al., 2010; Macut et al., 2013). At those places androgens 
stimulate the transformation of fine, unpigmented vellus-like hair into coarse, pigmented, thickened 
terminal hair (Balen et al., 2005). The widely used method to evaluate the degree of hirsutism is the 
modified version of the Ferriman-Gallwey scale (mFG scale) assessing the hair growth at nine sites of 
the body using a 5-point Likert scale (0 = absence of terminal hair; 4 = extensive terminal hair growth) 
(Ferriman and Gallwey, 1961; Azziz et al., 2009; Yildiz et al., 2010) (Figure 4). A score more than or 
equal to eight is classified as hirsute (Yildiz et al., 2010). 
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Figure 4: The modified Ferriman-Gallwey scale of hirsutism. 
 
Alopecia androgenetica is described as male pattern baldness which is characterized by hair loss on 
the frontal and sagittal part of the scalp (Balen et al., 2005). This is due to a shortening of the anagen 
phase resulting in an advanced conversion of terminal hair to vellus-like hair (Geisthövel, 2003; Balen 
et al., 2005). The prevalence of alopecia androgenetica in women with PCOS is not completely clear 
and may vary between 5% and 50% (Azziz et al., 2009). 
Acne is estimated to be present in 30% of the women with PCOS. Androgens stimulate the production 
of sebum and an abnormal keratinization of the pilosebaceous unit (Balen et al., 2005). Together this 
leads to clogged sebaceous glands, presented as pustules. 
 
1.3.5 Acanthosis nigricans 
Acanthosis nigricans is the clinical sign of IR. It is a thickening and dark discoloration of the epidermis 
in specific body parts such as the posterior neck and the axilla (Shivaprakash et al., 2013). Mani et al. 
(2015) found a significantly higher prevalence of acanthosis nigricans in South Asian women with PCOS 
(16.8%) when compared with White women with PCOS (3.1%, p < 0.001). On the other hand, in a 
sample of specific Indian women with PCOS, the prevalence of acanthosis nigricans was 56% 
(Shivaprakash et al., 2013). 
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In general, the assessment of most symptoms is subjective and requires an experienced physician as 
well as the use of standardized techniques and scales. Additionally, the assessment is often hindered 
by the use of drugs and one has to be aware of racial, ethnic and genetic differences that can modify, 
for example, the effects of androgens on the skin (Williamson et al., 2001; Balen et al., 2005).  
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1.4 PCOS and obesity 
The prevalence of overweight [body mass index (BMI) of 25-29.9 kg/m²] and obesity (BMI ≥ 30 kg/m²) 
in women with PCOS is estimated between 30% and 70% worldwide making this a substantial health 
problem in those women (Vrbikova and Hainer, 2009; World Health Organization, 2010). The wide 
range in the observed prevalence is due to racial, ethnical and cultural differences, as well as to 
differences in PCOS diagnostic criteria or the used BMI classification. In Europe, the prevalence of 
overweight and obesity (including morbid obesity) in women with PCOS is estimated at 18% and 43%, 
respectively (Pasquali et al., 2006). In general, the prevalence of obesity in the European female 
population is found to be 6.2% to 36.5% (Berghöfer et al., 2008). 
In women with PCOS, there is, regardless of the degree of overweight, mostly a central fat distribution 
whereby the adipose tissue is disproportionately accumulated in the intra-abdominal visceral depot 
(Kirchengast and Huber, 2001; Yildirim et al., 2003; Diamanti-Kandarakis, 2007). Therefore this type of 
obesity is called central, abdominal or visceral obesity. Central obesity in women is diagnosed in the 
presence of a waist circumference ≥ 80 cm and a waist circumference of > 88 cm is indicative of an 
increased metabolic risk (Després et al., 2001; Hoeger, 2007; International Diabetes Federation, 2012). 
When compared with the BMI and the waist to hip ratio, the waist circumference correlates better 
with the absolute amount of abdominal adipose tissue (Norman et al., 2002). Additionally, measuring 
the waist circumference is a simple, inexpensive and not time consuming technique. 
There is no causal relationship between obesity and PCOS in any direction (Escobar-Morreale et al., 
2005; Escobar-Morreale and San Millán, 2007). However it is clear that central obesity has a marked 
negative influence on the pathophysiology of the syndrome due to the (abnormal) hormonal and 
metabolic activities of the central fat tissue (Pasquali et al., 2006; Diamanti-Kandarakis, 2007) (see 
Figure 2). More specifically, the intravisceral adipocytes affect the insulin activity and the steroid 
metabolism (Diamanti-Kandarakis, 2007). Concerning the insulin activity, visceral adipocytes in women 
with PCOS show defects in the transmission of insulin messages rather than a defect in the binding-
process of insulin to its receptor (Diamanti-Kandarakis, 2007). This causes a decreased cellular glucose 
uptake resulting in increased impaired glucose tolerance and compensatory hyperinsulinemia 
(Gambineri et al., 2002; Diamanti-Kandarakis, 2007; Escobar-Morreale and San Millán, 2007; Hoeger, 
2007). Moreover, an increased lipolysis also worsens the degree of IR (Diamanti-Kandarakis 2007). 
Concerning the steroid metabolism, intravisceral adipocytes have the property to convert on the one 
hand inactive cortisone into metabolically active cortisol and on the other hand weak androgens (i.e., 
Δ-4 androstenedione) into strong androgens (i.e., testosterone), resulting in increased cortisol and 
testosterone levels, respectively. Additionally, estrogen (excess), produced by fat tissue among others, 
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causes an impaired feedback to the pituitary gland and the hypothalamus. Together with the 
hyperresponsiveness of the pituitary gland to GnRH in women with PCOS, this may result in increased 
serum LH concentrations and increased LH to FSH ratios (Diamanti-Kandarakis, 2007; Hoeger, 2007; 
Dafopoulos et al., 2009; Vrbikova and Hainer, 2009). 
The negative effects of central obesity on the pathophysiology of PCOS lead to a worse clinical 
manifestation of the syndrome. As such, obese women with PCOS present with an increased 
prevalence of hirsutism, menstrual cycle disturbances, anovulatory dysfunction and subsequent 
fertility problems when compared with normal weight women with PCOS (Gambineri et al., 2002; 
Laitinen et al., 2003; Pasquali et al., 2006; Diamanti-Kandarakis, 2007; Hoeger, 2007; Hirschberg, 2009). 
Although, the exact influencing pathway of obesity on the reproductive function in women with PCOS 
is not completely clear, there is evidence that obese women with PCOS have an increased need for 
assisted reproductive technology and have a higher incidence of blunted responsiveness to 
pharmacological ovulation induction (OI) agents (Gambineri et al., 2002; Hirschberg, 2009).  
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1.5 PCOS and psychological wellbeing 
The polycystic ovary syndrome is a trigger for psychological morbidity (i.e., higher depression rate, 
anxiety) (Jones et al., 2002; Elsenbruch et al., 2003; Snyder, 2006; Jones et al., 2008). In turn, this leads 
to an increased likelihood of experiencing a reduced health-related quality of life (HRQoL) (Thomson 
et al., 2010). 
 
1.5.1 PCOS and health-related quality of life 
Health-related quality of life is a subjective and multidimensional concept that comprises physical, 
emotional and social aspects associated with a specific disease or its treatment (Colwell et al., 1998). 
The HRQoL is an important outcome measure for any patient but it may be particularly of interest in 
patients with a chronic disease (e.g., PCOS) who must deal with their disease for a long period in time 
(Trent et al., 2002).  
There is evidence that PCOS has a substantial negative influence on a woman’s HRQoL (Ching et al., 
2007; Jones et al., 2008). As such, the level of HRQoL is found to be lower in women with PCOS when 
compared with women at reproductive age without PCOS (Elsenbruch et al., 2003; Hahn et al., 2005; 
Ching et al., 2007). Moreover, Coffey et al. (2006) found that PCOS had a worse impact on patient’s 
psychological well-being than other (chronic) medical conditions (i.e., asthma, epilepsy, diabetes, back 
pain, arthritis and coronary heart disease), while the impact of PCOS on patient’s physical well-being 
was found to be similar or milder when compared with those other mentioned medical conditions 
(Coffey et al., 2006). This is striking since the psychological impact of infertility (in general) was found 
to be similar to the psychological impact associated with other (serious) medical conditions (i.e., heart 
disease, cancer, hypertension and infection with HIV) (Domar et al., 1993; National Collaborating 
Centre for Women’s and Children’s Health, 2013). 
 
1.5.2 PolyCystic Ovary Syndrome Questionnaire 
To evaluate women’s subjective perception of the influence of specific PCOS characteristics on their 
level of quality of life, the disease-specific PolyCystic Ovary Syndrome Questionnaire (PCOSQ) was 
developed (Cronin et al., 1998). This is a patient-generated questionnaire, meaning that the included 
items are based upon patient interviews rather than upon the clinical opinion of health professionals 
(Cronin et al., 1998; Guyatt et al., 2004; Coffey et al., 2006). These interviews revealed that emotional 
wellbeing, body hair, weight, infertility problems and menstrual problems were the most important 
domains of HRQoL affected by PCOS (Cronin et al., 1998; Jones et al., 2002). This standardized 
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questionnaire consists of 26 items and each item is scored on a 7-point Likert scale (1 = high concern, 
7 = no concern) (Cronin et al., 1998). Higher scores indicate a qualitatively higher level of HRQoL or a 
lower level of PCOS-related concern (Cronin et al., 1998). The test-retest reliability is found to be high 
(intra-class correlation coefficients > .80) and the internal consistency is acceptable to excellent 
(Cronbach’s α ≥ .70) (Guyatt et al., 2004; Jones et al., 2004; Coffey et al., 2006). The face validity was 
evaluated by Jones et al. (2004) by performing semi-structured interviews in 12 women with PCOS. 
They concluded that the validity of the PCOSQ could be improved by the addition of an acne domain 
to the PCOSQ (Jones et al., 2004). On the other hand, the construct, discriminant and longitudinal 
validity were confirmed by research (Guyatt et al., 2004; McCook et al., 2005; Coffey et al., 2006). The 
latter supports the use of this disease-specific questionnaire as an evaluative instrument in clinical 
trials (Guyatt et al., 2004). This is important because the use of HRQoL as an outcome parameter 
provides valuable extra information from the patient’s perspective about the effectiveness of a 
treatment (Cronin et al., 1998; Jones et al., 2002). 
 
1.5.3 Influence of PCOS characteristics on HRQoL 
Using this standardized questionnaire, several researchers concluded that weight (i.e., weight gain and 
problems to maintain weight at a normal level) is the domain of highest concern in women with PCOS 
when compared with the other four PCOSQ domains (Guyatt et al., 2004; Jones et al., 2004; McCook 
et al., 2005; Coffey et al., 2006; Ching et al., 2007). Furthermore, McCook et al. (2005) and Ching et al. 
(2007) found a significant negative correlation between different BMI classifications and all PCOSQ 
domain scores on the one hand and between BMI and the weight PCOSQ domain score (r = -.33, p 
= .001) on the other hand. In contrast, the Hashimoto et al. (2003) study didn’t find a significant 
difference of the body hair, weight, infertility problems and menstrual problems PCOSQ domain score 
between several BMI categories in a sample of Austrian women. The reproductive history, more 
specifically “the delivery of a viable child”, was determined as a significant predictor for the infertility 
problems PCOSQ subscale score (McCook et al., 2005). But there was no significant correlation 
between the fertility status and the other PCOSQ subscale scores (McCook et al., 2005). The body hair 
PCOSQ subscale score was found to be significantly negatively correlated with clinical (i.e., mFG-score) 
and biochemical (i.e., testosterone) signs of hyperandrogenism (McCook et al., 2005; Harris-Glocker et 
al., 2010; Thomson et al., 2010). 
Generally, the observed differential influence and the severity of the influence of PCOS characteristics 
must be interpreted within a certain socio-cultural and ethnic context (Hashimoto et al., 2003; Schmid 
et al., 2004).  
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1.5.4 Influence of PCOS on sexual and relational satisfaction 
The polycystic ovary syndrome does not only have an impact on a woman’s quality of life, but also 
affects her concept of self as being a female or feminine based partially on physical characteristics as 
well as on psychological and social pressure (i.e., gender identity) (Kitzinger and Willmott, 2002). On 
the one hand, symptoms of PCOS associated with a rather “masculinized” physical appearance (i.e., 
hirsutism, alopecia androgenetica, acne, overweight) cause body dissatisfaction in women with PCOS 
(Kitzinger and Willmott, 2002; Snyder, 2006; Jones et al., 2008; de Niet et al., 2010). On the other hand, 
women with PCOS often can’t meet the expected female behavior due to the presence of menstrual 
disturbances and the inability to conceive a child (Kitzinger and Willmott, 2002; Snyder, 2006). Both 
factors make them feel different and less feminine when compared with other women without PCOS 
(Kitzinger and Willmott, 2002; Snyder, 2006).  
Given the PCOS symptomatology, one should expect that PCOS women’s feeling of reduced femininity 
may cause problems with her level of sexual functioning and satisfaction. As such, women with PCOS 
often report to feel less satisfied with their sexual life when compared with women without PCOS 
(Elsenbruch et al., 2003; Drosdzol et al., 2007; Tan et al., 2008; Månsson et al., 2011). Evidence about 
the association of specific objective PCOS characteristics with the level of sexual satisfaction in women 
with PCOS is scarce and conflicting (Elsenbruch et al., 2003; Hahn et al., 2005; Drosdzol et al., 2007; 
Månsson et al., 2011; Stovall et al., 2012). For example, the mFG-score of hirsutism on the one hand, 
and the serum testosterone level on the other hand were found to be negatively and not associated, 
respectively, with PCOS women’s level of sexual satisfaction (Drosdzol et al., 2007; Stovall et al., 2012). 
Also no significant association of the objective presence of acne with the level of sexual satisfaction 
and sexual functioning of women with PCOS was documented by Hahn et al. (2005) and Stovall et al. 
(2012). There is conflicting evidence too about the association of PCOS women’s BMI with their sexual 
satisfaction and functioning. Namely, a negative association, on the one hand, and the absence of an 
association, on the other hand, is described (Elsenbruch et al., 2003; Hahn et al., 2005; Månsson et al., 
2011; Stovall et al., 2012). Finally, the presence of a wish to conceive is not related to PCOS women’s 
sexual satisfaction (Tan et al., 2008).  
To date, there is no evidence about the association of PCOS women’s subjective perception of PCOS 
with their level of sexual satisfaction. This should however be interesting and valuable information 
since the subjective perception of a stressor (i.e., PCOS) is theoretically and empirically more directly 
related to individual and relational well-being than its objective characteristics (Trent et al., 2002; 
Weber, 2011). Furthermore, a strong association of couple’s sexual satisfaction with their level of 
relational satisfaction is well-documented (Christopher and Sprecher, 2000). Therefore, it might be 
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interesting to study the association of PCOS characteristics with non-sexual aspects of a long term 
intimate relationship, like the relational satisfaction.  
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1.6 Treatment of anovulatory subfertility in PCOS 
1.6.1 Weight loss as first-line treatment 
 
The 2013 NICE guidelines recommend infertile anovulatory women with a BMI ≥ 30 kg/m² to first lose 
weight in order to increase their chance to conceive spontaneously (National Collaborating Centre for 
Women’s and Children’s Health, 2013). According to the Thessaloniki consensus, weight loss is also the 
recommended first-line treatment in overweight and obese women with PCOS (Thessaloniki 
ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2008). 
 
1.6.1.1 Effect of weight loss on physical parameters 
The existing evidence shows that a modest weight loss of 5-10%, regardless of the degree of 
overweight or obesity, results in an improvement of metabolic and endocrine parameters in women 
with PCOS. More specifically, an improved insulin sensitivity as well as lower fasting insulin levels, 
lower LH levels, increased SHBG levels, and decreased fT levels are observed (Huber-Buchholz et al., 
1999; Norman et al., 2002). These changes result indirectly in a reduction of hirsutism, an improvement 
of the menstrual regularity, restoration of ovulation and consequently increases the chance of a 
spontaneous conception (Huber-Buchholz et al., 1999; Hoeger et al., 2004; Thessaloniki ESHRE/ASRM-
Sponsored Consensus Workshop Group, 2008; Thomson et al., 2008). 
In order to achieve a modest but sustained effect, the recommended strategy to lose weight is focused 
on modifying one’s lifestyle into a more healthy and regular one. Therefore, a combination of diet, 
exercise and cognitive-behavioral therapy (CBT) is advised (Norman et al., 2002; Shaw et al., 2005; 
Hoeger, 2006). The fact that the clinical manifestation of PCOS will probably return or possibly even 
become worse after weight regain, stresses the importance of a lasting weight loss (Norman et al., 
2002). Hence, achievable goals that meet the needs and the capabilities of each individual are crucial 
(Norman et al., 2002). In women with PCOS, lifestyle modification programs (LMPs) have proven their 
effectiveness in terms of weight loss, endocrine parameters, menstrual regularity, frequency of 
spontaneous ovulation, chance of pregnancy and live birth rate (Hoeger et al., 2004; Tang et al., 2006; 
Thomson et al., 2008). The longest period over which the effectiveness of LMPs has been observed is 
48 weeks, but strikingly, also after a shorter time limit of 20 and 24 weeks lifestyle modification had 
already a positive effect (Tang et al., 2006; Hoeger et al., 2004; Hoeger, 2007; Thomson et al., 2008). 
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1.6.1.2 Effect of weight loss on HRQoL 
Although body weight is the highest concern in women with PCOS and HRQoL is an important marker 
from the patient’s perspective for the efficacy of a treatment, little research has been done using 
HRQoL as outcome parameter for the efficacy of weight loss interventions in the general population 
as well as in the specific population of women with PCOS (Jones et al., 2008; Harris-Glocker et al., 2010; 
Thomson et al., 2010; Lasikiewicz et al., 2014). Some evidence indicates that (a) HRQoL improvements 
depend on weight losses greater than 5%, and that (b) an even greater improvement is observed when 
weight loss exceeds 10% of initial body weight (Lasikiewicz et al., 2014). 
Till now, only two research groups focused on the effect of lifestyle modification on HRQoL in 
overweight and/or obese women with PCOS (Harris-Glocker et al., 2010; Thomson et al., 2010). More 
specifically, Harris-Glocker et al. (2010) studied the HRQoL, as measured by the PCOSQ, during a 24-
week LMP in a group of obese (BMI > 95th percentile) adolescent (12-18 years) women with PCOS. The 
LMP consisted primarily of group support by a dietician, psychologist, and structured group exercise, 
alternated with individual meetings as needed. The results of that study revealed that a treatment of 
lifestyle modification and oral contraceptives, in combination with or without metformin, had a 
positive effect on the HRQoL in those women. As such, this indicates that metformin had no additional 
effect in terms of HRQoL. Despite the significant decrease in BMI in the group with and without 
metformin (i.e., 4%, p = .008 and 5.2%, p = .001, respectively) and despite the significant increase in all 
PCOSQ domain scores over the period of 24 weeks, there was only a trend towards a correlation 
between the decrease in BMI and the increase in HRQoL (r = -0.333, p = .06). Similarly, Thomson et al. 
(2010) performed a 20-week lifestyle modification treatment in overweight and obese (BMI = 25–
55kg/m2) adult (18-41 years) women with PCOS investigating the additional value of exercise in a 
program consisting of hypocaloric diet only. The exercise subprogram comprised aerobic exercise or 
combined aerobic-resistance exercise. The researchers found that lifestyle modification, consisting of 
diet with or without exercise, had a positive impact on HRQoL in overweight and obese adult women 
with PCOS. They observed a significant weight loss in all treatment groups (p ≤ .001), as well as a 
significant improvement of all PCOSQ domain scores (p ≤.001), except for the body hair domain score. 
A significant correlation between changes in weight and changes in PCOSQ emotion domain scores (r 
= -.35, p ≤ .01) and between changes in weight and changes in PCOSQ body weight domain scores (r = 
-.43, p ≤ .01) were found. 
The latter study indicates that exercise has no added value to diet only in terms of HRQoL. Although, 
when investigating the isolated effect of exercise on body image distress, Liao et al. (2008) found that 
a self-directed walking program significantly reduced the level of body image distress in overweight 
and obese women with PCOS. Furthermore, the effectiveness of diet in terms of depression rate and 
level of self-esteem is proven to depend on the diet composition (Galletly et al., 2007). Concerning 
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psychological support, Shaw et al. (2005) has proven that the addition of CBT to a multi-component 
LMP is important to obtain a maximum effect in terms of weight loss. To date, there is no evidence 
about the effect of psychological interventions on the psychological well-being of women with PCOS. 
Since HRQoL is an important marker from the patient’s perspective for the efficacy of a treatment, 
additional research on this topic is needed (Cronin et al., 1998; Jones et al., 2008). Moreover, as earlier 
studies have not accounted for the influence of acne on women’s HRQoL it is of interest to evaluate 
this when studying HRQoL in women with PCOS (Jones et al., 2004).   
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1.6.2 Pharmacological and surgical treatment 
The essence of a pharmacological treatment of anovulatory subfertility is OI through indirect influence 
of the hypothalamic-pituitary axis or via directly increasing the circulating FSH level (Balen et al., 2005). 
Due to the disturbed gonadotrophic environment, the number of available FSH-sensitive antral follicles 
is larger in a polycystic ovary compared to a normal ovary. Subsequently those ovaries are especially 
prone to excessive multiple follicle development. 
The Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group (2008) and the National 
Collaborating Centre for Women’s and Children’s Health (2013) recommend a treatment with 
clomiphene citrate (CC) as the first-line treatment for OI in PCOS. Nevertheless, a treatment with low-
dose FSH is also described as a possible first-line treatment (see Chapter 1.6.2.2 Gonadotropin therapy). 
 
1.6.2.1 Clomiphene citrate 
Clomiphene citrate is a selective estrogen receptor modulator. It blocks the binding of circulating E2 
to the oestrogen receptors in the hypothalamus by attaching itself to those receptors. This causes a 
loss of feedback from circulating E2 and restores the pituitary secretion of LH and FSH (McDowell et 
al., 2013). As such, CC has an indirect effect on the ovarian function. 
Clomiphene citrate is administered from day 3 to 7 of a spontaneous or induced menstrual bleeding, 
with a starting dose of 50 mg/day and a maximum dose of 150 mg/day (Balen et al., 2005). It is advised 
to administer this drugs for no longer than 6 cycles. Although, monitoring the ovarian response through 
ultrasound is required, the prevalence of the ovarian hyperstimulation syndrome (OHSS) and multiple 
pregnancies after a treatment with CC is rather rare (van Wely et al., 2004; Balen et al., 2005; National 
Collaborating Centre for Women’s and Children’s Health, 2013). 
About 15-20% of the subfertile women with PCOS are “clomiphene resistant”, meaning that they do 
not respond to a maximum daily dose of 150 mg CC/day for 5 subsequent days in the early follicular 
phase (Nugent et al., 2000; Bayram et al., 2004; Farquhar et al., 2004; van Wely et al., 2004; Balen et 
al., 2005; Farquhar et al., 2012 ). The exact cause of CC resistance is largely unknown but several factors 
have been suggested to influence the response to CC (Overbeek et al., 2009). As such, obesity and 
hyperandrogenism were associated with a decreased ovulation rate after OI with CC (Imani et al., 2000). 
The response to CC seems also mediated by the sensitivity of the FSH receptor (FSHR). More specifically, 
a Ser680Ser-polymorphism of the FSHR gene is associated with a low sensitivity of the FSHR for FSH 
that makes it incapable to respond adequately to the raised FSH levels in OI therapy (Overbeek et al., 
2009). 
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The two alternative treatments currently used for OI in these women are, on the one hand, 
gonadotropin therapy and, on the other hand, ovarian drilling (OD) (Thessaloniki ESHRE/ASRM-
Sponsored PCOS Consensus Workshop Group, 2008; Farquhar et al., 2012; National Collaborating 
Centre for Women’s and Children’s Health, 2013). 
 
1.6.2.2 Gonadotropin therapy 
The principle of gonadotropin therapy is direct ovarian stimulation using human menopausal 
gonadotropin (hMG), or either urinary (uFSH) or recombinant FSH (rFSH) (van Wely et al., 2003; 
Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, 2008; Farquhar et al., 2012). 
Human menopausal gonadotropin contains equal amounts of LH and FSH, while LH is absent in uFSH 
and rFSH (van Wely et al., 2003). 
In general, gonadotropin therapy increases the risk of multiple follicle development, multiple 
pregnancies (about 20%), OHSS and cyst formation (Nugent et al., 2000; Farquhar et al., 2002; Farquhar 
et al., 2004; Balen et al., 2005; Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop 
Group, 2008; Farquhar et al., 2012). In order to achieve a more controlled follicle stimulation and to 
avoid these iatrogenic risks several dose regimens (i.e., low-dose step-up and low-dose step-down 
regimen) have been used in combination with intensive ultrasound and endocrine monitoring (i.e., E2) 
(Christin-Maitre and Hugues, 2003; van Wely et al., 2003; Thessaloniki ESHRE/ASRM-Sponsored PCOS 
Consensus Workshop Group, 2008). The prospective, randomized multicentric study by Christin-Maitre 
and Hugues (2003) showed that a low-dose step-up protocol was the most efficient and safest for use. 
As mentioned in the introduction of this chapter (see Chapter 1.6.2.), gonadotropin therapy is not only 
a second-line treatment in case of “clomiphene resistance”, but is also a possible first-line OI treatment 
in women with PCOS. Moreover, Homburg et al. (2012) has proven that the reproductive outcome 
after OI with low-dose FSH is significantly better than after OI with CC, with respect to clinical 
pregnancy rate (PR) and live birt rate (LBR) per (first) cycle, cumulative clinical PR and LBR over three 
cycles and time-to-pregnancy. The low-dose FSH treatment was also not associated with anti-
endometrial effects when compared with CC treatment (Homburg et al., 2012). 
 
1.6.2.3 Ovarian drilling 
Ovarian drilling is a procedure that creates multiple holes in the ovarian cortex and stroma by laser 
vaporization or electrocoagulation (Farquhar et al., 2012). The mechanism of OD is generally unknown 
but it is thought that this procedure destroys ovarian androgen-producing tissue and decreases the 
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peripheral conversion of androgens to estrogens (Hendriks et al., 2007; Gordts et al., 2009; Farquhar 
et al., 2012). Hence disturbances of the ovarian-pituitary feedback mechanism are corrected and the 
hormonal environment is restored (Hendriks et al., 2007; Gordts et al., 2009; Farquhar et al., 2012). 
To date, there is no consensus about the number of punctures to perform per ovary in order to achieve 
an optimal effect. A retrospective study by Amer et al. (2002) showed that performing three punctures 
per ovary is sufficient to achieve a significant higher ovulation and pregnancy rate when compared 
with ≤ 2 punctures per ovary (p < .05 and p < .05, respectively). On the other hand, the prospective 
randomized study by Tabrizi et al. (2005) concluded that a 15-point electrocauterization is significantly 
more effective than a 5- or 10-point electrocauterization in terms of 12-month pregnancy and live birth 
rate (p = .016 and p = .004, respectively). In 2008, the Thessaloniki ESHRE/ASRM-Sponsored PCOS 
Consensus Workshop Group agreed upon the fact that > 10 punctures per ovary should be discouraged 
because of the risk of excessive (permanent) ovarian tissue damage, peri-adenexal adhesions and the 
association with premature ovarian failure (Weerakiet et al., 2007; Thessaloniki ESHRE/ASRM-
Sponsored PCOS Consensus Workshop Group, 2008). Yet, the degree of ovarian tissue damage not 
only depends on the number of punctures but is also related to the used technique (i.e., monopolar 
and bipolar coagulation, laser vaporization, or ovarian biopsies) (Hendriks et al., 2010). It has been 
proven that bipolar electrocoagulation resulted in significantly more destruction per burn than the CO2 
laser and monopolar electrocoagulation technique (Hendriks et al., 2010). 
Two methods for performing an OD are described depending on the surgical procedure: (a) 
laparoscopic ovarian drilling (LOD) and (b) transvaginal hydrolaparoscopic ovarian drilling (THLOD). 
Laparoscopic ovarian drilling was first described by Gjönnaess in 1984 (Gjönnaess, 1984). Ovarian 
drilling through this method has been proven to have a positive effect on consecutive spontaneous 
ovulations (80%) and conception (61%) rates, as well as on the ovarian responsiveness to OI agents 
(Amer et al., 2002; Farquhar et al., 2002; Nahuis et al., 2011; Farquhar et al., 2012). This technique also 
has the advantage to avoid OHSS and multiple pregnancies (Farquhar et al., 2002). Moreover, the 
positive effect of LOD seems to last for at least 12 months after surgery (Kovacs and Norman, 2007; 
Nahuis et al., 2011). But, one has to keep in mind that LOD is an invasive procedure which possibly 
brings along short and long term complications due to surgery and anesthetics (Farquhar et al., 2002; 
Farquhar et al., 2004; Balen et al., 2005).  
On the other hand, THLOD is a less invasive procedure when compared with LOD and is associated 
with a low risk of intra- and postoperative complications. The effectiveness of THLOD in terms of 
ovulation and pregnancy rate is also described to be similar to LOD (Fernandez et al., 2001; Shibahara 
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et al., 2006; Badawy et al., 2009; Gordts et al., 2009; Catenacci and Goldberg, 2011). Nevertheless, the 
latter needs to be confirmed by long term research. 
 
1.6.2.4 Cost-effectiveness of gonadotropin therapy versus ovarian drilling in clomiphene 
resistant women 
Till now, the cost-effectiveness of gonadotropin therapy has only been compared with the laparoscopic 
method of ovarian drilling. Three cost-effectiveness analyses (CEAs) comparing gonadotropin therapy 
with LOD in CC resistant women with PCOS were published (Farquhar et al., 2004; van Wely et al., 
2004; Nahuis et al., 2012). Farquhar et al. (2004) (n = 50) performed a prospective CEA alongside a 
randomized controlled trial and concluded that LOD without additional drug treatment was the most 
cost-effective option from the societal perspective in terms of cost per pregnancy and cost per live 
birth over a time period of 6 months. Since no multiple pregnancies occurred in both treatment groups 
a cost for multiples pregnancies was not taken into account when calculating the cost per live birth. In 
contrast to these results, van Wely et al. (2004) (n = 168), who performed a prospective CEA alongside 
a multicentre randomized clinical trial, found a comparable cost-effectiveness from the societal 
perspective of both treatments over a time period of 12 months in terms of the mean total cost per 
woman until an ongoing pregnancy. The LOD strategy was followed by a treatment with CC or rFSH if 
anovulation persisted for 8 weeks or when patients became anovulatory again after LOD. Besides those 
two short term CEAs, Nahuis et al. (2012) performed a CEA alongside a long term follow-up study over 
a period of 8 to 12 years. In this study, only the cost for the public payer was considered. The authors 
concluded that LOD was the most cost-effective option when looking into the cost per (first) live birth, 
including costs until 6 weeks after delivery.  
In conclusion, current evidence on the cost-effectiveness of gonadotropin therapy and LOD in CC 
resistant women with PCOS is scarce, conflicting, and performed from different health-economic 
perspectives and over different lengths of time. Moreover, a CEA from the societal perspective based 
on real-life data is missing.  
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1.7 PCOS and pregnancy, delivery and neonatal outcome 
The risk of an adverse pregnancy, delivery and neonatal outcome is increased in women affected by 
PCOS. There is evidence that women with PCOS are at increased risk of a (recurrent) miscarriage, which 
might be linked to pre-pregnancy LH hypersecretion, hyperandrogenemia, hyperinsulinemia and/or 
thrombophilia (Regan et al., 1990; Okon et al., 1998; Wang et al., 2001; Kazerooni et al., 2013). 
Furthermore, an ongoing pregnancy in women with PCOS is often complicated by pregnancy induced 
hypertension, pre-eclampsia (PE) and gestational diabetes mellitus (GDM) (Altieri et al., 2010). GDM 
in PCOS is the result of a state of IR as induced by the pregnancy itself, in combination with a 
predisposition of glucose-intolerance in women with PCOS (Altieri et al., 2010; Mikola et al., 2001; 
Turhan et al., 2003). Pre-eclampsia in women with PCOS may be caused by low levels of insulin-like 
growth factor binding globulin-1 which is a regulator of the insulin-like growth factor-1 activity (Altieri 
et al., 2010; Kjerulff et al., 2011).  
These pregnancy complications give directly or indirectly rise to an increased risk of preterm delivery,  
Caesarean section (CS) or assisted vaginal delivery (Altieri et al., 2010). The new-born babies stay more 
frequently in a neonatal intensive care unit (NICU) and the perinatal mortality is also higher (Boomsma 
et al., 2006; Qin et al., 2013). 
 
1.7.1 Influence of overweight on pregnancy, delivery and neonatal outcome in women 
with PCOS 
In the general population, multiple studies have focused on the association of pre-pregnancy maternal 
overweight and obesity with the obstetric and neonatal outcome. As such, there is evidence showing 
an increased risk of GDM, PE, CS, instrumental delivery, postpartum haemorrhage, infection, 
prolonged hospital stay, congenital malformations, macrosomia and an increased NICU admission in 
overweight and obese women (Sarwer et al., 2006; Heslehurst et al., 2008; Poobalan et al., 2009; 
Blomberg, 2013; Cnattingius et al., 2013; Wahabi et al., 2014). Considering the risk of preterm birth in 
overweight and obese women, the evidence is conflicting. Some studies indicate an association of an 
increase of the BMI with an increase of the risk of preterm birth (< 37 weeks gestation) (Khatibi et al., 
2012; Cnattingius et al., 2013). On the other hand, the systematic review and meta-analysis of 
McDonald et al. (2010) reports no association of overweight and obesity with an increased risk of 
preterm birth. Also, Nohr et al. (2007) found no increased risk of induced preterm birth in obese 
women (BMI ≥ 30 kg/m²). However, this was only the case after adjustment for obesity-related 
diseases (such as PE, hypertension and diabetes mellitus). Pre-pregnancy maternal obesity also has 
been associated with an increased risk of preterm birth, GDM and stillbirth specifically in twin 
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pregnancies (Salihu et al., 2010; Simões et al., 2011; Dickey et al., 2012; Dickey et al., 2013). 
Additionally, an excessive gestational weight gain (GWG) is described to have an additional deleterious 
effect on the risk of PE, CS, macrosomia and postpartum weight retention in singleton and twin 
pregnancies in obese women (Cedergren, 2006; Nohr et al., 2008; Bogaerts et al., 2012; Gavard and 
Artal, 2014). 
On the other hand, the existing evidence about the influence of overweight and obesity on the 
pregnancy, delivery and neonatal outcome in women with PCOS is scarce and not unambiguous. A few 
retrospective studies investigating the pregnancy, delivery and neonatal outcome in women with PCOS 
versus women without PCOS have adjusted their analyses for BMI (Mikola et al., 2001; Turhan et al., 
2003). Based on the results of those multivariate analyses, pre-pregnancy overweight (BMI > 25 kg/m²) 
was found to be an important predictor of GDM (Mikola et al., 2001; Turhan et al., 2003). In contrast, 
de Wilde et al. (2014) – who studied preconception predictors of GDM – concluded that BMI, waist 
circumference and waist/hip ratio were no significant predictors of GDM in adult women with PCOS. 
Han et al. (2011) studied the influence of overweight (BMI > 25kg/m²) on the pregnancy outcome in 
Asian women with PCOS. Using a case-control design of overweight versus normal weight women, 
their results showed a significantly increased prevalence of GDM and fetal macrosomia in overweight 
women with PCOS when compared with normal weight women with PCOS (p < .014 and p < .001, 
respectively).  
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1.8 Aim of this dissertation and methodology  
  
The general objective of this dissertation is to do research about psychological, perinatal, lifestyle and 
health-economic aspects of the polycystic ovary syndrome that really matter for the patient, her family 
and the society.  
More specifically, the following research questions are studied: 
1) How are objective PCOS characteristics and PCOS-related concerns associated with the level of 
sexual and relational satisfaction of women with PCOS and their partners? 
A cross-sectional study is set up and a validated questionnaire (i.e., the Maudsley Marital 
Questionnaire; MMQ) is used to measure the level of sexual and relational satisfaction of women 
with PCOS as well as of their partner. Dyadic statistical analyses are performed to take into account 
the interdependence of both partners in a couple and to explore potential differences between 
partners in the association of subjective and objective PCOS characteristics with the satisfaction 
level (Chapter 3). 
2) What is the influence of overweight on the pregnancy, delivery and neonatal outcome in women 
with PCOS? 
A retrospective comparative cohort study is set up and multivariate statistical analyses are 
performed in order to investigate the influence of overweight and to take into account the possible 
influence of several confounding variables (Chapter 4). 
3) What is the evolution of the HRQoL and the BMI of overweight adult women with PCOS during a 
24-week lifestyle modification program? 
A 24-week lifestyle modification program, consisting of an individualized diet, exercise and 
psychological subprogram is set up for overweight (BMI ≥ 25 kg/m²) adult (age of 18-43 years) 
women with PCOS. Using a prospective within-patient design, changes in BMI and HRQoL of those 
women are evaluated. The PCOSQ is used to measure the perceived level of HRQoL and an acne 
parameter is included to evaluate the influence of acne on the perceived level of HRQoL (Chapter 
5). 
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4) What is the cost-effectiveness of gonadotropin therapy and LOD in clomiphene citrate resistant 
women with PCOS? 
A retrospective CEA comparing gonadotropin therapy with LOD in CC resistant women with PCOS 
is performed using a societal approach. As such, the total cost covered by the society is studied, 
including (a) the cost covered by the public payer (i.e., direct medical cost), (b) the cost covered by 
the patient (i.e., direct medical cost and transportation cost), and (c) the costs related to 
productivity loss . Effectiveness of treatment is expressed in ongoing pregnancy rate and number 
of live-born children (Chapter 6). 
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Abstract 
 
Study question: How are objective characteristics of the polycystic ovary syndrome (PCOS) and PCOS-
related concerns associated with the sexual and relational satisfaction of PCOS women and their 
partners? 
Summary answer: Both objective PCOS characteristics (parity, women’s body mass index (BMI) and 
current unfulfilled wish to conceive) and PCOS-related concerns (women’s infertility-related and acne-
related concerns) were associated with sexual and/or relational satisfaction, although some 
associations differed for PCOS women and their partners. 
What is known already: There is some evidence indicating an association between objective PCOS 
characteristics and sexual satisfaction of PCOS women, but this evidence is conflicting, scarce, and 
often no validated questionnaires are used to evaluate sexual satisfaction. No evidence is available 
about the association of (i) PCOS with relational satisfaction; (ii) PCOS-related concerns with sexual 
and relational satisfaction; and (iii) PCOS with sexual and relational satisfaction as experienced by 
partners of PCOS women. 
Study design, size, duration: We set up a cross sectional study from April 2007 till April 2009 including 
31 overweight (BMI ≥ 25 kg/m²) women with PCOS at reproductive age as well as their partners with 
who they had a committed intimate relationship at the time of recruitment. 
Participants/materials, setting, methods: The study was performed at the fertility center of the Ghent 
University Hospital. Objective PCOS characteristics were registered and PCOS-related concerns were 
evaluated by the PCOS Questionnaire. Sexual (SS) and relational (RS) satisfaction were measured by the 
Maudsley Marital Questionnaire (MMQ). Dyadic statistical analyses were performed using linear mixed 
models (α < 0.05). 
Main results and the role of chance: A lower parity tended to be associated with higher levels of sexual 
and relational satisfaction, with a significantly stronger association in PCOS women than their partners 
(p(SS) = .015 and p(RS) = .009). A higher BMI tended to be associated with lower and higher satisfaction 
levels (sexual and relational) in PCOS women and their partners, respectively, with a significantly 
stronger association in the partners (p(SS) = .029 and p(RS) = .021). The presence of a current unfulfilled 
wish to conceive and a higher level of infertility-related concerns was significantly stronger associated 
with a higher level of PCOS women’s relational satisfaction than their partners’ (p(RS) = .021 and p(RS) 
= .011, respectively). And higher levels of acne-related concern were significantly associated with lower 
levels of sexual satisfaction in PCOS women (p(SS) = .025) and their partners (p(SS) = .002). 
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Limitations, reasons for caution: The fact that this study was performed in a sample of PCOS women 
who were all overweight and the small sample size are important limitations. Data were partially 
missing in some couples but this limitation was dealt with by using linear mixed models. 
Wider implications of the findings: Our results suggest a differential association of PCOS with sexual 
and relational satisfaction between PCOS women and their partners. This should be kept in mind 
during the psychological guidance of couples dealing with PCOS. 
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Introduction 
The polycystic ovary syndrome (PCOS) is a common endocrine disorder in women of reproductive age 
(Broekmans et al., 2006). It is characterized by menstrual disorders, anovulatory subfertility, hirsutism, 
acne, biochemical signs of hyperandrogenism, obesity and insulin resistance (The Rotterdam 
ESHRE/ASRM-sponsored PCOS consensus workshop group, 2004; Drosdzol et al., 2007). Due to these 
characteristics, PCOS is found to be a trigger for psychological morbidity, with PCOS women reporting 
to feel different, less feminine, and more depressed when compared with non-PCOS women 
(Elsenbruch et al., 2003; Snyder, 2006; Jones et al., 2008). There is also preliminary evidence that PCOS 
characteristics negatively affect various aspects of women’s sexual life. More specifically, PCOS women 
often report to feel less attractive and to be less sexually satisfied when compared with non-PCOS 
women (Elsenbruch et al., 2003; Drosdzol et al., 2007; Tan et al., 2008; Månsson et al., 2011).  
Although these results are promising, existing research on how PCOS affects women’s sexual and 
intimate relationships is limited in several ways. Firstly, findings from studies on the specific objective 
characteristics of PCOS that affect women’s level of sexual satisfaction appear to be contradictory. 
More specifically, indicators of hyperandrogenism were found to have a negative effect (i.e. Ferriman-
Gallwey score of hirsutism) in the Drosdzol et al. (2007) study but no effect (i.e. self-reported state of 
hirsutism and total serum testosterone) in the Stovall et al. (2012) study on PCOS women’s sexual 
satisfaction. Similar conflicting evidence has been found for the association of PCOS women’s body 
mass index (BMI) with their sexual satisfaction and functioning (Elsenbruch et al., 2003; Hahn et al., 
2005; Månsson et al., 2011; Stovall et al., 2012). Secondly, previous PCOS-studies focusing on sexuality 
relied on questionnaires that were often not psychometrically validated. Also, sexual satisfaction was 
at times measured by means of questionnaires evaluating women’s sexual functioning, rather than 
satisfaction, and including only some items pertaining to their level of sexual satisfaction (Elsenbruch 
et al., 2003; Hahn et al., 2005; Drosdzol et al., 2007; Tan et al., 2008; Månsson et al., 2011). Thirdly, 
studies to date did not examine how women’s subjective experience of PCOS-related characteristics is 
related to their sexual life. This is surprising, as a stressor’s (like PCOS) objective characteristics need 
to be conceptually and methodologically differentiated from a person’s perception of and reaction to 
a stressor; moreover, the perception of a stressor is theoretically and empirically more directly related 
to individual and relational well-being than its objective characteristics (Weber, 2011). Fourthly, as 
existing research on PCOS and sexual satisfaction/functioning exclusively focused on the perspective 
of PCOS women, little is known about how partners of PCOS women experience their intimate 
relationship. Finally, previous studies limited their scope to sexual satisfaction whereas they did not 
investigate how PCOS affects other non-sexual aspects of long-term intimate relationships, like a 
couple’s level of relational satisfaction. The latter refers to how good or bad couples judge their 
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intimate relationship to be, and reflecting partners’ feelings of mutual understanding, tensions in the 
relationship, their commitment to the relationship, etc. (Bradbury & Karney, 2010). Furthermore, 
couple’s relational satisfaction correlates strongly with their level of sexual satisfaction (Christopher & 
Sprecher, 2000; Sprecher & Cate, 2004). 
Sexual as well as relational satisfaction are essential characteristics of intimate relationships, and 
important predictors of both relationship stability and partner’s subjective well-being (Bradbury & 
Karney, 2010). Given its symptomatology, PCOS is assumed to be a chronic stressor for couples to deal 
with, and to have the potential to undermine both partners’ sexual and relational satisfaction. In order 
to develop evidence-based psychological interventions for PCOS women and their partners, research 
on the intimate life of couples facing PCOS is essential. Therefore, the present study examined how (i) 
both objective PCOS characteristics and PCOS-related concerns relate to (ii) sexual as well as relational 
satisfaction, of (iii) PCOS women and their intimate partner. As a point of major empirical and clinical 
interest, we also explored potential differences between PCOS women and their partners in the 
association between PCOS characteristics on the one hand and sexual and relational satisfaction on 
the other hand, by performing dyadic statistical analyses. Psychometrically validated questionnaires 
were used to assess all the variables included in the current study.  
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Materials and methods 
We set up a cross sectional study at the Department of Reproductive Medicine of the Ghent University 
Hospital from April 2007 till April 2009. This study was performed in the context of a lifestyle 
modification program for overweight women with PCOS between the age of 18 and 43 years old (n = 
33). The PCOS women who were involved in a committed intimate relationship at the start of that 
program (n = 31) were eligible for the current study. At the start of the lifestyle modification program, 
all 31 PCOS women as well as their partners were informed about the current study by the treating 
physician and all agreed to participate. PCOS was diagnosed by a gynecologist according to the 
Rotterdam criteria (The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group, 2004). 
Objective characteristics of PCOS 
Overweight was diagnosed as a BMI of ≥ 25 kg/m² (WHO, 2010). Clinical hyperandrogenism was 
diagnosed by evaluating the presence of visible hair growth and facial acne. The degree of visible hair 
growth was indicated by the modified Ferriman-Gallwey (mFG) scale and women were classified as 
hirsute when they had an mFG-score ≥ 8 (Ferriman & Gallwey, 1961; Yildiz et al., 2010). The acne 
parameter was evaluated by asking women whether facial acne was present or not. 
Hyperandrogenemia was diagnosed by the presence of a free testosterone (fT) level > 0.50 ng/dL, 
which was determined at Day 2 or 3 of a spontaneous or induced menstrual cycle. The menstrual cycle 
was categorized as irregular in case of no menstrual bleeding for > 35 days or > 6 months. Parity and 
gravidity, both indicators of subfertility, were registered and women were also asked if they had a 
current unfulfilled wish to conceive.  
PCOS-related concerns 
To evaluate women’s subjective PCOS-related concerns, the PolyCystic Ovary Syndrome Questionnaire 
(PCOSQ) and an acne Visual Analogue Scale (VAS) were used (Cronin et al., 1998; Guyatt et al., 2004). 
All PCOS women were given basic instructions to fill out the questionnaire around their first 
consultation in the lifestyle modification program. The 26-item PCOSQ consists of five domains: 
emotions (e.g., ‘being worried about having PCOS’ or ‘having a low self-esteem as a result of having 
PCOS’), body hair, weight, infertility problems and menstrual problems. Each item of the questionnaire 
was scored on a 7-point Likert scale (1 = high concern, 7 = no concern), with higher scores 
corresponding with lower levels of PCOS-related concern (Cronin et al., 1998). For each PCOS woman, 
the mean score of all domain-specific items and the mean score of the five domain scores generated 
the score of each PCOSQ domain and the total PCOSQ score, respectively. Whereas, in the original 
version of the PCOSQ, a time frame of 2 weeks is chosen for PCOS women to report their subjective 
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experience of PCOS (Cronin et al., 1998), the current study used a time frame of 6 months in order to 
have a view on the patient’s subjective experience of PCOS over a larger period of time. In the current 
study, the total PCOSQ scale and the 5 separate PCOSQ domain scales showed acceptable to excellent 
reliability (Cronbach’s alpha’s between .61 and .95). In order to evaluate the subjective experience of 
the presence of facial acne, PCOS women indicated to what extent the presence of facial acne 
influenced their quality of life on a VAS (0 = no influence, 10 = great influence). Contrary to the PCOSQ 
scores, higher VAS scores reflect higher levels of acne-related concern. 
Sexual and relational satisfaction 
Sexual and relational satisfaction of PCOS women and their partners were assessed by means of the 
Maudsley Marital Questionnaire (MMQ; Arrindell et al., 1983). The MMQ was filled out by the PCOS 
women as well as by their partners around their first consultation in the lifestyle modification program. 
The MMQ includes 20 items, each rated on a 9-point Likert scale that ranges from 0 = high satisfaction 
to 8 = low satisfaction. The sexual satisfaction subscale and the marital satisfaction subscale were used 
to assess each participant’s subjective evaluation of their sexual life and intimate relationship, 
respectively. Subscale-scores were calculated separately for the PCOS women and their partners by 
computing the sum of their responses on all items in the respective subscales. Scores on the sexual 
satisfaction subscale could range from 0 to 40 and on the marital satisfaction subscale from 0 to 80, 
with higher scores reflecting lower levels of satisfaction. The psychometric qualities of the Dutch 
version of the MMQ are confirmed (Arrindell et al., 1983; Arrindell & Schaap, 1985; Joseph et al., 2007). 
In this study, Cronbach’s alpha’s were adequate to good (between .70 and .84) indicating an acceptable 
internal consistency for all the subscales. 
Ethical consent 
This study has been authorized by the Ethics Committee of the Ghent University Hospital. Couples gave 
their written informed consent for participation and follow-up. 
Statistical analysis 
The association between PCOS characteristics on the one hand, and sexual satisfaction (SS) and 
relational satisfaction (RS) of PCOS women and their partners on the other hand, was analyzed by using 
linear mixed models (LMM). Dyadic analyses were performed to take into account the 
interdependence of both partners in a couple and to explore potential differences between partners 
in the association of PCOS characteristics with satisfaction. For each outcome variable separately, a 
mixed model accounting for the correlation within dyads was fitted. Models with objective predictors 
(i.e. objective PCOS characteristics) and subjective predictors (i.e. PCOS-related concerns) separately 
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were built using forward-stepwise regression. For each of the predictors we allowed for a different 
association for the PCOS women and their partners. Couples with a missing outcome in one of the 
partners were included in the LMM analysis, but missingness in the predictors implied the deletion of 
the data from that couple. Effect sizes reflecting the effect of each predictor on the PCOS woman’s and 
their partner’s outcome together were calculated using Cohen’s f² (Selya et al., 2012). f² effect sizes of 
0.02, 0.15, and 0.35 are termed small, medium, and large, respectively. The MMQ sexual and relational 
satisfaction subscale scores of both PCOS women and their partners were compared with published 
normative data from a sample of heterosexual, married adults (Joseph et al., 2007) by means of a one-
sample t-test. The LMM analyses, including the calculation of the effect sizes, were performed using 
SAS version 9.3. All other statistical analyses were performed using SPSS version 22.0. The statistical 
significance level was set at α < 0.05.  
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Results 
Descriptive statistics 
The PCOS women and their partners had an average age of 30.1±5.1 and 34±6.3 years respectively (p 
= .01). The median length of their relationship was 63 (IQR 89.7) months and 20/31 (64.5%) were 
married. One couple was lesbian. 
The values for objective PCOS characteristics, PCOS-related concerns (reported by PCOS women), as 
well as sexual/relational satisfaction (reported by both partners) are presented in Table I. Ninety 
percent (28/31) of the PCOS women filled out the PCOSQ. The response rate on the MMQ was 27/31 
(87.1%) and 24/31 (77.4%) for PCOS women and their partners, respectively. The MMQ sexual and 
relational satisfaction subscale-scores were significantly higher in PCOS women in comparison to their 
partners (p(SS) = .017 and p(RS) = .007). There was a significant positive correlation for sexual and 
relational satisfaction between PCOS women and their partners (r = .83, p < .001 and r = .88, p < .001, 
respectively). 
Dyadic analyses 
When testing for the association of objective PCOS characteristics with participants’ level of sexual and 
relational satisfaction, the following results emerged (Table II): Firstly, a lower parity tended to be 
associated with higher levels of sexual and relational satisfaction in both PCOS women and their 
partners. However, this association was significantly stronger for PCOS women than for their partners 
(p(SS) = .015 and p(RS) = .009). Secondly, a higher BMI of PCOS women tended to be associated with lower 
levels of sexual and relational satisfaction of PCOS women, whereas a higher BMI of PCOS women 
tended to be associated with higher levels of sexual and relational satisfaction of their partners. This 
association of BMI was significantly different between the PCOS women and their partners (p(SS) = .029 
and p(RS) = .021). Thirdly, the presence of a current unfulfilled wish to conceive tended to be associated 
with higher levels of relational satisfaction in both PCOS women and their partners. This association 
was significantly stronger in PCOS women than their partners (p(RS) = .021). 
Analyses for the PCOS-related concerns – as reported by PCOS women – (see Table II) revealed that 
higher levels of infertility-related concern were significantly associated with higher levels of relational 
satisfaction in PCOS women (p(RS) = .028). Higher levels of infertility-related concern also tended to be 
associated with higher levels of relational satisfaction in the partners of PCOS women. This association 
was significantly stronger in PCOS women than their partners (p(RS) = .011). Finally, higher levels of 
acne-related concern were significantly associated with lower levels of sexual satisfaction of PCOS 
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women (p(SS) = .025) and their partners (p(SS) = .002). This association was not significantly different 
between PCOS women and their partners. 
The effect sizes for all the associations discussed above can be considered as at least medium, except 
for the association of subjective acne-related concern with sexual satisfaction (see Table II). 
Comparison of participants’ sexual/relational satisfaction scores with normative data 
Joseph et al. (2007) reported a mean (± standard deviation) MMQ sexual and relational satisfaction 
subscale score of 9.15 (± 7.25) and 14.91 (± 11.76), respectively for a sample of heterosexual, married 
women (n = 396). For heterosexual, married men (n = 391) the scores were 8.18 (± 7.14) and 12.24 (± 
9.54), respectively (Joseph et al., 2007). 
In our study, sexual satisfaction levels of the PCOS women and their partners (figures see Table I) 
tended to be lower (p = 0.7) and higher (p = 0.7), respectively, when compared with that reference 
sample. Relational satisfaction levels of the PCOS women and their partners were significantly higher 
(p = 0.01 and p = 0.002, respectively) when compared with that reference sample.  
Chapter 2 
60 
Discussion 
In the current study, we investigated the association of PCOS (i.e. objective PCOS characteristics and 
PCOS-related concerns) with the sexual and relational satisfaction of couples dealing with PCOS, as 
well as differences in those associations between PCOS women and their partners. Our results suggest 
that objective PCOS characteristics (parity, women’s BMI and current unfulfilled wish to conceive) as 
well as subjective PCOS-related concerns (women’s infertility-related and acne-related concerns) are 
associated with the sexual and/or relational satisfaction of couples dealing with this chronic disease. 
Most of these associations were significantly different for PCOS women and their partners. 
Firstly, we found that a lower parity tended to be associated with higher levels of sexual and relational 
satisfaction in both PCOS women and their partners. In contrast, the case-control study by Månsson 
et al. (2011) concluded that having children or not was not associated with sexual functioning of PCOS 
women, as measured by the McCoy female sexual rating scale. Additionally, we observed that the 
presence of a current unfulfilled wish to conceive and a higher level of infertility-related concerns was 
(significantly) associated with higher levels of relational satisfaction in both PCOS women and their 
partners. This pattern of results might be explained by the fact that childless couples (i.e. parity = 0) 
have possibly more time for each other than couples with children (Claxton & Perry-Jenkins, 2008; 
Lawrence et al., 2008), and that, in case of unwanted childlessness, couples with fertility problems 
probably have a more stable and satisfying relationship (Månsson et al., 2011). It should be noted, 
however, that existing evidence on the infertility-satisfaction association is inconsistent. For example, 
Bringhenti et al. (1997) reported, on the one hand, a significantly higher level of relational satisfaction 
in women with explained infertility when compared with women without fertility problems, but – on 
the other hand – no significant differences in relational satisfaction level in women with unexplained 
infertility when compared with women without fertility problems. Also, Monga et al. (2004) found 
significantly and non-significantly lower levels of relational satisfaction in infertile versus fertile women 
and infertile versus fertile men, respectively. 
In our study, we observed no association of a current unfulfilled wish to conceive and infertility-related 
concerns with sexual satisfaction in PCOS women and their partners. This is in line with the Tan et al. 
(2008) study in which no difference was found in women’s satisfaction with their sex life – as measured 
by using a VAS – between a group of PCOS women with or without a wish to conceive. Similarly, the 
Iris et al. (2013) study found no significant differences in sexual satisfaction levels between a sample 
of infertile women and a control group. In contrast Shoji et al. (2014) reported lower sexual satisfaction 
levels in both partners of infertile couples when compared with both partners of pregnant couples. 
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Secondly, since PCOS is often accompanied by changes in women’s physical appearance (e.g., obesity, 
hirsutism and acne), one should expect a substantial influence of these symptoms on couple’s sexual 
and relational satisfaction. In line with this expectation we observed – taking into account that only 
overweight women with PCOS were included in the current study – a trend towards an association 
between a higher BMI and lower levels of sexual and relational satisfaction in PCOS women. To our 
knowledge, there is currently no evidence available about the association of BMI with relational 
satisfaction in a general female population. Our findings on sexual satisfaction are in line with the study 
by Månsson et al. (2011) in which a trend towards a negative association of an increased BMI with 
PCOS women’s sex life was found. Also in the Yaylali et al. (2010) study a significant negative 
correlation between weight and the level of sexual satisfaction was found; Brody & Weiss (2013) 
reported a significant negative correlation between a woman’s waist circumference and her level of 
sexual satisfaction.  
A series of studies also documents the opposite pattern. For example, Elsenbruch et al. (2003) and 
Stovall et al. (2012) concluded that differences in BMI status were not associated with PCOS women’s 
level of sexual satisfaction. Similarly, two studies – performed in a general female sample – found that 
overweight and obesity (as expressed by BMI) were no risk factors for sexual satisfaction (as measured 
by the Female Sexual Function Index) (Kadioglu et al., 2010; Yaylali et al., 2010).  
Within partners of PCOS women, a higher BMI of PCOS women tended to be associated with higher 
levels of sexual and relational satisfaction. To our knowledge, there is currently no evidence available 
from other PCOS studies, nor from non-PCOS studies about this association in a general male sample 
with which our results could be compared. 
We also observed that higher levels of acne-related concern in PCOS women were significantly 
associated with lower levels of sexual satisfaction within both PCOS women and their partners. The 
study by Hahn et al. (2005) and by Stovall et al. (2012) reported no significant association of the 
objective presence of acne with the level of sexual satisfaction and sexual functioning of PCOS women. 
However, our results reflect the association of PCOS women’s concern about the presence of acne 
with satisfaction, rather than the  association of the objective degree of acne with satisfaction. 
As the evidence about the association of PCOS characteristics (e.g., BMI, infertility) with 
sexual/relational satisfaction is inconsistent across samples of infertile and obese women, no 
conclusions can be drawn about the nature of these associations within those samples. Moreover, 
since we do not know with certainty whether all women included in these studies were women without 
PCOS, it is not possible to make a statement about these associations in a non-PCOS population. Taken 
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together, it is hard to compare our findings with evidence from a non-PCOS population and it is even 
harder to decide if our findings are unique to a PCOS population.  
It should be noted however, that the association of PCOS characteristics with the level of 
sexual/relational satisfaction might possibly be explained by the influence of confounding factors. For 
example, depression might influence the association of PCOS with sexual satisfaction, given – on the 
one hand – the increased depression level in PCOS women compared with age-matched controls 
(Elsenbruch et al., 2003), and – on the other hand - the significant association of an increased 
depression level with a decreased sexual satisfaction level in a general sample of sexually active 
females (Kadioglu et al., 2010). Unfortunately, we were not able to correct our analyses for this 
confounding factor since we had no detailed information about the presence of depression at the time 
of recruitment. Nevertheless, given this existing evidence, caution is warranted when interpreting the 
association of PCOS with the level of sexual satisfaction as reflecting a direct association. This also 
stresses the importance of adjusting the performed analyses for confounding factors in future research. 
Thirdly, we found significantly lower levels of sexual and relational satisfaction in PCOS women when 
compared with their partners. Thus far, only one study reported on the differential influence of a 
chronic disease on the satisfaction of both partners in a couple. A study by Van Son-Schoones (1994), 
investigating the sexual and relational satisfaction (among others) of patients with a chronic kidney 
disease, observed significantly higher levels of relational satisfaction in patients than their partners (t 
= -3.46, p < .001). It should be noted, however, that the study by Van Son-Schoones (1994) included 
female as well as male patients and the interdependence of both partners in a couple was not taken 
into account (only half of the patient’s partners participated in the study and no dyadic statistical 
analyses were performed). 
To further clarify this finding we compared our results with published normative data on the MMQ 
(Joseph et al., 2007).  In that reference sample, the level of sexual and relational satisfaction seemed 
to be lower in married women than in married men. Although no significance level is reported by 
Joseph et al. (2007), this finding is in line with our results. However, we must be aware of the fact that 
our group of partners include one female partner. 
The observed relational satisfaction levels of the PCOS women as well as their partners in our sample 
were both found to be significantly higher than those in a reference sample (Joseph et al., 2007). These 
findings suggest that couples participating in our study were generally satisfied about the non-sexual 
aspect of their intimate relationship; our results therefore await replication within samples of 
distressed couples dealing with PCOS. 
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The present study both complements and elaborates upon existing research on PCOS and intimate 
relationships. An important strength of this study is that dealing with PCOS was analyzed from a dyadic 
point of view, by including PCOS women and their partners, focusing on multiple aspects of intimate 
relationships, and by conducting dyadic statistical analyses taking into account the interdependence 
of both partners in a couple. We should, however, note some limitations of the current study. The 
most important of these undoubtedly have to do with the small sample used in the present study.  A 
simulation study to explore the power to detect effects of varying size in the current study was 
performed. Mimicking the data-structure and the observed within-cluster correlation, we found that 
with 30 couples the study has about 80% power to detect large effects at the 5% significance levels. 
The power to detect low to medium effects is smaller than 50%. This might be a reason why certain 
small effects, found in other studies, were not detected in our study. And although the response rate 
on all questionnaires was quite high, data were partially missing in some couples which resulted in an 
unbalanced data set. This limitation was dealt with by using linear mixed models. Due to these 
limitations we suggest that this study should be replicated in a larger sample using the same 
standardized questionnaires and statistical dyadic analytic techniques in order to enhance the 
generalizability of the results. Additionally - since this study was performed in a sample of PCOS women 
who were all overweight - it is also recommended to recruit from a broader population including 
normal weight PCOS women as well, in order to further clarify the association of overweight with 
couple’s sexual and relational satisfaction and to enhance the generalizability of the results to a general 
population of couples dealing with PCOS. Finally, causal relationships can’t be tested in the present 
data and the issue of causal ordering remains for future research to resolve. 
In conclusion, our results suggest that objective PCOS characteristics as well as subjective PCOS-related 
concerns are associated with the sexual and relational satisfaction of couples dealing with this chronic 
disease. The second conclusion that can be drawn from our findings is that there is a differential 
association of these characteristics with satisfaction levels for PCOS women and their partners. This is 
an important finding which should be kept in mind during the psychological guidance of couples 
dealing with PCOS.  
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Table I. Descriptive statistics of predictors and outcome variables. 
  
Predictors  
Objective characteristics of the polycystic ovary syndrome (PCOS)  
Presence of hirsutism 13/30 (43.3%) 
Presence of facial acne 15/31 (48.4%) 
Free testosterone (ng/dL) 0.73 (0.77) 
Body mass index (kg/m²) 33.7 (7) 
Current unfulfilled wish to conceive 24/31 (77.4%) 
Gravidity  
     0 21/31 (67.7%) 
     1 5/31 (16.1%) 
     ≥2 5/31 (16.1%) 
Parity  
     0 24/31 (77.4%) 
     1 5/31 (16.1%) 
     2 2/31 (6.5%) 
Irregular menstrual cycle 29/31 (93.5%) 
PCOS-related concernsa  
Emotions 4.1 (1.4) 
Body hair 4.8 (3.7) 
Weight 2.7 (1.8) 
Infertility problems 3 (1.4) 
Menstrual problems 3.3 (1.7) 
Acne 1 (6.6) 
  
Outcome variablesb  
Women with PCOS  
Sexual satisfaction 9.85±8.01 
Relational satisfaction 10.59±8.13 
Partners  
Sexual satisfaction 7.63±6.05 
Relational satisfaction 8.13±5.74 
    
Continuous measurements are summarized as mean±SD if symmetrically distributed, and as 
median (interquartile range) otherwise. 
Nominal measurements are summarized as n(%). 
aPCOS-related concerns as measured by the PolyCystic Ovary Syndrome Questionnaire and an 
acne Visual Analogue Scale. 
bOutcome variables as measured by the sexual and marital satisfaction subscale of the 
Maudsley Marital Questionnaire. 
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Abstract 
 
Study question: Do overweight women with polycystic ovary syndrome (PCOS) have a higher risk of 
perinatal complications than normal weight women with PCOS? 
Summary answer: Overweight women with PCOS with an ongoing singleton pregnancy have an 
increased risk of preterm birth as well as an increased risk of giving birth to a baby with a higher 
birthweight than normal weight women with PCOS. 
What is known already: There is evidence that overweight (BMI > 25 kg/m²) has a negative influence 
on the prevalence of gestational diabetes mellitus and fetal macrosomia in women with PCOS. 
Study design, size, duration: We set up a retrospective comparative cohort study of 93 overweight 
(BMI ≥ 25 kg/m²) and 107 normal weight (BMI < 25 kg/m²) women with PCOS who were scheduled for 
fertility treatment between January 2000 and December 2009 and achieved a pregnancy as a result of 
a treatment cycle, or spontaneously before or between treatment cycles. 
Participants/materials, setting, methods: All data (patient characteristics, medical information, 
pregnancy, delivery and neonatal outcome) were retrieved from patient medical files. All pregnancy, 
delivery and neonatal outcome parameters were adjusted for age and pre-pregnancy smoking 
behaviour. The neonatal outcome parameters were additionally adjusted for gestational age.    
Main results and the role of chance: The median BMI in the overweight and normal weight women 
was, respectively, 30.8 kg/m² [interquartile quartile range (IQR) 5.8] and 20.9 kg/m² (IQR 2.3) (P < 
0.001). Baseline characteristics did not differ between groups, except for free testosterone and fasting 
insulin levels, which were higher, and sex hormone-binding globulin, which was lower, in overweight 
versus normal weight women (all P < 0.001). The time-to-pregnancy was significantly higher in the 
overweight group (P = 0.01). Multivariate analyses of the ongoing singleton pregnancies showed 
significantly more preterm births in overweight (10/61) versus normal weight (2/71) women [adjusted 
odds ratio 14.2, 95% confidence interval (CI) 1.8 to 155.6, P = 0.01]. The mean birthweight of newborns 
was significantly higher in overweight (3386±663 g) than in normal weight (3251±528 g) women 
(adjusted mean difference 259.4, 95% CI 83.4 to 435.4, P = 0.004). 
Limitations, reason for caution: Our results only represent the pregnancy, delivery and neonatal 
outcome of ongoing singleton pregnancies. The rather small sample size and observational nature of 
the study are further limitations.  
Wider implications of the findings: Our results suggest the importance of pre-pregnancy weight loss 
in overweight women with PCOS in order to reduce the risk of adverse perinatal outcomes. 
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Introduction 
Polycystic ovary syndrome (PCOS) is an endocrine disorder present in approximately 5-10% of women 
of reproductive age (Hoeger et al., 2004; Broekmans et al., 2006). It is characterized by the presence 
of oligo- or amenorrhea, polycystic ovaries, hirsutism, raised LH:FSH ratio, insulin resistance (IR) and 
compensatory hyperinsulinemia (The Rotterdam ESHRE/ASRM-sponsored consensus workshop group, 
2004). IR has an important influence on the development of diabetes type 2 and hypertension 
(Perciaccante et al., 2006). Hypertension is thought to be associated with androgen excess and a 
subsequent increased stimulation of sympathetic nerve activity (Perciaccante et al., 2007, Studen et 
al., 2013). Abdominal overweight and obesity – also important components of PCOS that affect about 
30-70% of the PCOS population (Pasquali et al., 2006; Vrbikova & Hainer, 2009) – are associated with 
IR, increased testosterone production (Pasquali et al., 2006) and increased stimulation of sympathetic 
nerve activity (Troisi et al., 1991; Scherrer et al., 1994). 
Polycystic ovary syndrome in itself has a negative influence on the perinatal outcome for these women. 
There is evidence that women with PCOS are at increased risk of early pregnancy loss and miscarriages 
(Wang et al., 2001), which could possibly be caused by pre-pregnancy LH hypersecretion (Regan et al., 
1990), hyperandrogenemia (Okon et al., 1998; Kazerooni et al., 2013), overweight (Fedorcsák et al., 
2000), hyperinsulinemia and/or thrombophilia (Kazerooni et al., 2013). In women with PCOS, 
pregnancy is often complicated by pregnancy-induced hypertension, preeclampsia and gestational 
diabetes mellitus (GDM) and also the risk for a preterm delivery or a delivery by Caesarean section is 
raised (Boomsma et al., 2006; Altieri et al., 2010; Kjerulff et al., 2011; Qin et al., 2013). The newborn 
babies stay more frequently in a neonatal intensive care unit and perinatal mortality also occurs more 
frequently (Boomsma et al., 2006; Qin et al., 2013). Since it has been proven that pre-pregnancy 
maternal overweight and obesity have a negative influence on the perinatal outcome (Bogaerts et al., 
2012; Blomberg , 2013; Cnattinguis et al., 2013; Crane et al., 2013), existing retrospective studies 
comparing the perinatal outcome in women with PCOS versus women without PCOS have matched 
the samples for BMI or have adjusted the analyses for BMI. As such, Mikola et al. (2001) and Turhan et 
al. (2003), looking into the pregnancy, delivery and neonatal outcome in women with PCOS, concluded 
that pre-pregnancy overweight (BMI > 25 kg/m²) is an important predictor of GDM. A study by Han et 
al. (2011) of Asian women looked into the influence of overweight (BMI > 25 kg/m²) on the pregnancy 
outcome in women with PCOS, using a case-control design of overweight versus non-overweight 
women, and showed that the prevalence of GDM and fetal macrosomia was significantly higher in 
overweight versus normal weight women with PCOS. 
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Since these studies are rather scarce and, to date, only performed in an Asian population, we 
performed a retrospective cohort study comparing the pregnancy, delivery and neonatal outcome in 
overweight versus normal weight women with PCOS using multivariate analyses.   
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Materials and methods 
Design 
A retrospective comparative cohort study was conducted at the Department of Reproductive Medicine 
of the Ghent University Hospital, Ghent, Belgium. The study population included 93 overweight and 
107 normal weight women with PCOS between the age of 18 and 43 years who were pregnant (i.e. 
positive hCG at 4 weeks after the start of the last menstrual cycle) as a result of a treatment cycle, or 
spontaneously before the start or between treatment cycles. All study participants were scheduled for 
a treatment at the fertility center between January 2000 and December 2009. There was no upper BMI 
limit impeding women from undergoing a fertility treatment. Only the first pregnancy was taken into 
account. PCOS was diagnosed using the diagnostic criteria of the Rotterdam consensus 2003 (The 
Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group, 2004). Women scheduled for a 
fertility treatment between 2000 and 2003 were reclassified as PCOS patients according to the 
Rotterdam criteria. Those women who fulfilled these criteria, were included in the study. Women with 
pathologies (such as congenital adrenal hyperplasia, Cushing’s syndrome, and androgen-secreting 
tumors) which present or imitate the same characteristics as PCOS were excluded. All data (patient 
characteristics, medical information, pregnancy, delivery and neonatal outcome) were retrieved from 
patient medical files. If delivery took place in another hospital, data on pregnancy, delivery and 
neonatal outcome were obtained through the treating gynecologist of that hospital. 
Measures 
A polycystic ovarian morphology (PCOM) was diagnosed by means of transvaginal ultrasound showing 
the presence of ≥ 12 follicles with a diameter of 2-9 mm and/or an increased ovarian volume of > 10 
cm³ (using the formula 4/3 π abc). Participants were described as having an irregular menstrual cycle 
if they had oligomenorrhea (i.e. no menstrual bleeding for > 35 days) or amenorrhea (i.e. no menstrual 
bleeding for > 6 months). Hirsutism was diagnosed by the presence of a self-reported mild or severe 
degree of visible hair growth, and hyperandrogenemia was diagnosed by the presence of a free 
testosterone (fT) level  > 0.50 ng/dL. An LH:FSH ratio > 2 was classified as abnormal. Basal hormone 
levels [i.e. LH, FSH, testosterone, fT and sex hormone-binding globulin (SHBG)] were determined at 
day 2 or 3 of a spontaneous or induced menstrual cycle and – in case of a hormonal treatment – prior 
to that therapy. Fasting insulin and glucose levels were also assessed. Biochemical analyses were 
performed at the laboratory of the Ghent University Hospital using the electrochemiluminiscence 
immunoassay  technique (Modular, Roche Diagnostics, Mannheim, Germany). Pre-pregnancy 
overweight was defined as a BMI of ≥ 25 kg/m² (WHO, 2010). All normal weight women had a pre-
pregnancy BMI below 25 kg/m2. The participant’s body weight and height were measured before the 
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fertility treatment by using an electronic personal scale and a stadiometer respectively in order to 
calculate their BMI. The pre-pregnancy smoking behaviour was evaluated as present (i.e. at least one 
cigarette a day) or not (yes/no answer). It could not be determined whether the women who were 
known to be smokers, continued smoking or quitted during pregnancy. 
To study the pregnancy outcome, data on the presence of miscarriage, multiple pregnancy, 
hypertension during pregnancy, preeclampsia and diabetes during pregnancy were collected. A 
miscarriage was classified as a first or second trimester miscarriage when loss of the fetus occurred in 
the first 13 weeks of pregnancy or between 14 and 25 weeks of pregnancy, respectively. Since we had 
no data on blood pressure and the diabetic status of each woman before pregnancy, we used the term 
hypertension during pregnancy (HDP) and diabetes during pregnancy (DDP) instead of pregnancy-
induced hypertension and GDM, respectively. Preeclampsia was diagnosed by the presence of 
hypertension during pregnancy (i.e. a blood pressure > 140/90 mmHg) and proteinuria > 300 mg/day. 
According to the guidelines of the American Diabetes Association, DDP was diagnosed at 
approximately 24 weeks of gestation using the oral glucose tolerance test (American Diabetes 
Association, 2014).  
To study the delivery outcome, data on gestational age and mode of delivery were gathered. A 
gestational age of < 32 weeks (starting from the first day of the last menstrual period) and between 32 
and 37 weeks was classified as a very preterm birth and a preterm birth, respectively. The mode of 
delivery was observed as a variable with two categories, i.e. Caesarean section or vaginal delivery. The 
use of an epidural analgesia during a vaginal delivery was also registered. 
Regarding the neonatal outcome, the birthweight was expressed in grams and a distinction was made 
between a low and a very low birthweight, representing a birthweight between 1500 and 2500 grams 
or < 1500 grams, respectively. Macrosomia was diagnosed if birthweight was more than 4000 grams. 
If children had adaptation problems, admission to a neonatal (intensive) care unit was also registered. 
Ethical approval 
This retrospective study was authorized by the Ethics Committee of the Ghent University Hospital. 
Informed consent from patients was not obtained but patient information was anonymized and de-
identified prior to analysis. 
Statistical analyses 
Statistical analyses were performed using SPSS version 21.0. Independent samples t-tests, Mann-
Whitney U, Chi-square and Fisher Exact tests were used where appropriate and were performed at the 
5% significance level. The normal distribution of continuous variables was graphically inspected using 
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QQ-plots. Univariate odds ratios (OR) and confidence intervals (CI) were based on small sample 
adjustments where needed (Jewell, 2003). Given the observational nature of the study, multiple linear 
and logistic regression was performed to adjust for confounding factors in all outcome analyses. In 
particular, the analyses of the miscarriage rate, the ongoing multiple pregnancy rate and the ongoing 
singleton pregnancy, delivery and neonatal outcomes were adjusted for age and pre-pregnancy 
smoking behaviour, since research has proven their negative influence on the perinatal outcome (Lowe 
et al., 1998; Delbaere et al., 2007; Cnattingius et al., 2013). The neonatal outcome parameters were 
additionally adjusted for gestational age (Land, 2006). Effects of overweight on neonatal outcome 
parameters must therefore be interpreted as reflecting the effects that cannot be explained by 
intermediate effects via gestational age. Adjusted odds ratios (AOR) and 95% CI were calculated for all 
outcome parameters and residual analyses confirmed the adequacy of the models. 
Since multiple pregnancies have an important negative influence on perinatal outcome (The ESHRE 
Capri Workshop Group, 2000), we focused our analyses on the pregnancy, delivery and neonatal 
outcome of ongoing singleton pregnancies.  
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Results 
Baseline characteristics 
Our sample consisted of 200 pregnant women with PCOS of whom 119/200 (59.5%) had full-blown 
PCOS, 31/200 (15.5%) suffered from oligo- or anovulation and hyperandrogenism, 39/200 (19.5%) had 
PCOM and oligo- or anovulation, and 11/200 (5.5%) suffered from hyperandrogenism and PCOM.  
The baseline characteristics of the overweight and normal weight group are summarized in Table I. 
The difference in median BMI between groups was 9.9 kg/m² (P < 0.001). The LH:FSH ratio was less 
than 2 in both groups and this ratio was not significantly different between the overweight and normal 
weight women. There was a significant difference in the fT, SHBG and fasting insulin levels, as well as 
in the time-to-pregnancy. The fT level was significantly higher in the overweight group and the SHBG 
level was significantly lower in the overweight group. The fasting insulin level was only elevated in the 
overweight group. 
Perinatal outcome 
In the overweight and normal weight group there were 22/93 (23.7%) and 25/107 (23.4%) miscarriages, 
resulting in 71 and 82 ongoing pregnancies, respectively (AOR 1, 95% CI 0.5 to 2.0, P = 0.9). All 
miscarriages, except one in the overweight group, were first trimester miscarriages. In both groups 
there were two ectopic pregnancies. The prevalence of ongoing multiple pregnancies was 8/69 (11.6%) 
in the overweight group and 9/80 (11.3%) in the normal weight group (AOR 1.1, 95% CI 0.4 to 3.1, P = 
0.9). In each group one triplet pregnancy occurred.  
Data on the pregnancy, delivery and neonatal outcome of ongoing singleton pregnancies in overweight 
and normal weight women are reported in table II. No significant differences were detected in the 
prevalence of HDP and preeclampsia between the overweight and normal weight group. In one normal 
weight woman preeclampsia evolved to eclampsia. Despite the significant difference in fasting insulin 
levels between the two groups, there was no significant difference in prevalence of DDP. The age of 
the study participant was a significant predictor of the prevalence of DDP (P = 0.03), namely the older 
the participant, the more likely she was to develop DDP.  
There was marginal evidence of a difference in gestational age between overweight and normal weight 
women (adjusted mean difference -4.8, 95% CI -9.7 to 0.1). The prevalence of preterm birth was 
significantly higher in overweight versus normal weight women. In the overweight group, one very 
preterm birth (25 weeks of pregnancy) occurred. With regard to the mode of delivery, there was 
marginal evidence of a difference in the prevalence of Caesarean sections versus vaginal deliveries 
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between groups. Reasons for delivery through Caesarean section were fetal distress, a 
malpresentation, a narrowed pelvis and a prolonged labour. In the overweight group one caesarean 
section was performed under general anesthesia. An epidural analgesia was used otherwise.  
There was a significantly higher birthweight in babies of overweight versus normal weight women, 
even after additional adjustment for gestational age (adjusted mean difference 259.4, 95% CI 83.4 to 
435.4). We found no evidence of a higher prevalence of macrosomia in overweight versus normal 
weight women. In the overweight group, there was one newborn with a very low birthweight of 700 
grams due to a very preterm birth. 
Since the study included one overweight woman with a very preterm birth (gestational age of 25 weeks) 
of a very low birthweight baby (700 grams), a sensitivity analysis was performed by removing this case 
from the analysis of the pregnancy, delivery and neonatal outcome in ongoing singleton pregnancies. 
The exclusion of this study participant had no influence on the results. 
We also performed a scenario analysis using the cut-off of 30 kg/m² instead of 25 kg/m² to evaluate 
the influence of obesity on the perinatal outcome in women with PCOS. The results showed marginal 
evidence of a higher prevalence of Caesarean sections versus vaginal deliveries in the obese group 
(AOR 2.5, 95% CI 1.1 to 5.9, P = 0.04) and of a difference in preterm birth between both groups (AOR 
3.5, 95% CI 1 to 12.4, P = 0.05). All other results were similar to those of the original analysis.  
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Discussion 
The results of our study support the hypothesis that pre-pregnancy overweight in women with PCOS 
has, in addition to the negative effect of the syndrome in itself, a negative influence on the prevalence 
of preterm birth and the birthweight of singletons. Marginal evidence is found of a shorter gestational 
age and a higher prevalence of Caesarean sections in ongoing singleton pregnancies of overweight 
versus normal weight women. No significant difference in miscarriage rate was observed between 
overweight and normal weight women.  
Concerning the miscarriage rate, our results are the opposite of those in the retrospective cohort study 
by Fedorcsák et al. (2000) investigating the influence of overweight (BMI ≥ 25 kg/m²) on the prevalence 
of early pregnancy loss in a sample of infertile women who received IVF or ICSI. They conclude that 
overweight was an independent risk factor for early pregnancy loss before 12 weeks of gestation 
(Fedorcsák et al., 2000). A cohort study by Wang et al. (2001) found evidence that a pre-pregnancy 
BMI of 30 to 34.9 kg/m² has a significant negative and independent influence (AOR 1.79, 95% CI 1.16 
to 2.75) on the prevalence of pregnancy loss before 20 weeks of gestation in women with PCOS. 
Our findings suggest that pre-pregnancy overweight has a negative influence on the prevalence of 
preterm birth. A similar result was found by Cnattingius et al. (2013), studying the association between 
maternal obesity and the risk of preterm delivery in Swedish women using a retrospective design. 
These authors observed that obesity (BMI ≥ 30 kg/m² to ≥ 40 kg/m²) had a significant influence on the 
prevalence of preterm birth (gestational age < 37 weeks) and this negative influence was highest in 
extremely preterm births (gestational age of 22 to 27 weeks). We cannot confirm this last statement 
because there was only one very preterm birth (gestational age of  25 weeks) in the overweight group, 
which was due to blood loss and preterm contractions. In contrast, the case-control study by Han et 
al. (2011) found no significant influence of overweight (BMI > 25  kg/m²) in women with PCOS on the 
prevalence of preterm birth. It has to be mentioned that these analyses were not adjusted for other 
important covariates.  
In line with the conclusions of Han et al. (2011), our results showed that the birthweight of the 
newborn was significantly higher in overweight women in comparison to normal weight women. In 
contrast to Han et al. (2011), this result was only significant after adjustment for gestational age among 
others, which emerged as a significant predictor of birthweight. Our results thus express the direct 
effect of pre-pregnancy overweight on neonatal outcome, other than via gestational age, rather than 
the overall effect reported by Han et al. (2011).  
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Our findings do not confirm the existing evidence that overweight has an influence on the prevalence 
of macrosomia and GDM (Mikola et al., 2001; Turhan et al., 2003; Han et al., 2011). Although we did 
not find a significant difference in DDP, none of the normal weight women had DDP in comparison to 
8.2% in the overweight group. 
Although there is evidence that a treatment with IVF/ICSI has a negative influence on the prevalence 
of preterm birth in singleton pregnancies (Maman et al., 1998; Dhont et al., 1999), we could not 
confirm this since the treatment-to-pregnancy (i.e. the last treatment that has led to pregnancy) was 
not significantly associated with outcome in any of the analyses performed. 
While we have adjusted for the confounding factors pre-pregnancy smoking behaviour and maternal 
age, a limitation of our study is that the comparison of overweight versus normal weight women with 
PCOS may be confounded by other, possibly unmeasured, factors. Caution is therefore warranted 
when interpreting all results as reflecting the influence of overweight. A further limitation is that our 
results for pregnancy, delivery and neonatal outcome can only be generalized to singleton ongoing 
pregnancies and that our analysis may also be vulnerable to selection bias due to the restriction to 
pregnant women who had experienced fertility problems. This restriction, while difficult to avoid, may 
induce bias as a result of the fact that pregnancy and fertility problems may themselves be influenced 
by overweight (Rosenbaum, 1984). For this reason the results may not be generalizable to the general 
PCOS community. Finally, because of the rather small sample size of ongoing singleton pregnancies 
(n=132) and the resulting lack of power, non-significance of certain associations should not necessarily 
be interpreted as indicating the lack of association. A larger confirmatory study is therefore indicated, 
as well as a similar study looking into the influence of pre-pregnancy overweight in women with PCOS 
on the pregnancy, delivery and neonatal outcome in multiple pregnancies. 
In our study, we focused on the influence of pre-pregnancy overweight rather than the gestational 
weight gain on perinatal outcome. In women without PCOS, gestational weight gain is also found to be 
an important predictor of perinatal complications (Bogaerts et al., 2012) and therefore an important 
factor to keep in mind during the medical supervision of pregnancy, delivery and postpartum. It would 
be interesting in the future to perform a prospective follow-up study looking into the difference in 
influence of pre-pregnancy BMI versus gestational weight gain on perinatal outcome in women with 
PCOS. 
We conclude that pre-pregnancy overweight in women with PCOS has, in addition to the influence of 
the syndrome in itself, an important negative influence on the prevalence of preterm birth and the 
birthweight of the newborn singleton. Therefore we suggest the importance of pre-pregnancy weight 
loss in overweight women with PCOS in order to reduce the risk of adverse perinatal outcomes.  
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Table I. Baseline characteristics of overweight versus normal weight women with polycystic ovary syndrome. 
Characteristics Overweight (n = 93) Normal weight (n = 107) P 
Age (years) 29±4.2 28.4±3.1 0.3 
BMI (kg/m²) 30.8 (27.7-33.5) 20.9 (20-22.3) <0.001 
Smoking 22/91 (24.2%) 18/101 (17.8%) 0.3 
Primigravida 70/93 (75.3%) 87/107 (81.3%) 0.3 
PCOMa 73/87 (83.9%) 96/105 (91.4%) 0.1 
Irregular menstrual cycle 86/93 (92.5%) 103/107 (96.3%) 0.4 
Hirsutism 38/64 (59.4%) 46/77 (59.7%) 1 
LH:FSH ratio 1.5 (0.9-2.2) 1.6 (1-2.5) 0.4 
Testosterone (ng/dL) 48.6 (38.5-61.9) 46.9 (34-62.6) 0.3 
Free testosterone (ng/dL) 0.8 (0.6-1.1) 0.5 (0.4-0.8) <0.001 
SHBGb (nmol/L) 33.6 (21.9-50.6) 62.1 (46.9-82.9) <0.001 
Fasting insulin (µU/mL) 14 (7.8-22.5) 7.3 (4.7-10) <0.001 
Treatment-to-pregnancyc   0.4 
     Spontaneous pregnancy 11/93 (11.8%) 12/107 (11.2%)  
     Timed coitus 12/93 (12.9%) 21/107 (19.6%)  
     Intrauterine insemination 36/93 (38.7%) 39/107 (36.4%)  
     IVF/ICSI 34/93 (36.6%) 35/107 (32.7%)  
Time-to-pregnancyd (months) 32 (20.3-49) 26 (17-36.5) 0.01 
Continuous measurements are summarized as mean±SD if symmetrically distributed, and as median (1st 
quartile-3rd quartile) otherwise. 
Nominal measurements are summarized as n(%). 
aPCOM = polycystic ovarian morphology. 
bSHBG = sex hormone-binding globulin. 
cTreatment-to-pregnancy = the last treatment that has led to pregnancy. 
dTime-to-pregnancy = the duration of the desire to have children. 
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Abstract 
 
Objective: This study was performed to evaluate changes in body mass index (BMI) and health-related 
quality of life (HRQoL), including an acne parameter, of overweight adult women with polycystic ovary 
syndrome (PCOS) during a lifestyle modification program. 
Design: Prospective longitudinal within-patient study. 
Setting: Department of Reproductive Medicine of the Ghent University Hospital (Belgium). 
Participants: Thirty-three overweight (BMI ≥ 25 kg/m²) women with PCOS between the age of 18 and 
43 years. 
Methods: Participants followed a 24-week lifestyle modification program, consisting of a diet, exercise, 
and psychological subprogram. BMI was assessed at week 0, 8, 16 and 24 of the program. The HRQoL 
was measured at week 0, 12 and 24 of the program using the PolyCystic Ovary Syndrome 
Questionnaire (PCOSQ) and a Visual Analogue Scale (VAS) evaluating the influence of acne on HRQoL.  
Results: Over a 24-week period no significant decrease in BMI occurred (mean difference = 1.71, 95% 
CI [-1.38, 4.81]. During that period, there was a significant positive evolution of the total PCOSQ score 
(F(2,37.5) = 23.7), the emotions (F(2,37.9) = 4.2), weight (F(2,42.1) = 24.8), body hair (F(2,35.6) = 3.3), 
and infertility problems domain scores (F(2,43.1) = 15.64) of the PCOSQ, as well as of the acne VAS 
score (F(2, 29.3) = 4.2). These effects primarily occurred during the first 12 weeks. 
Conclusion: In spite of no significant changes in BMI, the HRQoL of overweight adult women with PCOS 
significantly improved during a 24-week lifestyle modification program.  
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Introduction 
The polycystic ovary syndrome (PCOS) is a common endocrine disorder in women of reproductive age 
worldwide (Broekmans et al., 2006). Overweight and obesity are present in 30-70% of women with 
PCOS and worsen the PCOS symptom profile. More specifically, the prevalence of hirsutism, menstrual 
cycle irregularities, anovulation, and infertility is higher in overweight and obese women with PCOS 
when compared with normal weight women with PCOS (Gambineri, Pelusi, Vicennati, Pagotto, & 
Pasquali, 2002; Vrbikova & Hainer, 2009). Overweight in women with PCOS also has in itself as well as 
via the above mentioned PCOS characteristics, a negative influence on women’s health-related quality 
of life (HRQoL)  (Jones, Hall, Balen, & Ledger, 2008). Weight loss is therefore a crucial first step in the 
treatment of PCOS in overweight women. A weight loss of 5-10% through lifestyle modification 
improves menstrual regularity, restores ovulation, and consequently increases the chance to become 
pregnant (Hoeger, 2006; Hoeger et al., 2004; Huber-Buchholz, Carey, & Norman, 1999; Norman, 
Davies, Lord, & Moran, 2002; Tang et al., 2006; Thessaloniki ESHRE/ASRM-Sponsored Consensus 
Workshop Group, 2008). There is also increasing evidence that lifestyle modification has a positive 
effect on women’s HRQoL. A 24-week randomized controlled trial in obese adolescent women with 
PCOS, revealed that a treatment of lifestyle modification and oral contraceptives, with or without 
metformin, had a positive effect on HRQoL (Harris-Glocker, Davidson, Kochman, Guzick, & Hoeger, 
2010). Similarly, a 20-week lifestyle modification treatment, consisting of diet with or without exercise, 
had a positive impact on HRQoL in overweight and obese adult women with PCOS (Thomson et al., 
2010). 
Evidence about the isolated effect of exercise and diet interventions on psychological well-being in 
women with PCOS is limited. Liao et al. (2008) found that a self-directed walking program significantly 
reduced the level of body image distress in overweight and obese women with PCOS. Galletly et al. 
(2007) reported a lower depression rate and higher level of self-esteem after a high-protein diet when 
compared with a low-protein diet. To date, there is no evidence about the isolated effect of 
psychological interventions on the psychological well-being of women with PCOS. 
Notwithstanding the promising results of the Harris-Glocker et al. (2010) and Thomson et al. (2010) 
studies, their findings are limited in several respects. Firstly, only one of these studies focused on the 
effect of lifestyle modification in adult women with PCOS. Secondly, that study did not include an 
individual psychological subprogram in the treatment of overweight and obesity that seems to be 
important in weight loss programs in order to obtain a maximum effect (Shaw, O’Rourke, Del Mar, & 
Kenardy, 2005). Finally, neither of the two studies included an evaluation of the influence of acne on 
women’s HRQoL although this was reported as a limitation when studying HRQoL in women with PCOS 
(Jones et al., 2004). Since HRQoL is an important marker from the patient’s perspective for the efficacy 
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of a treatment (Cronin et al., 1998), additional research on this topic is needed. Accordingly, we studied 
changes in body mass index (BMI) and HRQoL, including an acne parameter, of overweight adult 
women with PCOS during a 24-week lifestyle modification program, consisting of a diet, exercise and 
psychological subprogram. Therefore, we hypothesized that (a) the BMI decreases and (b) the level of 
HRQoL increases during the 24-week LMP in overweight women with PCOS.  
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Methods 
Ethics approval 
This study has been reviewed and approved by the Ethics Committee of the Ghent University Hospital. 
Participants gave their written informed consent for participation in the study. 
Design, setting and participants 
We set up a prospective longitudinal within-patient study at the Department of Reproductive Medicine 
of the Ghent University Hospital (Belgium). Participants were recruited by the treating gynecologist 
during consultation from April 2007 till April 2009 using convenience sampling. Data collection ended 
in October 2009. Inclusion criteria stipulated that women had to be (a) diagnosed with PCOS, (b) 
overweight (BMI ≥ 25 kg/m²), and (c) between the age of 18 and 43 years. PCOS was diagnosed by a 
gynecologist using the Rotterdam criteria (The Rotterdam ESHRE/ASRM-sponsored PCOS consensus 
workshop group, 2004). 
Demographic and clinical characteristics 
Data on demographic and clinical characteristics were gathered by the program coordinator at the 
start of the LMP. Age and highest level of education (i.e., secondary or higher education) of each 
participant were collected during interview. Hirsutism was diagnosed by using the modified Ferriman-
Gallwey (mFG) scale. The program coordinator classified the participants as hirsute when they had a 
mFG score ≥ 8 (Ferriman & Gallwey, 1996; Yildiz, Bolour, Woods, Moore, & Azziz, 2010). The presence 
of facial acne was evaluated by questioning the participants if they were bothered by facial acne or 
not. Hyperandrogenemia was diagnosed in the presence of a free testosterone level > 0.50 ng/dL, 
which was determined at day 2 or 3 of a spontaneous or induced menstrual cycle. Menstrual cycle 
irregularity was diagnosed when participants reported no menstrual bleeding for > 35 days (i.e., 
oligomenorrhea) or for > 6 months (i.e., amenorrhea). Gravidity and parity were observed as nominal 
variables answering the questions “Have you already been pregnant at least once?” and “Have you 
already given birth at least once?”, respectively. Participants were also asked whether they had a 
current unfulfilled wish to conceive or not.  
Intervention 
All participants followed a 24-week lifestyle modification program (LMP) consisting of a diet, exercise 
and psychological subprogram. Throughout the duration of the LMP, consultations with a team of 
professionals were planned at fixed moments in time (Table 1). Consultations with the dietician and 
the physiotherapist were planned at week 0, 4, 8, 16, and 24 of the LMP. The frequency of the diet and 
exercise intervention was higher during the first part of the LMP in order to make sure that the 
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participants adapted well to the new dietary and exercise pattern. Afterwards it was assumed that 
participants were informed well enough to execute the diet and exercise advice on their own for a 
longer period of time (Mertens, Vlayen, & Muls, 2003). The first consultation with the dietician and the 
physiotherapist lasted one hour and the following consultations lasted 30 minutes. Consultations with 
the psychologist were planned at week 0, 12, and 24 of the LMP. In addition to these fixed 
psychological consultations, an extra moment of psychological counseling was possible upon the 
demand of the participant at week 4, 8, 16, and 20 of the LMP. During these psychological counseling 
sessions fertility problems were mostly discussed. Each psychological consultation lasted one hour.  
All participants were coached individually and interventions were tailored to each participant’s degree 
of overweight and individual abilities. Upon participant’s wish, an important other (e.g., partner, 
mother) was allowed to attend all consultations. A schematic overview with the key content 
components for the diet, exercise and psychological subprogram are reported in Table 2. Next, the 
content for each subprogram is described in detail. 
The diet subprogram was led by a dietician and consisted of a mild energy restricting diet (i.e., calorie 
restriction of 450 to 850 Kcal/day) in order to achieve an average weight loss of 0.5 kg (i.e., 1.1 lbs) per 
week. At the start of the program, participants were taught some general dietary principles: (1) 
following a daily dietary pattern of three principal meals alternated with three snacks; (2) consuming 
healthy food; (3) a balanced meal composition; and (4) consuming at least 1.5 L of calorie free drinks 
per day (e.g., water, light drinks). Additionally, all participants received personalized advice that was 
based on written information about a participant’s eating habit received via the use of a diet diary, on 
the one hand, and based on oral information about a participant’s taste preferences received during 
consultation, on the other hand. The diet diary was a very detailed registration of the participant’s 
consumed foods and drinks during three days during the week (i.e., two week days and one weekend 
day) (Becker-Woudstra, van Kuijeren, & Linden-Wouters, 2003). The personalized advice was 
supported by a list of foods and drinks that should be chosen and those that should be limited in use. 
The exercise subprogram was led by a physiotherapist and was focused on raising the level of physical 
activity during daily life. The participant’s level of physical activity was monitored during the entire 
duration of the LMP by counting the number of steps per day by means of a pedometer (i.e., the Yamax 
Digiwalker SW-200) (Crouter, Schneider, Karabulut, & Basset, 2003). This tool was used since it has 
been shown to be a motivational aid for increasing an individual’s physical activity level (Merom et al., 
2007). During the first week of the LMP, every participant was asked to provide her total number of 
steps per day while performing usual daily activities in order to determine her baseline activity level. 
Starting from week two of the LMP, participants started to follow up the advice of the physiotherapist. 
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This advice consisted of suggestions on how to raise physical activity during daily life at home (e.g., 
going to the store on foot or with the bike instead of by car, taking the stairs instead of the elevator) 
and at work (e.g., taking a walk during the break in case of a sedentary job, going to your colleague 
instead of making a call to discuss something with her/him). Further, the physiotherapist provided 
concrete advice about how to practice a chosen sport. 
The psychological subprogram was led by a psychologist and encompassed individual cognitive 
behavioral therapy (CBT) (Shaw et al., 2005). Behavioral and cognitive strategies were offered for PCOS 
related problems (such as body image and eating behavior) and for problems associated with the LMP 
itself (such as motivation and stress). CBT was focused on defining and changing negative thoughts, 
like “Life is too busy to go to the gym” or “I can’t live without my sweets”. Other techniques consisted 
of problem solving strategies (“If I start eating candy, I can’t stop”), goal setting (“I will eat healthy this 
week”) and increasing social support (“My partner buys a lot of chocolate every week”).  
The program coordinator had personal or telephonic contact with each participant every two weeks 
to evaluate and solve problems (e.g., concerns about the progression of the LMP, rescheduling 
appointments) experienced by them during the LMP. 
Outcome measures 
BMI 
The participant’s BMI was measured at week 0, 8, 16, and 24 of the LMP by the dietician. In order to 
calculate the BMI (in kg/m²) participant’s body weight (in kg) and height (in m) were measured by using 
an electronic personal scale and a stadiometer. 
HRQoL 
The HRQoL was assessed using the PolyCystic Ovary Syndrome Questionnaire (PCOSQ) at week 0, 12, 
and 24 of the LMP (Cronin et al., 1998; Guyatt, Weaver, Cronin, Dooley, & Azziz, 2004). Upon the start 
of the LMP, the psychologist gave basic instructions to the participants on how to fill out the PCOSQ. 
The PCOSQ is a disease-specific questionnaire that evaluates women’s subjective perception of the 
effect of specific PCOS characteristics on their quality of life. The 26-item PCOSQ consists of five 
domains: emotions, body hair, weight, infertility problems and menstrual problems. Each item was 
scored on a 7-point Likert scale (1= high concern, 7= no concern) (Cronin et al., 1998). The mean score 
of all domain-specific items and the mean score of the five domain scores generated the score of each 
PCOSQ domain and the total PCOSQ score, respectively, with higher scores indicating qualitatively 
higher levels of HRQoL. We retained the original time frame of two weeks for the HRQoL measurement 
LIFESTYLE MODIFICATION 
  97 
at 12 and 24 weeks of the LMP (Cronin et al., 1998). To measure the baseline HRQoL at the start of the 
LMP, we used a time frame of six months. In this study, the separate PCOSQ domain scores and the 
total PCOSQ score showed good reliability (Cronbach’s alpha’s ranging from .73 to .95), with the 
exception of the menstrual problems domain scores at the start of the LMP (Cronbach’s alpha .57) 
(Table 3). The construct, content, discriminant, and longitudinal validity were confirmed by prior 
research (Coffey, Bano, & Mason, 2006; Guyatt et al., 2004; McCook, Reame, & Tatcher, 2005). Jones 
et al. (2004) assessed the face validity by interviewing 12 adult women with PCOS. About 25% raised 
their concern about the lack of questions that addressed the influence of acne on HRQoL. Given the 
fact that acne is a common symptom of PCOS, this result suggested that the face validity could be 
improved by the addition of an acne domain to the questionnaire. Therefore, we additionally assessed 
to what extent the facial acne influenced participant’s HRQoL by means of a Visual Analogue Scale 
(VAS) (0= no influence, 10= great influence). Contrary to the PCOSQ scores, lower VAS scores reflect a 
better quality of life. 
Statistical methods 
In order to test the hypothesis that (a) there is a decrease in BMI and (b) an increase in the level of 
HRQoL during the 24-week LMP, we analysed the evolution of the BMI, the total PCOSQ score, the five 
PCOSQ domain scores and the acne VAS score, separately. 
Linear mixed models 
Linear mixed model (LMM) analyses were used to account for correlated measures of the same 
individual at different points in time. In LMM analyses - under the assumption that missing data are 
random - all observations, available for a given participant, are used in the analysis (West, Welch, & 
Galecki, 2006), meaning that a participant with missing observations is not completely removed from 
the dataset (i.e., listwise deletion).  
To find the best fitting model, we used a top-down model building strategy (see West et al., 2006 for 
more details). The covariates time (weeks in program), age and education level, as well as a model-
specific set of time-invariant covariates, all assessed at the start of the LMP, were included in each 
model. The time-invariant covariates were the BMI at the start of the program for the weight domain; 
the mFG score and the free testosterone level for the body hair domain; the presence of a current 
unfulfilled wish to conceive and the parity for the infertility problems domain; the presence of 
menstrual irregularity for the menstrual problems domain; and the presence of facial acne for the acne 
VAS. All continuous covariates were centred. Initially, each of the covariates’ interactions with the time 
variable was entered in the model. Non-significant interactions were removed following a backward 
procedure. To provide an absolute value for the goodness-of-fit, marginal and conditional R2 values 
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were calculated for each model following the procedures described in Nakagawa & Schielzeth (2013). 
Residual analyses did not reveal severe violations of the assumptions underlying the linear model. F 
values reported for the LMM analyses are Type III Wald F tests with Kenward-Roger degrees of 
freedom. 
Planned contrasts 
Once the best fitting model was found, appropriate planned contrasts between time points were 
examined in order to scrutinize temporal effects. The p values for each contrast were Bonferroni 
corrected to account for the familywise error rate due to multiple testing in each domain.  
Software  
The LMM analyses were performed using the lme4 package version 1.0-4 in R version 3.0.2 (Bates, 
Maechler, Bolker, & Walker, 2013; R Core Team, 2013). All other statistical analyses were performed 
using SPSS version 21.0. The statistical significance level was set at α < .05.   
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Results 
Thirty-three study participants met the inclusion criteria. Thirty-one of them effectively participated in 
the study and started the LMP. Sample characteristics at the start of the LMP are reported in Table 4. 
In total, 8/31 (25.8%) of the included women dropped out, of which six dropped out before 12 weeks 
and another two after 12 weeks of the LMP. After 16 weeks, no dropouts occurred. The dropout group 
did not differ from the remaining group in terms of demographic and clinical characteristics (all p values 
≥ .05). The response rate on the PCOSQ at week 0, 12, and 24 of the LMP was 30/31 (96.8%), 22/25 
(88%) and 22/23 (95.7%), respectively. Seven participants used one or more extra sessions of 
psychological counseling.  
During the LMP, 13/31 (42%) participants received a fertility treatment. Three participants in the non-
dropout group became pregnant during the LMP. There was no significant difference (p ≥ .05) in all 
outcome parameters between the pregnant and non-pregnant participants at the different moments 
in time. 
Baseline PCOSQ and VAS scores 
At baseline, weight was of highest concern with a median domain score of 2.6 [Interquartile range (IQR) 
= 1.85] followed by infertility problems (Mdn = 3, IQR = 1.38), menstrual problems (Mdn = 3.38, IQR = 
1.63), emotions (Mdn = 4.13, IQR = 1.31) and body hair domains (Mdn = 4.8, IQR = 3.7). Although body 
hair was of least concern, the median body hair domain score in hirsute women was 3.1 (IQR = 2.5) 
when compared with 6.6 (IQR = 2.6) in non-hirsute women (p = .001). The infertility problems domain 
correlated significantly and positively with parity (rs = .441, p = .02). The score for this domain was also 
significantly different between participants with (Mdn = 2.75, IQR = 1) and without a current unfulfilled 
wish to conceive (Mdn = 4.25, IQR = 2, p < .001), hence reflecting a significant higher HRQoL in the 
latter group. Participants educated up to secondary level reported a significant lower HRQoL on the 
emotions domain (Mdn = 3.5, IQR = 1.88) when compared with higher educated participants (Mdn = 
4.31, IQR = 1.16, p = .02). The weight domain was not correlated with any of the baseline characteristics 
and additionally, none of the PCOSQ domains were significantly correlated with the BMI measured at 
the start of the LMP. The median VAS score for acne was 1.1 (6.4) reflecting a low level of perceived 
facial acne. However, there was a significant difference in median VAS score between participants with 
(Mdn = 6.65, IQR = 6.98) and without facial acne (Mdn = 0.8, IQR = 1.6, p = .002). 
Effect of time on BMI, PCOSQ and VAS scores 
During the LMP, participants lost on average one kilogram per month and the mean BMI decreased 
from 35.49±5.96 kg/m² to 33.78±4.84 kg/m² over a period of 24 weeks (p = .27). Furthermore, between 
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week 0 and 24, there was marginal evidence of a negative correlation between the decrease in BMI 
and the increase of the total PCOSQ scores (r = -.45, p = .06), the emotions domain (r = -.46, p = .05) 
and the body hair domain scores (r = -.41, p = .07). 
Next, we report the results of the LMM analyses investigating the effect of time on the total PCOSQ 
score, the PCOSQ domain scores and the acne VAS score separately (Table 5). We observed a significant 
positive effect of time on the total PCOSQ score (F(2,37.5) = 23.7, p < .001), the emotions (F(2,37.9) = 
4.2, p < .05), weight (F(2,42.1) = 24.8, p < .001), body hair (F(2,35.6) = 3.3, p < .05) and infertility 
problems domain scores (F(2,43.1) = 15.64, p < .001) over a time period of 24 weeks. This increase was 
each time significant between week 0 and week 12, but not between week 12 and week 24 (Table 6). 
With regard to the menstrual problems domain, only a marginal increase in this domain score was 
observed over the period of 24 weeks (F(2,38.8) = 3.08, p = .057).  
The effect of time on the emotions domain scores interacted with the educational level of the 
participant. Over the period of 24 weeks the significant increase in emotions domain scores was less 
pronounced for higher educated participants (mean predicted difference = 1.11, p < .001) when 
compared with lower educated participants (mean predicted difference = 2.2, p < .001). The effect of 
time on the body hair domain scores interacted with the mFG score. The significant increase of the 
body hair domain scores during the first 12 weeks of the LMP, was only there for participants with an 
average or higher than average mFG score (mean predicted difference = 0.79, p < .001 and mean 
predicted difference = 1.32, p < .001, respectively). For participants showing lower than average mFG 
scores, no significant differences were observed between each of the time points. The infertility 
problem domain scores were influenced by the presence of a current unfulfilled wish to conceive and 
by the parity. The presence of a current unfulfilled wish to conceive had a negative effect (F(1, 23.1) = 
21.94, p < .001) while the presence of a child had a positive effect on the PCOSQ scores (F(1, 24.4) = 
4.32, p < .05). 
With regard to the influence of facial acne on the HRQoL, a positive evolution was observed over the 
24-week period which interacted with age (F(2, 29.3) = 4.2, p < .05). The pattern of overall decrease 
was different for younger participants when compared with older participants. For instance, predicting 
average acne VAS scores for young women (using the 25th percentile of age), showed a significant 
decrease from week 0 to week 24 and from week 12 to week 24 (week 0 vs. week 24: mean predicted 
difference = -1.31, p < .01; week 12 vs. week 24: mean predicted difference = -0.76, p < .05). For older 
women (75th percentile of age), the significant decrease from week 0 to week 24 was primarily situated 
between week 0 and week 12 (week 0 vs. week 24: mean predicted difference = -1.88, p < .001; week 
0 vs. week 12: mean predicted difference  = -1.51, p < .001).  
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Discussion 
In the current study, we investigated changes in BMI and HRQoL in overweight adult women with PCOS 
during a 24-week LMP, consisting of a diet, exercise and psychological subprogram. Our findings point 
to the following conclusions: Firstly, we observed an overall increase in women’s HRQoL after 12 and 
24 weeks of the LMP. This supports the findings of Harris-Glocker et al. (2010) and Thomson et al. 
(2010) that the HRQoL is increased at the end of a lifestyle modification period. Our findings also point 
to a second conclusion that the positive evolution of the HRQoL was primarily situated during the first 
12 weeks of the LMP. This is in line with the study of Thomson et al. (2010) where they observed an 
important increase in PCOSQ domain scores during the first 10 weeks of a 20-week LMP. Despite this 
important increase in HRQoL during a short period of 12 weeks, it doesn’t seem justified to shorten a 
LMP to that time period since there is still an increase in HRQoL after 12 weeks which is possibly not 
at its highest level after 24 weeks of LMP. Further, a period of 24 weeks of LMP could still be too short 
to achieve a long-term weight reduction and maintenance according to the study of Lally, van 
Jaarsveld, Pott and Wardle (2010), reporting that it can take up to 254 days to form a new habit. 
Additional research on this issue is therefore needed.  
Furthermore, our results confirm that body weight, irrespective of the BMI, is a high concern in women 
with PCOS (Coffey et al., 2006; Vrbikova & Hainer, 2009). In addition, over the period of 24 weeks, 
there was a decrease of 5% in BMI and a trend towards a correlation between the decrease in BMI and 
the increase in HRQoL. This confirms the findings of Harris-Glocker et al. (2010) who observed a trend 
towards a correlation between the decrease in BMI and the increase in PCOSQ weight domain scores 
over a period of 24 weeks in a group of obese adolescent women with PCOS (r = -.333, p = .06). A 
similar correlation was found by Thomson et al. (2010) for the emotions and weight domain scores (r 
= -.35 and r = -.43, p ≤ .01, respectively) in overweight and obese adult women with PCOS. These results 
suggest that a modest weight loss is sufficient to elicit an increase in HRQoL, in addition to its positive 
effects observed with respect to the endocrine and metabolic features of PCOS (Hoeger et al., 2004; 
Thomson et al., 2008).  
In our study, the presence of visible hair growth appeared to be the least concern when compared 
with the other PCOSQ domains at the start of the LMP. We also observed a significant negative 
correlation between the presence of hirsutism and HRQoL similar to earlier findings by Harris-Glocker 
et al. (2010) and Mc Cook et al. (2005). There is evidence that lifestyle treatment leads to an 
amelioration of hirsutism (Moran, Hutchinson, Norman, & Teede, 2011), however, as the life span of 
hair follicles is six months, the effect of LMP on the presence of hirsutism can be adequately assessed 
only after this time period (Castelo-Branco & Cancelo, 2010). Interestingly, we observed a positive 
Chapter 4 
102 
evolution of the body hair domain scores over the whole study period. This cannot be confirmed by 
the study of Thomson et al. (2010), where no significant evolution in body hair domain scores was 
observed over the 20-week study period. In our study, the increase in body hair domain scores was 
significant during the first 12 weeks of LMP, followed by a decrease during the second half of the 
program. 
Since acne is also a clinical sign of hyperandrogenism, some studies have highlighted the necessity to 
include the presence of visible acne in the evaluation of the HRQoL of women with PCOS (Harris-
Glocker et al., 2010; Jones et al., 2004). Consequently, we assessed the influence of visible facial acne 
on the HRQoL of the participants. Indeed, we observed a significant improvement of the influence of 
acne on the HRQoL during the total length of the LMP. Our findings thereby underscore the importance 
of including acne as an additional indicator of treatment efficacy for HRQoL outcomes. In the future, 
an acne domain should be included in the PCOSQ and this modified version of the PCOSQ should be 
validated in a group of adolescent and adult women with PCOS. 
A study by Elsenbruch et al. (2006) described that the level of education, among other parameters, is 
an important determinant of emotional distress in women with PCOS. Hence, we took this into account 
while performing all our analyses. Indeed, we observed a lower PCOSQ emotions domain score in 
secondary educated study participants at the start of the LMP. Also, the level of education had a 
significant influence on the effect of time on the PCOSQ emotions domain score.  
Fertility problems are an important consequence of PCOS, especially in overweight women (Vrbikova 
& Hainer, 2009). In our study, 71% of the participants had an unfulfilled wish to conceive and 77% had 
never given birth at the start of the LMP. Forty-two percent had a fertility treatment during the LMP. 
Since McCook et al. (2005) describes that the delivery of a viable child has a significant impact on the 
infertility problems domain score of the PCOSQ, we adjusted the analyses of that domain for the 
variable parity. Additionally, we took the objective evaluation of the presence of a current unfulfilled 
wish to conceive into account as the PCOSQ infertility problems domain looks into the participant’s 
subjective perception of fertility problems (Cronin et al., 1998). Three participants became pregnant 
during the LMP but that didn’t affect the outcome measures. 
Strengths and limitations 
We used a prospective longitudinal within-subject design creating the possibility to study the effect of 
time at different moments in time and having the advantage to minimize the recall error (Polit & Beck, 
2004). On the contrary, this had the disadvantage of inducing the Hawthorne effect (Polit & Beck, 
2004). The fact that women knew they were under study could possibly have influenced the way they 
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felt, as well as the way they answered the questionnaire. Psychological therapy (i.e., CBT) was 
described by Shaw et al. (2005) to be important in weight loss programs in order to obtain a maximum 
effect, and it was therefore included in our LMP. However, the design of the current study did not 
allow to test the additional value of this subprogram to the LMP. Neither it was possible to evaluate 
the benefit of the other two components of this LMP (i.e., the diet and exercise subprogram). 
Therefore future research using a randomized controlled study design is needed. 
We also have to acknowledge the small sample size of 31 women with PCOS and a large number of 
missing data at different moments in time. This was due to women who failed to complete the 
questionnaire, and due to women who dropped out during the LMP. This missing information resulted 
in an unbalanced data set. This limitation was partly accounted for by using a LMM analysis (Verbeke 
& Molenberghs, 2000; West et al., 2006). The small sample size might also be a reason for low 
Cronbach’s alpha scores of the PCOSQ (Rouquette & Falissard, 2011). 
The drop-out rate in our study was 25.8% which is much lower than the drop-out rate during the 20-
week LMP performed by Thomson et al. (2010) (i.e., 55.32%). It is described that the risk of attrition is 
especially large when the length of time between points of data collection is long (Polit & Beck, 2004). 
Interestingly, in our study most drop-outs occurred during the first part of LMP although the time 
between the consultations was longer when the program progressed. On the other hand, this is in line 
with the Iannaccone et al. (2013) study which reports that the risk of attrition is especially large during 
the beginning of longitudinal studies. A study by Galletly et al. (2007) mentions that a better 
compliance is possibly related to better feelings of psychological well-being. This might have been an 
influencing factor for drop-out but we have not registered the reason for drop-out due to lack of 
follow-up data. 
Implications for Practice 
Several health professionals play an important role in treating and counseling overweight women with 
PCOS (i.a., physicians, nurses and midwives, psychologists). Based on results of our study, it is clear 
that HRQoL in overweight women with PCOS evolves positively during a 24-week LMP. Additionally, 
earlier research described the positive effect of lifestyle modification on physical parameters in women 
with PCOS (Hoeger, 2006; Hoeger et al., 2004; Huber-Buchholz et al., 1999; Norman et al., 2002; Tang 
et al., 2006; Thessaloniki ESHRE/ASRM-Sponsored Consensus Workshop Group, 2008). Nurses and 
midwives who come into contact with those women should be aware of this existing evidence and, 
consequently, they should inform women about the benefits of lifestyle modification in terms of 
HRQoL. Nurses and midwives could contribute to the provision of adequate care to women with PCOS 
by referring them to the professionals whom are part of a multidisciplinary lifestyle modification team 
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(i.e., physician, physiotherapist, dietician, psychologist). Furthermore, nurses and midwives may also 
play an active role by coordinating a LMP, encouraging women to participate in a LMP, and by 
supporting them to maintain a modified lifestyle. 
Recommendations for Future Research 
To determine if a psychological subprogram has an additional benefit to a LMP, a randomized 
controlled trial should be performed. In addition, a long term cost-effectiveness analysis is needed to 
make a decision about the acceptable length of LMPs in terms of weight reduction, weight 
maintenance, and HRQoL in overweight women with PCOS. 
Conclusion 
In summary, our findings indicate that the HRQoL of overweight adult women with PCOS evolved 
positively, especially during the first 12 weeks of a 24-week LMP, consisting of a diet, exercise and 
psychological subprogram. Based on these results as well as on the results of the study of Thomson et 
al. (2010), overweight adult women with PCOS should be encouraged to follow a lifestyle modification 
program in order to increase their HRQoL.  
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Table 1.              
Schedule of consultation with the appropriate professional per subprogram during the 24-week 
lifestyle modification program (LMP) 
  Week of LMP 
Subprogram 0 2 4 6 8 10 12 14 16 18 20 22 24 
Diet subprogram *  *  *    *    * 
Exercise subprogram *  *  *    *    * 
Psychological subprogram *   (*)   (*)   *   (*)   (*)   * 
Note. (*) = extra consultation on demand of the participant. 
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Table 2. 
Key content components for the diet, exercise and psychological subprogram 
Subprogram Key content components 
Diet subprogram Mild energy restriction (i.e., -450 to -850 Kcal/day) 
 General dietary principles 
      Daily dietary pattern of three principal meals alternated with three snacks 
      Healthy food 
      Balanced meal composition 
      ≥ 1.5 L of calorie free drinks per day 
  
Exercise subprogram Raising daily physical activity level through increasing number of steps per day 
 Practicing sports 
  
Psychological subprogram Cognitive behavioral therapy 
 Additional techniques: 
      Problem solving 
      Goal setting 
      Increasing social support 
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Table 3. 
Psychometric properties of the PolyCystic Ovary Syndrome Questionnaire (PCOSQ) and the acne 
Visual Analogue Scale (VAS) 
    week 0   week 12   week 24 
PCOSQ  Cronbach’s alpha coefficient 
Five domains          
     Emotions   .74   .86   .84 
     Weight   .83   .84   .93 
     Body hair   .94   .95   .94 
     Infertility problems   .73   .81   .92 
     Menstrual problems   .57   .74   .80 
Total PCOSQ   .40   .65   .81 
          
VAS  Mdn IQR  Mdn IQR  Mdn IQR 
     Acne problems  1.1 6.4  0.9 2.38  0.2 1.5 
          
Note. IQR = interquartile range; Mdn = Median 
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Table 4.      
Demographic and clinical characteristics of the participants at the start of the lifestyle modification program 
Characteristic n Mdn IQR Frequency % 
Demographic characteristic 
Age in years 31 29 5   
Highest level of education      
     Secondary education 29   7 24 
     Higher education 29   22 76 
Clinical characteristic 
Gravidity 31   9 29 
Parity 31   7 23 
Current unfulfilled wish to conceive 31   22 71 
Duration of unfulfilled wish to conceive in days 31 731 944   
Body mass index in kg/m² 31 33.74 7.8   
Irregular menstrual cycle 31   29 94 
Presence of hirsutism 30   13 43 
Presence of facial acne 31   15 48 
Free testosterone in ng/dL 31 0.82 0.95   
Note. Mdn = Median, IQR = interquartile range. Gravidity = number of women who had been pregnant at least 
once, Parity = number of women who had given birth at least once. 
Continuous measurements are summarized as Median (IQR) since they are not symmetrically distributed. 
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Table 5.  
Fixed effects and their interactions for all models from the linear mixed effects analysis using restricted 
maximum likelihood estimation 
Dependent variable Predictor b SE(b) t 
PCOSQ domain     
     Emotions Intercept 4.40 0.23 19.50 
 Time (week 12) 0.82 0.23 3.55 
 Time (week 24) 1.11 0.24 4.63 
 Age in years -0.01 0.03 -0.35 
 Secondary education (yes) -1.06 0.45 -2.34 
 Time x Education    
      Time (week 12) x Secondary education (yes) 1.33 0.50 2.67 
      Time (week 24) x Secondary education (yes) 1.08 0.50 2.15 
          R²glmm(m) = 31.79%     
          R²glmm(c) = 71.25%     
     
     Weight Intercept 2.45 0.25 9.76 
 Time (week 12) 1.51 0.27 5.61 
 Time (week 24) 1.75 0.27 6.37 
 Age in years -0.02 0.03 -0.71 
 Secondary education (yes) 0.51 0.45 1.13 
 Body mass index in kg/m² -0.07 0.04 -1.86 
          R²glmm(m) = 35.32%     
          R²glmm(c) = 63.18%     
     
     Body hair Intercept 4.79 0.33 14.59 
 Time (week 12) 0.79 0.20 3.93 
 Time (week 24) 0.53 0.20 2.62 
 Age in years -0.02 0.05 -0.43 
 Secondary education (yes) -0.09 0.65 -0.13 
 mFG score -0.19 0.04 -4.42 
 Free testosterone level in ng/dL 0.12 0.18 0.67 
 Time x mFG score    
      Time (week 12) x mFG score 0.08 0.03 2.58 
      Time (week 24) x mFG score 0.03 0.04 0.79 
          R²glmm(m) = 36.03%     
          R²glmm(c) = 87.59%     
     
     Infertility problems Intercept 4.09 0.35 11.81 
 Time (week 12) 1.29 0.30 4.28 
 Time (week 24) 1.57 0.31 5.11 
 Age in years 0.01 0.03 0.32 
 Secondary education (yes) 0.32 0.37 0.86 
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 Current unfulfilled wish to conceive (present) -1.56 0.33 -4.71 
 Parity (yes) 0.97 0.46 2.10 
          R²glmm(m) = 52.66%     
          R²glmm(c) = 59.82%     
     
     Menstrual problems Intercept 5.61 1.07 5.26 
 Time (week 12) 0.55 0.29 1.88 
 Time (week 24) 0.68 0.30 2.30 
 Age in years -0.01 0.05 -0.25 
 Secondary education (yes) -0.76 0.61 -1.24 
 Menstrual cycle irregularity (present) -1.77 1.04 -1.70 
          R²glmm(m) = 14.19%     
          R²glmm(c) = 65.29%     
     
Total PCOSQ Intercept 3.72 0.20 18.79 
 Time (week 12) 1.00 0.18 5.42 
 Time (week 24) 1.19 0.19 6.22 
 Age in years 0.001 0.03 0.03 
 Secondary education (yes)  0.05 0.37 0.14 
          R²glmm(m) = 25.91%     
          R²glmm(c) = 69.65%     
     
Acne VAS     
     Acne problems Intercept 1.13 0.59 1.92 
 Time (week 12) -0.32 0.40 -0.80 
 Time (week 24) -0.73 0.55 -1.34 
 Age in years 0.08 0.08 0.96 
 Secondary education (yes) -0.79 0.74 -1.07 
 Acne (present) 4.27 0.91 4.69 
 Time x Age    
      Time (week 12) x Age in years -0.19 0.07 -2.96 
      Time (week 24) x Age in years -0.12 0.08 -1.52 
 Time x Acne    
      Time (week 12) x Acne (present) -1.51 0.64 -2.36 
      Time (week 24) x Acne (present) -1.77 0.84 -2.11 
          R²glmm(m) = 27.65%     
          R²glmm(c) = 93.08%     
          
Note. Parity was observed as a nominal variable answering the question "Have you already been pregnant at 
least once?". PCOSQ = PolyCystic Ovary Syndrome Questionnaire; mFG =  modified Ferriman-Gallwey; VAS = 
Visual Analogue Scale. R²glmm(m) = marginal R² (i.e., variance explained by fixed factors); R²glmm(c) = conditional R² 
(i.e., variance explained by the entire model) (Nakagawa & Schielzeth, 2013). 
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Abstract 
 
Background: Gonadotropin therapy and laparoscopic ovarian drilling (LOD) are treatment options for 
ovulation induction (OI) in clomiphene citrate (CC) resistant polycystic ovary syndrome (PCOS) 
patients. The current evidence on the cost-effectiveness of both treatments is scarce, conflicting and 
performed from different health-economic perspectives. 
Methods: A retrospective health-economic evaluation was performed from a societal perspective in 
which human Menopausal Gonadotropin (hMG) therapy (n=43) was compared with LOD (n=35), 
followed by OI with CC and/or hMG if spontaneous ovulation didn’t occur within 2 months. Data were 
collected till patients were pregnant, with a time limit of 6 months after the onset of treatment. 
Outcomes were expressed in ongoing pregnancy rate and the number of live-born children. 
Results: The ongoing pregnancy rate was 21/35 (60%) after LOD and 30/43 (69.8%) after hMG 
treatment (relative risk 0.85, 95% CI 0.61-1.19). The societal cost per patient, up to an ongoing 
pregnancy, was significantly higher after LOD versus hMG treatment (adjusted mean difference €1073, 
95% CI €180-€1967). 
Conclusion: This economic evaluation based on real life data shows that the societal cost up to an 
ongoing pregnancy is less after hMG treatment when compared with LOD surgery in CC resistant PCOS 
patients.
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Introduction 
Both gonadotropins and laparoscopic ovarian drilling (LOD) are treatment options currently used for 
ovulation induction (OI) in clomiphene citrate (CC) resistant polycystic ovary syndrome (PCOS) patients 
[1-3]. These treatments are proven to be effective but entail important costs and possibly bring along 
short and long-term complications [4-7]. In 2004 two health-economic evaluations from a societal 
perspective comparing both treatment strategies were published [8, 9]. Farquhar et al. [8] concluded 
that LOD was the most cost-effective option,  whereas van Wely et al. [9]  found a comparable cost-
effectiveness of both treatments. A health economic evaluation, performed alongside a long term 
follow-up study, by Nahuis et al. [10] concluded that LOD was the most cost-effective option from a 
public payer perspective. 
The current evidence on the cost-effectiveness from the societal perspective of gonadotropin 
treatment versus LOD in CC resistant PCOS patients is scarce and conflicting. Therefore we assessed 
the cost-effectiveness of these treatments applying a societal perspective, including direct medical 
costs covered by the public payer and the patient as well as productivity loss and transportation related 
costs, all based on retrospectively collected real life data. 
 
Materials and Methods 
The study was performed at the Department of Reproductive Medicine of Ghent University Hospital 
and was authorized by the Ethics Committee of that hospital. Informed consent was not obtained but 
patient information was anonymized and de-identified prior to analysis. Seventy-eight patients with 
PCOS, according to the Rotterdam consensus criteria [11], who were subfertile for >1 year and CC 
resistant (i.e. failure to ovulate with CC 150 mg/day for 5 days), were included. Forty-three patients 
were treated with hMG and 35 patients underwent LOD, based on patient’s informed choice. All 
patients, except one, were treated between 2000 and 2009. 
To administer hMG (Humegon, Organon, Oss, The Netherlands or Menopur, Ferring, Aalst, Belgium) a 
low-dose step-up protocol with a starting dose of 37.5 IU/day was used. When 1 or 2 follicles were >18 
mm diameter, ovulation was triggered with hCG 5000 IU (Pregnyl, Organon, Oss, The Netherlands). 
Patients had intercourse or in case of mild male subfertility, underwent intrauterine insemination (IUI),  
36 to 40 hours later. LOD was performed with a diathermy needle making 5 to 12 holes (3-4 mm in 
diameter) in each ovary, depending on its size. A standardised monopolar coagulation current set at 
30 Watt was used. If no spontaneous ovulation occurred within 2 months after LOD, OI with CC and/or 
hMG was started (fig. 1).  
Data were collected from patient’s medical files and collection ended when patients became pregnant 
or after maximum 6 months of treatment. Effectiveness of treatment was expressed in ongoing 
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pregnancy rate and the number of live-born children. A miscarriage was defined as a loss of the foetus 
before 12 weeks of gestation. To calculate the direct medical costs, the medical resource items used 
per patient (e.g. injection of drugs, hospital visit, transvaginal ultrasound, laparoscopy) were identified 
and multiplied with their unit cost. The latter information was obtained via the patient invoices or from 
the Belgian public insurer (National Institute for Health and Disability Insurance). To calculate the costs 
related to productivity loss, the number of days of work leave was estimated per patient and multiplied 
with the societal cost for one day of work leave (€217.57), which was based on a report from Securex, 
a social and employment service organization [12]. The unemployment rate in 2007 was taken into 
account to calculate this amount [13]. An outpatient visit was counted as half a day of work leave. The 
duration of the hospital stay and the recovery phase at home were also registered. Travel distances 
were estimated per patient and multiplied with a standard price of €0.2940/km (www.bibf.be) to 
calculate the transportation cost. Costs were expressed in Euro and prices of the year 2007 were used. 
If prices of the year 2007 were not traceable, the cost was inflated to that year using the Belgian health 
index data. 
Statistical analysis 
Independent samples t-tests, Mann-Whitney U, Chi-square and Fisher Exact tests were used where 
appropriate and the statistical significance level was set at p < 0.05. The primary outcome was the cost 
until an ongoing pregnancy and sensitivity analyses were performed to evaluate the influence of 
several cost items on this analysis. Additionally a scenario analysis was done to study the cost until 3 
months postpartum, including the cost for both singleton and twin pregnancies. For the latter purpose, 
the costs of the perinatal period (i.e. between 12 weeks of gestation until 3 months postpartum) were 
retrieved from Gerris et al. [14] for both singleton and twin pregnancies. All cost analyses were 
performed by using multiple linear regression to adjust for confounding factors [body mass index (BMI) 
and LH:FSH ratio] and residual analyses confirmed the adequacy of the models. Where appropriate, an 
incremental cost-effectiveness ratio (ICER) was calculated along with 95% nonparametric bootstrap 
percentile intervals based on 10000 bootstrap resamples. This is a popular nonparametric technique 
for calculating CI, based on repeating the data analysis for each of 10000 samples that are randomly 
drawn from the available data set (with replacement) and evaluating the variability in analysis results 
from sample to sample [15]. Statistical analyses were performed using SPSS version 19.0; bootstrap 
confidence intervals (CI) were obtained using the package boot in RStudio Version 0.97.168.  
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Results 
Patient characteristics per treatment strategy are reported in table 1 [16]. The patient characteristics 
were not significantly different between the two groups, except for primary subfertility which was 
significantly more prevalent in the LOD group when compared with the hMG group.. The effectiveness 
of each treatment strategy after 6 months is reported in table 2.  
The LOD surgery necessitated 1.46±0.74 days of hospital stay, followed by a recovery phase of 
7.06±2.01 days at home. The median number of days of work leave per patient after LOD was 10 (IQR 
4.4) versus 5.5 (IQR 6.5) after hMG treatment (p < 0.001). After LOD, a mean of 2.5±1.36 cycles of OI 
were performed. In that group, 11/21 (52.4%) ongoing pregnancies were achieved with additional drug 
therapy (i.e. 9.66±4.46 tablets of 50 mg CC/cycle and 1162.5±1170.34 IU of hMG/cycle) and the other 
10/21 (47.6%) were spontaneous ongoing pregnancies (i.e. 5 after timed coitus and 5 without cycle 
monitoring). In the hMG group, the average number of hMG cycles was 2.7±1.5 with 1131.61±646.25 
IU/cycle. 
The societal cost per patient was significantly higher after LOD versus hMG treatment (table 3). 
Respectively 60.6% and 42.3% of this cost was due to productivity loss. In the LOD and hMG group, the 
drug cost accounted for 6.7% and 44.1% of the total direct medical cost, respectively.  
Observing the substantial contribution of the cost of productivity loss to  the societal cost after LOD, a 
sensitivity analysis was done by reducing the cost of productivity loss with 25% and 50%. A 50% 
reduction of that cost would make LOD the least expensive option (i.e. €2778±€1249 per patient) for 
the society  , although not significant (p = 0.6). The adjusted incremental cost per ongoing pregnancy 
for a hMG treatment versus LOD would then be €3879 (bootstrap 95% CI -€52077 to €54181). We also 
studied the sensitivity of the societal cost after LOD to a change in the amount of drugs, since only 11 
(52.4%) patients of this group needed additional drug therapy to achieve an ongoing pregnancy. The 
drug cost was varied between 0% and 200%, but the societal cost was not sensitive to that variation.  
In the scenario analysis where we included the published cost until 3 months postpartum for singleton 
and twin pregnancies, we obtained a total societal cost of €8004±€7143 per patient after LOD and 
€11105±€12560 per patient after hMG treatment (adjusted mean difference €1597, 95% CI -€7706 to 
€4511). The adjusted incremental cost per live-born child for a treatment with hMG versus LOD was 
€15816 (bootstrap 95% CI -€83714 to €112657). 
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Discussion 
This study compared the cost-effectiveness of LOD with hMG treatment for OI in CC resistant PCOS 
patients. 
No significant difference was found in ongoing pregnancy rate and in the number of live-born children 
between both treatment groups, which is in line with Farquhar et al. [5] and Bayram et al. [6]. In our 
research, we had no data to confirm whether patients underwent a hysterosalpingography or 
diagnostic laparoscopy before treatment was started, although Tsuji et al. [17] advised to perform a 
diagnostic laparoscopy when timing therapy as well as when controlled ovarian hyperstimulation fails. 
It is possible that the patency of both tubes was evaluated during laparoscopic surgery for ovarian 
drilling but this could not be confirmed as well. 
Despite the use of a low-dose step-up protocol for hMG administration the number of twin 
pregnancies was highest in the hMG group. This is similar to Bayram et al. [6] where the number of 
twin pregnancies after gonadotropin therapy was even significantly higher compared to the LOD 
strategy (RR 0.11, 95% CI 0.01-0.88). 
We found that the societal cost per patient up to an ongoing pregnancy was significantly higher after 
LOD versus hMG treatment. In contrast, van Wely et al. [9] found a comparable societal cost up to an 
ongoing pregnancy between the two treatment strategies and Farquhar et al. [8] concluded that LOD 
was the least expensive option in CC resistant PCOS patients. Both studies used a societal approach as 
well. In our study the societal cost was mostly ascribed to productivity loss after LOD, which was in 
turn mainly caused by a long recovery phase at home. Only a 50% reduction of the cost of productivity 
loss made LOD less expensive for the society than hMG treatment. In our study, we have no 
information to justify the duration of the recovery phase. Interestingly, transvaginal hydrolaparoscopic 
ovarian drilling (THLOD) has been associated with a productivity loss of maximum 3 days [18]. And 
since there is evidence that THLOD results in a similar ovulation and pregnancy rate as LOD and is 
associated with a low risk of intra- and postoperative complications, this technique might be a valuable 
alternative to LOD in order to reduce the societal cost of an ovarian drilling [18-21]. 
When considering the societal cost per patient until 3 months postpartum, LOD was the least expensive 
option. This is an important finding since in this calculation the cost of a multiple pregnancy – which 
might be up to 5 times higher than the cost of a singleton pregnancy [14, 22] - was taken into account. 
Although in our study, the number of multiple pregnancies was not significantly higher after hMG 
treatment when compared with LOD, when the additional cost of these pregnancies was included, this 
had a substantial influence on the societal cost. Our finding concerning this cost is in line with the 
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conclusion of Farquhar et al. [8] even though there were no multiple pregnancies included in that study. 
Furthermore, one has to be aware that the higher risk of complications (e.g. preterm birth) associated 
with a multiple pregnancy results in an increased prevalence of disabled children [14]. This induces a 
lifelong additional societal cost. Aside from this medical-induced financial impact, raising twins in 
general has a larger societal impact as well since costs are double (in most cases) at the same moment 
in time. 
In the long term follow-up study by Nahuis et al. [23], performed over a period of 8 to 12 years, it was 
proven that laparoscopic electrocautery resulted in a higher prevalence of regular menstrual cycles 
and a higher spontaneous pregnancy rate when compared with gonadotropin therapy. The 
consequently lower need for OI or assisted reproductive technology (ART) lead to a lower mean cost 
per live birth after laparoscopic electrocautery when compared with gonadotropin therapy [10]. 
Although in this economic evaluation only a public payer perspective is considered, this is an important 
finding since the long term effectiveness and costs of both treatments were taken into account. 
In our study, we have to acknowledge the small sample size of 78 patients, which is about half the 
sample size in the study of Bayram et al. [6], but is larger than in the study of Farquhar et al. [5]. We 
used a retrospective design having the advantage of avoiding the Hawthorne effect as well as protocol 
induced effects and costs [24]. Hence the real clinical practice (i.e. the real clinical and financial impact 
of a treatment) and not an idealized practice is reflected [25]. For clinicians as well as patients, it is 
important to base their clinical decisions also on such evidence in order to better manage uncertainty. 
Furthermore, there is also a growing interest in real life data on effectiveness and costs at the time 
when policy makers take reimbursement and pricing decisions [25]. On the other hand the non-
randomized setting enhances the risk for confounding bias [24]. We attempted to reduce the influence 
of confounding factors on the calculated costs by regression adjustment for BMI and LH:FSH ratio, 
which were the sole two variables of clinical relevance having a significant influence on cost. 
Nevertheless we cannot exclude the possibility that the groups are not entirely comparable in terms 
of unmeasured factors. Even though the prevalence of primary subfertility was significantly higher 
after LOD, this variable did not have a significant influence on the cost analyses. We have to recognize 
that the mean BMI in our sample is < 30 kg/m². Moreover 76.7% and 66.6% of the LOD and hMG group, 
respectively, were not obese according to the WHO BMI classification (Table 1) [16]. This 
acknowledgement is important to make since in the general PCOS population up to 70% of the PCOS 
patients suffer from obesity [26]. A study by Amer et al. [27] proved that a BMI ≥ 35 kg/m² has an 
important negative influence on the efficacy of LOD. Therefore, one has to be careful when 
generalizing these results, also because the costs were calculated within the Belgian health care system. 
The mentioned incremental cost per ongoing pregnancy in the sensitivity analysis and per live-born 
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child in the scenario analysis should be interpreted with caution since the differences in both costs and 
effects are not significant [28]. 
We conclude that hMG treatment is the least expensive option for CC resistant PCOS patients from a 
societal perspective in terms of ongoing pregnancy. Only if the pre-, per- and postnatal period until 3 
months postpartum is included, LOD is the least expensive option, although not significant. Considering 
the same time frame, further research is needed to make a statement about the cost-effectiveness of 
both treatments from a public payer and a patient perspective. Further research is also needed to 
assess the cost-effectiveness of both treatments from a societal perspective over a long term.
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Figure 1: Flowchart of the treatments that participants received. 
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Table 1. Patient characteristics of the study population per treatment strategy. 
  LOD hMG   
Characteristic (n=35) (n=43) P-value 
Age (years) 28.57±3.49 28.14±3.13 0.6 
Body mass index (kg/m²) 24.4 (20.4-30) 23.4 (20.4-32.4) 0.9 
BMI categoriesa   0.9 
     Underweight (< 18.5 kg/m²) 2/30 (6.7%) 3/42 (7.1%)  
     Normal weight (18.5-24.9 kg/m²) 15/30 (50%) 20/42 (47.6%)  
     Overweight (25-29.9 kg/m²) 6/30 (20%) 5/42 (11.9%)  
     Obesity class I (30-34.9 kg/m²) 5/30 (16.7%) 9/42 (21.4%)  
     Obesity class II (35-39.9 kg/m²) 2/30 (6.7%) 4/42 (9.5%)  
     Obesity class III (≥ 40 kg/m²) 0 1/42 (2.4%)  
Hirsutism 11/18 (61.1%) 20/29 (69%) 0.6 
LH:FSH ratio 2 (1.2-2.5) 1.5 (1-2.7) 0.7 
Testosterone (ng/dL) 54.2 (36.5-85.2) 49.4 (38.5-64.8) 0.2 
FAI 130.2 (75.5-266.4) 112.9 (48.2-214.6) 0.3 
Insuline (µU/mL) 7.4 (4.2-16) 10.2 (6.2-26) 0.4 
PCOMb 35/35 (100%) 38/43 (88.4%) 0.1 
Irregular menstrual cycle 33/35 (94.3%) 39/43 (90.7%) 0.7 
Primary subfertility 30/35 (85.7%) 28/43 (65.1%) 0.04 
Smoking 5/29 (17.2%) 10/40 (25%) 0.4 
aThe international BMI classification of the World Health Organization is used [16]. 
bPolycystic ovarian morphology on transvaginal sonography. 
Continuous measurements are summarized as mean±SD if symmetrically distributed, and as 
median (1st quartile - 3rd quartile) otherwise. 
Nominal measurements are summarized as n(%). 
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Table 2. Effectiveness of each treatment strategy after a period of maximum 6 months. 
  LOD hMG       
Characteristic (n=35) (n=43) RR 95% CI P-value 
Ongoing pregnancy rate 21/35 (60%) 30/43 (69.8%) 0.85 0.61-1.19 0.5 
     Twin pregnancy rate 1/21 (4.8%) 5/30 (16.7%) 0.29 0.03-1.96 0.4 
Number of live-born children 22/35 (62.9%) 35/43 (81.4%) 0.77 0.57-1.03 0.3 
Measurements are summarized as n (%). 
RR = relative risk 
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The polycystic ovary syndrome is a chronic disease with a complex symptomatology wherewith the 
patient, as well as her family and the society have to deal. The general objective of this dissertation 
was to do research about psychological, perinatal, lifestyle and health-economic aspects of PCOS that 
really matter for the patient, her family and the society. 
Firstly, our findings indicate that objective PCOS characteristics (i.e., parity, women’s BMI, and current 
unfulfilled wish-to-conceive) as well as subjective PCOS characteristics (i.e., women’s infertility-related 
and acne-related concerns) are associated with the sexual and/or relational satisfaction level of 
couples dealing with this chronic disease. Additionally, we found a differential association of these 
characteristics with the satisfaction level between women with PCOS and their partners. 
Secondly, we observe an increased risk of preterm birth and an increased risk of giving birth to a baby 
with a higher birth weight in overweight versus normal weight women with PCOS having an ongoing 
singleton pregnancy.  
Thirdly, our results show an improvement of HRQoL in overweight adult women with PCOS during a 
24-week lifestyle modification program. This improvement is primarily situated during the first 12 
weeks of LMP. Furthermore, despite the lack of significant changes in BMI, we found a trend towards 
a correlation between a decrease in BMI and an increase in HRQoL. 
Finally, we found that, based on real life data, the societal cost up to an ongoing pregnancy was less 
after hMG therapy when compared with LOD surgery in CC resistant women with PCOS. However, 
when including the pre-, per- and postnatal period until 3 months postpartum, our results point into 
the direction of LOD being the least expensive option. 
Further on in this chapter these results as well as methodological issues of this dissertation are 
discussed per research item.  
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6.1 Sexual and relational satisfaction in couples where the woman has 
polycystic ovary syndrome: a dyadic analysis. 
 
6.1.1 Discussion 
Relational functioning in intimate relationships is complex and is described in several theoretical 
frameworks. The vulnerability-stress-adaptation model of Karney & Bradbury (1995) is seen as the 
most complete and comprehensive model. According to that model, relational functioning is driven by 
adaptive processes (i.e., conflict and support) which directly influence the relationship quality and 
relationship stability. Also, these adaptive processes function as a mediator between stressful events 
and the level of relationship satisfaction. Stressful events might be related to the intimate relationship 
itself but may also be personal to one of both partners in an intimate relationship. The latter counts 
for couples in which one partner has (chronic) health problems (e.g., PCOS). The capacity of couples to 
cope with stressful events through the above mentioned adaptive processes depends on each couple 
member’s strengths and vulnerabilities, as wel as on the kind and level of experienced stress (Karney 
& Bradbury, 1995; Bradbury & Karney, 2004). 
Bradbury & Karney (2004) mention that marital quality is lower among couples experiencing higher 
levels of chronic stress. This is of interest in the context of PCOS being a chronic stressor in a couple’s 
life. In contrast, our results report that the relational satisfaction levels of PCOS women and their 
partners were significantly higher when compared with a reference sample of heterosexual married 
women and men (Joseph et al., 2007). On the other hand, our results about the sexual satisfaction 
level were not unambiguous. More specifically, the sexual satisfaction levels of PCOS women and their 
partners were (not significantly) lower and higher, respectively, when compared with that reference 
sample (Joseph et al., 2007). 
PCOS, as a chronic stressor, is characterized by important changes in a woman’s physical appearance 
(i.e., hirsutism, acne, and overweight) which threaten her gender identity (Kitzinger and Willmott, 2002; 
Snyder, 2006). These changes in physical appearance are thought to have a negative impact on a 
couple’s intimate relationship. Considering the objective measurement of hirsutism, acne, and 
overweight, we only found an association of overweight, as expressed by BMI, with the level of sexual 
and relational satisfaction. More specifically, our results are indicative for a negative association of 
PCOS women’s BMI with their level of sexual and relational satisfaction. So far, in women with PCOS, 
the evidence about the association of overweight, as expressed by BMI, with sexual satisfaction and/or 
functioning is conflicting. Namely, a negative association, on the one hand, and the absence of an 
association, on the other hand, is described (Elsenbruch et al., 2003; Hahn et al., 2005; Månsson et al., 
2011; Stovall et al., 2012). In the general female population, an increased BMI is not associated with a 
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decreased level of sexual satisfaction (Kadioglu et al., 2010; Yaylali et al., 2010). But, when using the 
parameters weight and waist circumference to define overweight, a significant negative correlation 
with the level of sexual satisfaction is detected (Yaylali et al., 2010; Brody and Weiss, 2013). To our 
knowledge, there is currently no evidence available about the association of a woman’s BMI with her 
level of relational satisfaction in a sample of PCOS women as well as in the general female population 
wherewith our results could be compared. The same applies to the association of women’s BMI with 
the level of sexual and relational satisfaction as experienced by their partners. However, the Boyes and 
Latner (2009) study concluded that male partners of heavier women judge their women to be less 
attractive. In contrast, our results suggest a higher level of sexual satisfaction in partners of PCOS 
women with a higher BMI when compared with partners of PCOS women with a lower BMI. This might 
probably be explained by the fact that one has a better self-image and self-esteem in the presence of 
a heavier sexual partner. Yet, the latter is only hypothetical and warrants further research. Our study 
is performed in a sample of overweight (BMI ≥ 25 kg/m²) women with PCOS. Although our study 
provides interesting new information about the association of women’s BMI with the satisfaction level 
of both partners in a couple, our results can only be generalized to a population of couples dealing 
with PCOS where the woman is overweight. 
Considering a woman’s subjective perception of changes in physical appearance, we only found a 
significant negative association of the degree of acne-related concern with the level of sexual 
satisfaction in both women with PCOS and their partners. To date, there are no other studies in PCOS 
couples and in the general population reporting on the correlation of those concerns with sexual 
and/or relational satisfaction levels. 
Besides the changes in physical appearance, subfertility is an important consequence of PCOS and is 
present in 55-90% of women with PCOS (Balen et al., 2005; Badawy et al., 2009). Our results suggest a 
positive association of subfertility (i.e., the presence of a current unfulfilled wish to conceive and the 
subjective infertility-related concern) with the level of relational satisfaction in both PCOS women and 
their partners. Although, the existing evidence about this association in a population of women 
without PCOS is inconsistent, it is described that knowing the cause of infertility has a significant 
positive impact on the relational satisfaction level in women (Bringhenti et al., 1997; Monga et al., 
2004). Moreover, Månsson et al. (2011) mention that couples with fertility problems probably have a 
more stable relationship. This might interfere with the association of subfertility with the level of 
relational satisfaction. This indicates that one has to be careful when interpreting the results as 
reflecting the direct association of fertility problems with the level of relational satisfaction. 
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Weber (2011) describes that objective characteristics of a stressor (like PCOS) are conceptually and 
methodologically different from a person’s perception of and reaction to a stressor. The fact that we 
found different associations of objective measurements of PCOS characteristics, on the one hand, and 
subjective measurements of PCOS characteristics, on the other hand, with the level of sexual and 
relational satisfaction, supports this statement. Weber (2011) and Trent et al. (2002) also describe that 
a person’s subjective perception of a stressor is more directly related to one’s individual and relational 
well-being than its objective characteristics. In our study, we found important associations of PCOS 
women’s subjective experience of the syndrome with satisfaction levels which indicate that it is of 
interest to take into account the subjective perception of PCOS (as a chronic stressor). Unfortunately, 
in our study we were not able to attend the hypothesis that PCOS women’s subjective perception of 
the disease-related characteristics was more strongly associated with the satisfaction level when 
compared with the objective measurement of the PCOS characteristics. 
Our results show that the sexual and relational satisfaction level of women with PCOS was significantly 
lower when compared with their partners’. In contrast, the relational satisfaction level in patients with 
another chronic disease (i.e., kidney disease) was significantly higher than their partners’ (Van Son-
Schoones, 1994). A possible explanation therefor might be that PCOS has a worse impact on a patient’s 
psychological well-being when compared with other (chronic) medical conditions (Coffey et al., 2006). 
On the other hand, the fact that PCOS might have a less negative impact on their partners’ relational 
satisfaction level when compared with other chronic diseases can also not be excluded. 
While studying the effect of a disease on the satisfaction level of both partners in a couple, one needs 
to take into account the interdependence of both couple members. This is important since two 
individuals involved in a committed intimate relationship are voluntary linked to each other and they 
socially interact with one another (Cook et al., 2006). This phenomenon makes them non-independent 
from each other (Cook et al., 2006). Consequently, a partner’s experienced level of satisfaction does 
not simply reflect something about that single person but is driven in part by characteristics of the 
other one (e.g., a person’s strengths and vulnerabilities, coping ability with a stressor) as well as by the 
established unique relationship between both partners in a couple (e.g., spousal support). Therefore, 
the measurement of a partner’s level of satisfaction reflects the contribution of two individuals (Cook 
et al., 2006). This link between two partners in a couple is taken into account through performing 
dyadic statistical analyses (Cook et al., 2006). Using this analytic technique, our results show a 
significant differential association of PCOS characteristics with the satisfaction level between women 
with PCOS and their partners. 
GENERAL DISCUSSION and PERSPECTIVES FOR FUTURE RESEARCH 
  141 
The effect of a stressor (e.g., PCOS) on a couple’s relationship satisfaction might, besides the 
interdependence of both members in a couple, also be confounded or mediated by other external 
factors such as socio-cultural factors (e.g., culture and gender), experienced support by a professional 
and/or family, and other medical conditions whether or not related to the stressor (e.g., depression) 
(Elsenbruch et al., 2003; Berg and Upchurch, 2007; Kadioglu et al., 2010). It is important to adjust for 
such confounding factors in further research in order to clarify that the association found is reflecting 
a direct association. 
 
6.1.2 Perspectives for future research 
Although our results are promising, some limitations of this study must be addressed in order to clarify 
already existing as well as new research questions. 
Firstly, a larger confirmatory study is needed to avoid that certain associations, representing 
statistically low to medium effects of PCOS on the satisfaction level, cannot be detected due to a too 
small sample size and the resulting lack of power. Furthermore, it is advised to include overweight as 
well as normal weight women with PCOS in future research. This would help to clarify the association 
of overweight with sexual and relational satisfaction, as well as to enhance the generalizability of the 
results to the general population of couples dealing with this chronic disease. Also, further research 
should take into account the influence of possible confounding and mediating factors. 
Secondly, one should investigate if subjective rather than objective PCOS characteristics are more 
strongly associated with the satisfaction level in couples dealing with PCOS by using a multivariate 
statistical analytic model that includes objective predictors (i.e., objective PCOS characteristics) and 
subjective predictors (i.e., PCOS-related concerns) simultaneously. This might indicate whereupon to 
focus when treating and counseling those couples. 
Finally, it might be of interest to do research about how unique the associations found are for couples 
dealing with PCOS.  
In general, research about the sexual and non-sexual aspects of a long-term intimate relationship in 
couples dealing with PCOS is very rare. Given the importance of sexuality during reproduction, this 
topic warrants more scientific attention.  
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6.2 A retrospective study of the pregnancy, delivery and neonatal outcome 
in overweight versus normal weight women with polycystic ovary 
syndrome. 
 
6.2.1 Discussion 
Overweight is an important symptom in women with PCOS threatening their own health. On the other 
hand, overweight during the preconceptional period also entails an important risk for complications 
during pregnancy, delivery and the neonatal period and hence threatens the health of both mother 
and child. As such, overweight is associated with an increased prevalence of macrosomia in singletons 
of women with PCOS, as well as in the general female population (Sarwer et al., 2006; Han et al., 2011; 
Wahabi et al., 2014). Our results do not confirm this but they do report that the mean birth weight is 
significantly higher in overweight (3386±663g) versus normal weight (i.e., BMI < 25 kg/m²) (3251±528g) 
women with PCOS. Although, these results are statistically different, this difference doesn’t seem to 
be of clinical relevance. We also found a significant increased risk to deliver a singleton before 37 weeks 
of gestation in overweight women with PCOS. This finding is new in studies performed in a sample of 
women with PCOS (Mikola et al., 2001; Turhan et al., 2003; Han et al., 2011). In the general female 
population,  the existing evidence is conflicting with studies indicating a positive or no association of 
BMI with the risk of preterm birth (LaCoursiere et al., 2005; Nohr et al., 2007; McDonald et al., 2010; 
Khatibi et al., 2012; Cnattingius et al., 2013). Interestingly, Nohr et al. (2007) report a significant 
increased risk of induced preterm birth in obese women (BMI ≥ 30 kg/m²) when compared with normal 
weight women (18.5 ≤ BMI < 25 kg/m²) but that effect disappeared when the analyses were adjusted 
for obesity-related diseases (such as PE, hypertension, diabetes mellitus). The fact that we didn’t adjust 
for obesity-related diseases can be a possible explanation for the difference with our results.    
Pre-pregnancy overweight is described to be a significant predictor of GDM in the general female 
population (Sarwer et al., 2006). In women with PCOS, the evidence is conflicting. Mikola et al. (2001) 
and Turhan et al. (2003) indicate that pre-pregnancy overweight (BMI > 25 kg/m²) is a significant 
predictor of GDM, while de Wilde et al. (2014) showed that BMI, waist circumference and waist/hip 
ratio are no significant predictors of GDM. Our results are in line with the latter. Nevertheless, we have 
to recognize that we were probably not able to elucidate a difference due to the rather small sample 
size of our study and the subsequent lack of power. Moreover, due to the limited number of available 
data in our retrospective study, we were not able to make the diagnosis of, specifically, GDM since we 
had no information about the diabetic status of each woman before pregnancy and as such we used 
the term ‘diabetes during pregnancy’. 
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Some research groups suggest the adverse influence of an increased maternal age and an active pre-
pregnancy smoking behavior on the prevalence of very preterm birth, preterm labour and low birth 
weight (Lowe et al., 1998; Delbaere et al., 2007). Given this clinical relevance, we adjusted all analyses 
for these variables. Nevertheless, our results only showed that an increased maternal age and an active 
pre-pregnancy smoking behavior were significant predictors for diabetes during pregnancy and a 
shorter gestational age, respectively. Interestingly, the difference in DDP (p = 0.02) in the univariate 
analysis might partially and very carefully being attributed to a higher maternal age in overweight 
women with PCOS, being aware of the fact that this difference in maternal age was not significant.  
All women included in this study had fertility problems. Maman et al. (1998) and Dhont et al. (1999) 
described a increased risk of preterm birth, CS and perinatal mortality in singletons after a fertility 
treatment with IVF/ICSI. Moreover, Malchau et al. (2014) found a differential risk of adverse perinatal 
outcomes between singletons born after IUI and IVF. Based on our results, we cannot confirm this 
evidence since the treatment-to-pregnancy was no significant predictor of any of the studied outcome 
parameters. 
PCOS in itself has been proven to be a risk factor for a delivery by Caesarean section (Altieri et al., 
2010). Our results only showed marginal evidence for a higher prevalence of CS in overweight versus 
normal weight (i.e., BMI < 25 kg/m²) women with PCOS. This is in contrast to the results of studies in 
the general population which proved that obesity is a (significant) risk factor for a delivery by CS 
(Heslehurst et al., 2008; Wahabi et al., 2014). Since, in the general female population, obesity is related 
to macrosomia which is in turn an indication for a delivery by CS, macrosomia might a mediator in the 
association of obesity with CS. Further research about that is warranted. 
In this study, the BMI was used to define pre-pregnancy overweight. However, the waist circumference 
is evaluated as the best indicator of central obesity, which is common in obese women with PCOS 
(Norman et al., 2002; Diamanti-Kandarakis, 2007). An increased waist circumference (i.e., > 88 cm) is 
indicative of an increased metabolic risk and the latter might in turn enhance the occurence of 
complications during pregnancy (e.g., GDM) (Després et al., 2001; International Diabetes Federation, 
2012). As such, using the waist circumference to define pre-pregnancy overweight might be a valuable 
alternative to BMI in studies investigating the influence of overweight on the pregnancy, delivery and 
neonatal outcome in women with PCOS. 
Our study focused on the pregnancy, delivery and neonatal outcome in overweight versus normal 
weight  (i.e., BMI < 25 kg/m²) women with PCOS. Apart from these short-term complications in children 
born from mothers with PCOS, it is also important to be aware of more long-term consequences for 
those children. More specifically, children of mothers with hyperandrogenic PCOS have an increased 
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risk of Pervasive Developmental Disorders, the prevalence of hyperinsulinemia might be increased at 
the end of the pubertal period in girls whose mother has PCOS, and the pre-pubertal serum AMH 
concentrations might be increased in daughters of mothers with PCOS (Sir-Petermann et al., 2006; 
Kent et al., 2008; Palomba et al., 2012). However, the influence of overweight in mothers with PCOS 
on these long-term consequences is not clear and warrants further research. 
 
6.2.2 Perspectives for future research 
These results provide interesting new information but they also induce some ideas for future 
research. 
Firstly, it is advised to perform a larger confirmatory study since in our study some associations were 
possibly not detected due to a lack of power. 
Secondly, it might be worthwhile to focus on one outcome parameter in a time and to take into account 
the influence of all variables related to that specific parameter. That way, one can develop predictive 
models for each specific outcome parameter in women with PCOS. 
Thirdly, given the existing evidence about an adverse impact of overweight and obesity on 
complications in multiple pregnancies in the general population (Salihu et al., 2010; Simões et al., 2011; 
Dickey et al., 2012; Dickey et al., 2013), the target group should be extended with PCOS women having 
a multiple pregnancy. 
Fourthly, it might be interesting to study the association of the pre-pregnancy waist circumference 
with the pregnancy, delivery and neonatal outcome. Moreover, the differential association of pre-
pregnancy BMI and pre-pregnancy waist circumference with the pregnancy, delivery and neonatal 
outcome in women with PCOS could be evaluated.  
Fifthly, based on the existing evidence that excessive GWG is associated with an adverse pregnancy, 
delivery and neonatal outcome in the general female obese population (Cedergren, 2006; Nohr et al., 
2008; Bogaerts et al., 2012; Gavard and Artal, 2014), the question arises about a possible differential 
and/or cumulative influence of pre-pregnancy BMI and GWG in predicting the pregnancy, delivery and 
neonatal outcome in women with PCOS. 
Finally, in future research a prospective design might be considered in order to enable the inclusion of 
extra relevant outcome parameters (such as GDM) which were reported in studies in the general 
female population, but were unattended in our retrospective study due to lack of available data.  
GENERAL DISCUSSION and PERSPECTIVES FOR FUTURE RESEARCH 
  145 
6.3 Quality of life and body mass index in overweight adult women with 
polycystic ovary syndrome during a lifestyle modification program. 
 
6.3.1 Discussion 
The PCOS symptomatology has an important impact on women’s HRQoL (Ching et al., 2007; Jones et 
al., 2008). Based on studies which used the PCOSQ, weight is described to be the domain of highest 
concern in women with PCOS (Guyatt et al., 2004; Jones et al., 2004; McCook et al., 2005; Coffey et al., 
2006; Ching et al., 2007). Though that all women in our study had a BMI ≥ 25 kg/m² at the start of the 
LMP, our results support this finding. But, the baseline objective measurement of overweight (i.e., BMI) 
was not significantly correlated with any of the PCOSQ domains. In our study, the domain of lowest 
concern was the body hair domain. To date, there is conflicting evidence about the domain of lowest 
concern in earlier performed studies. Some studies confirm our finding (Jones et al., 2004; McCook et 
al., 2005), while other studies mention the emotion, menstrual problems and infertility problems 
domain as the domain of lowest concern (Guyatt et al., 2004; Coffey et al., 2006; Ching et al., 2007). 
The difference in these findings might possibly and at least partially be attributable to differences in 
demographic and clinical characteristics of the included study participants. Our results also show that 
a high level of infertility-related concern is significantly related to a low parity and the presence of a 
current unfulfilled wish-to-conceive. This is in line with the finding by McCook et al. (2005) which 
mentions that the delivery of at least one viable child is predictive for a lower level of infertility-related 
concern. 
In addition to the five PCOSQ domains, our results indicate that the presence of facial acne has an 
important negative influence on the HRQoL of adult women with PCOS as measured by a Visual 
Analogue Scale. This is an important finding, especially since facial acne was present in ~50% of our 
study sample. The rather high prevalence of acne in a sample of adult women with PCOS in 
combination with its significant negative influence on their HRQoL supports the added value of 
incorporating a full-fledged acne domain into the PCOSQ. Jones et al. (2004) made the same suggestion 
based on an evaluation of the face validity of the PCOSQ by semi-structured interviews in 12 adult 
women with PCOS. More specifically, this evaluation determined that the absence of an acne domain 
is a serious shortcoming of the PCOSQ so that the questionnaire addresses all relevant issues 
concerning the impact of this syndrome on a patient’s quality of life. During the item selection phase 
of the development of the questionnaire by Cronin et al. (1998) acne was not selected as an essential 
item. A lack of data saturation during that phase might be a possible explanation therefor. Neither the 
Cronin et al. (1998) study nor the Jones et al. (2004) study described the exact symptom profile of the 
women with PCOS who were interviewed in the context of evaluating the face validity. Hence, this 
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creates the presumption that the symptom profile of these women has influenced the non-selection 
of acne as an essential item for the PCOSQ. 
The measurement of the HRQoL provides extra information from a patient’s own perspective about 
the impact of a disease but also about the effectiveness of a treatment which might be of importance 
in the clinical-decision making process of both patients and health professionals (Cronin et al., 1998; 
Jones et al., 2002). The significant improvement of HRQoL that we observed over the total length of 
our LMP is in line with earlier findings (Harris-Glocker et al., 2010; Thomson et al., 2010). We observed 
that this improvement was primarily situated during the first part of the LMP which also corresponds 
to the study by Thomson et al. (2010). To date, there is no existing evidence describing the ideal length 
of LMP, which might probably be very individual and depending on the desired HRQoL level one wants 
to reach. Nonetheless, it doesn’t  seem justified to shorten the duration of LMP to a time period of 10 
to 12 weeks since in most treatment groups of the Thomson et al. (2010) study as well as in our study, 
there is still an increase of HRQoL after that time period, although not significant in our study. 
Moreover, the level of HRQoL is possibly even not at its highest level after 24 weeks of LMP. Also in 
terms of weight loss, which was moderate over the total length of our LMP, a period of 24 weeks could 
still be too short to achieve a long-term weight reduction and maintenance since a study by Lally et al. 
(2010) has proven that it can take up to 254 days to form a new habit. 
The length of a lifestyle modification program also has an influence on the adherence to the program. 
In general, a high drop-out rate is common in long-term health promotion trials (Toft et al., 2007; 
Groeneveld et al., 2009). While this phenomenon is also described in lifestyle modification trials in 
women with PCOS, the total drop-out rate in our study (i.e., 25.8%) was less when compared with, for 
example, the study by Thomson et al. (2010) (i.e., 55.3%). Attrition studies found that the risk of 
attrition is especially large during the beginning of longitudinal studies (Iannaccone et al., 2013). This 
is in line with the results of our study, in which 75% of the participants dropped out during the first 12 
weeks of LMP. Several factors are mentioned to be associated with drop-out: health problem-related 
items, dissatisfaction, depression, motivation towards lifestyle change, and length of time between 
points of data collection (Polit and Beck, 2004; Toft et al., 2007; Groeneveld et al., 2009; Iannaccone 
et al., 2013). Considering the latter, the risk of attrition is described to be higher as the length of time 
between points of data collection progresses (Polit and Beck, 2004). This is not the case in our study in 
which the frequency of the interventions (i.e., contact with the professionals) was highest during the 
first part of LMP, while that was the period counting most drop-outs. Unfortunately, we didn’t 
investigate the reason of drop-out due to lack of follow-up. Anyhow, better knowledge about the 
mediating and confounding variables of participation and adherence to LMPs in overweight women 
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with PCOS, is essential to promote participation and to create a better basis for developing a tailored 
and effective lifestyle intervention approach (Toft et al., 2007). 
Besides the ideal length of a lifestyle modification program, there is also no consensus about the ideal 
composition of such a program. The effectiveness of dietary interventions in terms of psychological 
well-being seems to depend on the dietary composition (Galletly et al., 2007). On the other hand, 
exercise is described to have a positive impact on one’s psychological well-being irrespective of the 
type of exercise (Fontaine et al., 1999; Penedo and Dahn, 2005), and Liao et al. (2008) found that a 
self-directed walking program significantly reduced the level of body image distress in overweight and 
obese women with PCOS. In contrast, the Thomson et al. (2010) study found that exercise had no 
additional effect to diet only in terms of HRQoL in women with PCOS. In terms of short-term weight 
reduction, an intervention of diet only and of diet in combination with exercise seem to be equally 
effective. But, in terms of long-term weight reduction, the combination of diet and exercise is 
described to be the most effective option. An intervention focused on exercise only is less effective 
than a combination of diet and exercise in terms of short-term as well as long-term weight loss (Johns 
et al., 2014). Concerning a psychological intervention, Shaw et al. (2005) concluded that CBT should be 
part of a multi-component weight loss program in order to obtain a maximum effect. Therefore we 
added CBT to our LMP. However, since we used a prospective within-patient follow-up design, we were 
not able to draw a conclusion about the additional value of this psychological subprogram in terms of 
HRQoL. 
Lifestyle modification is proven to result in a considerable weight reduction (Tang et al., 2006; 
Thomson et al., 2008) but, in our study, the decrease of the BMI was not significant after 24 weeks of 
LMP. Considering the negative effect of overweight and obesity on PCOS women’s HRQoL (Jones et al., 
2008), one should expect weight loss through lifestyle modification to be correlated with an increase 
in HRQoL. As such, the Thomson et al. (2010) study observed a significant correlation between a 
reduction in body weight and a HRQoL improvement in overweight and obese adult women with PCOS. 
Our results also showed a trend towards such a correlation. Taken together, these data suggest that a 
modest weight loss is sufficient to elicit a substantial increase in HRQoL. However, we must take into 
account that weight loss is possibly not the only factor that influences the change in HRQoL during 
LMP. 
Changes in PCOS characteristics, whether or not as a consequence of weight loss, might have 
confounded or mediated the change in HRQoL. For example, a change in the degree of hirsutism could 
have mediated the correlation between women’s change in body weight and their change in body hair 
related concern. But actually, this can only be assessed adequately after a time period of at least six 
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months since the life span of hair follicles takes that long (Castelo-Branco and Cancelo, 2010). 
Otherwise, one should also expect a confounding influence of pregnancy on a woman’s HRQoL. In our 
study, three women became pregnant during the LMP, but the outcome measures (i.e., BMI and 
HRQoL) between pregnant and non-pregnant women were not significantly different. Also, undergoing 
a fertility treatment might have a negative influence on the change of HRQoL in women with PCOS 
during an LMP (Moll et al., 2012; Heredia et al., 2013). And finally, psychological problems (such as 
depression), which are described to be more prevalent in women with PCOS when compared with 
women without PCOS (Moll et al., 2012), may mediate the association between lifestyle modification 
and HRQoL. Moreover, it is described that a good emotional wellbeing is associated with better 
adherence to the program, which might probably lead to a more successful program in terms of weight 
loss (Galletly et al., 2007).  
 
6.3.2 Perspectives for future research 
Our study provides interesting information about the change in HRQoL and BMI during lifestyle 
modification, but our results also give rise to some suggestions as well as some new research questions. 
Firstly, based on the results of this study as well as on the results of the study about the association of 
PCOS with couples’ satisfaction level, we suggest to incorporate a full-fledged acne domain in the 
PCOSQ and subsequently evaluate the psychometric properties of the modified version of the PCOSQ. 
Secondly, it might be of interest to investigate the added value of a psychological intervention (i.e., 
CBT) in LMP in terms of HRQoL.  
Finally, a larger study over a longer period of time followed by an adequate follow-up can be performed 
in order to investigate the most ideal length of LMP in terms of weight loss and weight maintenance, 
on the one hand, and in terms of HRQoL improvement and HRQoL maintenance, on the other hand. 
Additionally, the influence of confounding and mediating factors (such as the evolution of objective 
PCOS characteristics, pregnancy, fertility treatment and psychological morbidities) should be taken 
into account. 
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6.4 Gonadotropin therapy versus laparoscopic ovarian drilling in 
clomiphene citrate resistant polycystic ovary syndrome patients: a 
retrospective cost-effectiveness analysis. 
 
6.4.1 Discussion 
Laparoscopic ovarian drilling and gonadotropin therapy are both effective treatments in case of CC 
resistance in women with PCOS (Farquhar et al., 2012). In general, gonadotropin therapy is associated 
with an increased risk of OHSS and multiple pregnancies (Thessaloniki ESHRE/ASRM-Sponsored PCOS 
Consensus Workshop Group, 2008). The multiple pregnancy rate is described to be significantly lower 
after LOD when compared with gonadotropin therapy (Farquhar et al., 2012). In line with this, our 
results report a lower twin pregnancy rate after LOD when compared with hMG treatment, although 
the difference was not significant. The effectiveness of both treatments also depends on the patency 
of both tubes. Therefore a diagnostic laparoscopy is advised when timing therapy and controlled 
ovarian hyperstimulation fails (Tsuji et al., 2009). In our study, we could not assure that a diagnostic 
laparoscopy and/or a hysterosalpingography was performed.  
Our CEA, based on real life data, resulted in different conclusions about the cost-effectiveness of LOD 
versus gonadotropin therapy when, on the one hand, the cost until an ongoing pregnancy and, on the 
other hand, the cost until live birth was considered. The primary outcome parameter of our CEA was 
the cost until an ongoing pregnancy since we only had retrospectively collected real life data until 12 
weeks of gestation. To calculate that cost we applied a societal perspective, including costs covered by 
the public payer, costs covered by the patient, as well as costs related to productivity loss. Because we 
had detailed information about the costs covered by the public payer and the patient, we were able 
to report additionally the cost-effectiveness from the public payer and the patient perspective and to 
draw the following conclusions about this outcome parameter.. Our data suggest that LOD is more 
cost-effective from the public payer and patient’s perspective. On the other hand, our results show 
that gonadotropin therapy is significantly the most cost-effective option from the societal perspective. 
The latter finding is in contrast to the van Wely et al. (2004) study which used the same outcome 
parameter and found a comparable cost-effectiveness of both treatment strategies. Considering the 
cost until live birth, our results tended to confirm earlier evidence reporting LOD as the most cost-
effective option (Farquhar et al., 2004). This is an important finding since the ultimate goal of a fertility 
treatment is to achieve a live birth and not only to achieve an ongoing pregnancy. Moreover, as the 
cost of a multiple pregnancy might be up to 5 times higher than the cost of a singleton pregnancy 
(Gerris et al., 2004; Lukassen et al., 2004), it is clinically more relevant to investigate the cost until live 
birth which comprises not only the treatment related costs but the costs related to the subsequent 
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pregnancy, labour and delivery as well. Furthermore, a multiple pregnancy is related to an increased 
risk of complications during pregnancy, labour and delivery (e.g., preterm birth) which possibly results 
in lifelong additional costs due to a higher prevalence of disabled children (Gerris et al., 2004). In 
general, raising twins also has a larger societal impact since costs are mostly double at the same 
moment in time.  Apart from the impact of multiple pregnancies, the influence of complications due 
to treatment (e.g., postoperative infection after OD) should be considered. Since our results are based 
on real-life data, costs related to possible complications were taken into account. Nevertheless, we did 
not specifically identify what complications and how many complications occurred. As such, we cannot 
give a picture of the added cost due to treatment-related complications. In general, all consequences 
should be taken into account when the cost-effectiveness of LOD versus gonadotropin therapy is 
considered. 
A study by Nahuis et al. (2011) describes that LOD is associated with a higher spontaneous pregnancy 
rate over a period of 8-12 years when compared with gonadotropin therapy. Consequently, this long 
term advantage of LOD resulted in a lower mean cost per live birth when compared with gonadotropin 
therapy (Nahuis et al., 2012). Although only the public payer’s perspective was considered in that study 
this is an interesting finding. 
In our study, loss of time at work was the main contributor of the increased societal cost of LOD surgery. 
A reduction of that absenteeism related cost by at least 50% had a substantial influence on that cost 
making LOD less expensive than gonadotropin therapy. So our results suggest that one must try to 
reduce this cost after LOD. Therefore, it might be of value to study the cost-effectiveness of THLOD, 
since this technique has been associated with a low productivity loss of maximum 3 days and its 
effectiveness is described to be similar to LOD (Fernandez et al., 2001; Shibahara et al., 2006; Badawy 
et al., 2009; Gordts et al., 2009; Catenacci and Goldberg, 2011). Additionally, although we have no 
information justifying the duration of the recovery phase, it seems an option to sensitize patients not 
to stay at home longer than necessary. Nevertheless, this might be difficult to achieve since LOD was 
already shown to be the most cost-effective option for the patient herself when the absenteeism 
related cost was not reduced with 50%. As such, the patients themselves will financially not feel a 
difference.  
Our CEA is based on real-life data. This is especially interesting because that way the real clinical 
practice and not an idealized practice is reflected (Annemans et al., 2007). For health care providers as 
well as for patients, it is important to base their clinical decisions on evidence about the real clinical 
and financial impact of a treatment in order to better manage uncertainty (Annemans et al., 2007). In 
order to base our CEA on real-life data, we used a retrospective design having the advantage of 
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avoiding protocol-induced costs and effects, as well as avoiding the Hawthorne effect (Annemans, 
2007). This is in contrast to the Farquhar et al. (2004) and van Wely et al. (2004) study, who performed 
prospective CEA’s which were consequently protocol-directed and not a reflection of the daily clinical 
practice. In turn, these factors threaten the generalizability to women treated in a standard practice 
(Calvert et al., 2011). Nevertheless, a pitfall of the retrospective design we used, is selection bias 
through which we have to be aware of the possible influence of confounding factors. Hence, our 
analyses were corrected for clinically relevant variables that had a significant influence on the studied 
costs. In an attempt to bring together the positive aspects of a pro- and retrospective design to perform 
a CEA based on real life data, researchers are looking into the possibility to develop a new trial design, 
the so called “Real-World/EXPERIENCE trial” (Calvert et al., 2011).  
There is evidence that obesity has a negative influence on the effectiveness of OI treatments and that 
class II obesity (BMI ≥ 35kg/m²) is an independent predictor of success of LOD surgery in terms of 
ovulation and pregnancy rate (Gambineri et al., 2002; Amer et al., 2004; Hirschberg, 2009). Our results 
confirmed that an increase of the BMI was significantly associated with an increase of all costs under 
study. Since an ovarian drilling through laparoscopic surgery might be a risky procedure in obese 
women when compared with normal weight women and because this procedure causes not seldom 
complications (e.g., bleeding) and/or failure to entrance in obese women (Gordts et al., 2009), it might 
be a more safe and successful option to perform an ovarian drilling through transvaginal access in 
those women. 
Our CEA used clinical outcome parameters (i.e., ongoing pregnancy rate and number of live-born 
children) to assess the effectiveness of both treatments. Yet, it might be interesting to take into 
account the influence of both treatments on women’s HRQoL. The study of van Wely et al. (2004) 
concluded that LOD as well as gonadotropin therapy don’t really affect the HRQoL of the treated 
women. But, gonadotropin therapy was experienced to be a little more ‘burdensome’ when compared 
with the LOD strategy. In the study by Farquhar et al. (2002) the convenience and acceptability of both 
treatments was evaluated in women who underwent both treatment strategies. Their results show 
that 15/17 women (88.2%) preferred LOD for reasons such as ‘easier and less traumatic’ and ‘easier in 
the sense that you go through one traumatic event only once’ (Farquhar et al., 2002). Aside from these 
positive experiences in favor of LOD, the THLOD technique is ‘scarless’ which probably has a positive 
impact on a patient’s long term quality of life (Gordts et al., 2009). 
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6.4.2 Perspectives for future research 
Our study provides interesting new information about the cost-effectiveness of LOD versus 
gonadotropin therapy based on real-life data. However, there are still some items that have to be 
clarified and our findings also induce some new research questions. 
Firstly, it is advised to perform a long term CEA based on real life data, taking into account long-term 
effects and subsequent costs of both treatment strategies. To create the most complete image, such 
a CEA should be performed from the societal perspective, making a clear distinction between the cost 
for the public payer, the patient and the absenteeism related cost. 
Secondly, one should investigate the cost-effectiveness of a THLOD, especially as a way to reduce the 
absenteeism related cost and as a valuable and more safe alternative for obese women with PCOS. 
Thirdly, given the high prevalence of central obesity and its impact on the reproductive function in 
women with PCOS as well as since the waist circumference is described to be the best indicator of 
central obesity, it seems relevant to study the influence of the waist circumference on the cost-
effectiveness of LOD versus gonadotropin therapy in women with PCOS. 
Finally, it might be of interest to perform a CEA using HRQoL as an alternative parameter for the  
effectiveness of both treatments and thereby considering THLOD as an alternative to LOD.  
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The polycystic ovary syndrome is a complex and chronic disease that affects women at reproductive 
age, as well as their family and the society. This dissertation contributes to a better understanding of 
psychological, perinatal, lifestyle and health-economic aspects of PCOS that really matter for the 
patient, her family and the society. Health professionals (i.a., physicians, midwives and nurses, 
psychologists) should be acknowledgeable about this evidence and take this into account when 
treating and counseling women with PCOS. Furthermore, they have the task to inform women with 
PCOS adequately in order to help them with making joint clinical decisions. 
More specifically, this dissertation suggests that PCOS, as being a stressor in a couple’s life, is 
associated with their level of sexual and relational satisfaction. The satisfaction level of women with 
PCOS was found to be significantly lower than the satisfaction level of their partners. Interestingly, our 
results show an association of objective (i.e., parity, women’s BMI and current unfulfilled wish-to-
conceive) as well as subjective PCOS characteristics (i.e., women’s infertility- and acne-related 
concerns) with the level of sexual and relational satisfaction in one or both partners. This stresses the 
importance to not only focus on the objective features of PCOS but also pay attention to women’s 
subjective perception of the disease. As sexual and relational satisfaction are an integral part of a 
couple’s life, health professionals should keep this evidence in mind when treating and counseling 
couples dealing with PCOS. This is especially important in couples with a wish-to-conceive since 
sexuality is an essential aspect of reproduction. 
In addition to the negative impact of PCOS in itself on the perinatal outcome, this dissertation 
highlights the risk of preterm birth and giving birth to a baby with an increased birth weight in 
overweight women with PCOS having an ongoing singleton pregnancy. Although, we did not study the 
influence of overweight in multiple pregnancies, our results suggest the importance of pre-pregnancy 
weight loss in overweight women with PCOS in order to reduce the risk of adverse delivery and 
neonatal outcomes. 
Furthermore, this dissertation confirms earlier evidence which describes that body weight has the 
worst impact on HRQoL in women with PCOS. Interestingly, the presence of acne was also found to 
have a significant negative impact on women’s HRQoL. Our results showed that a moderate weight 
loss and a significant HRQoL improvement can be achieved through lifestyle modification in overweight 
adult women with PCOS. The latter was primarily situated during the first 12 weeks of a 24-week LMP. 
Although, we only observed a trend towards a correlation between weight loss and HRQoL 
improvement, these results support the encouragement of adult overweight women with PCOS to lose 
weight through lifestyle modification. Health professionals should refer those women to a 
multidisciplinary lifestyle modification team, and support them to maintain a healthy lifestyle.  
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Concerning the treatment of subfertile women with PCOS, this dissertation shows that both LOD and 
gonadotropin therapy are effective treatment strategies in CC resistant women with PCOS. Based on 
real-life data, our results indicate that LOD is the best option in terms of cost per ongoing pregnancy 
for the patient and the public payer. Moreover, our results tend to confirm that LOD is the most cost-
effective option from the societal perspective if the cost per live-born child is considered. The latter is 
especially of interest since the additional cost for a multiple pregnancy is taken into account. Based on 
these results, women should be counseled towards LOD. Yet, given the high cost of absenteeism after 
LOD, one should consider other techniques (e.g., transvaginal hydrolaparoscopic ovarian drilling) to 
perform an ovarian drilling in order to shorten the duration of loss of time at work. 
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The polycystic ovary syndrome (PCOS) is a chronic disease which is present in up to 10% of women at 
reproductive age. The syndrome is characterized by an irregular menstrual cyle, polycystic aspect of 
one or both ovaries, clinical and/or biochemical signs of hyperandrogenism, overweight and 
subfertility. Through these characteristics, PCOS has an important negative impact on the physical and 
psychological well-being of these women. Also her family (partner, children) and the society are 
affected by this disease. 
This dissertation has the aim to do research about psychological, perinatal, lifestyle and health-
economic aspects of PCOS that really matter for the patient, her family and the society. 
PCOS has a significant impact on women’s health-related quality of life (HRQoL). Problems to maintain 
weight and problems to lose weight, in case of overweight, are the highest concern of those women. 
This is also confirmed by the results of our study. Additionally, the presence of acne in adult women 
with PCOS seems to have an important negative impact on their HRQoL. Since HRQoL is an important 
subjective marker of patient’s well-being, it is important to be mindful of this evidence when treating 
and counseling women with PCOS. 
Characteristics of PCOS also have a negative impact on several aspects of women’s sexual life. As such, 
women with PCOS feel less attractive and have a lower level of sexual satisfaction when compared 
with women without PCOS. However, research about that topic is very limited and results are often 
conflicting. Our research focused on the association of PCOS characteristics with the level of sexual 
and relation satisfaction in couples dealing with this disease. The results show that the level of sexual 
and relational satisfaction is significantly lower in women with PCOS when compared with their 
partners’. Objective (i.e., parity, women’s BMI and a current unfulfilled wish-to-conceive) as well as 
subjective characteristics (i.e., women’s infertility- and acne-related concerns) are associated with the 
level of sexual and relational satisfaction in one or both partners. Although, partners live in continuous 
interaction with each other, the observed associations are clearly different between PCOS women 
themselves and their partners. Since sexual and relational satisfaction are an integral part of a couple’s 
life and since sexuality is an essential aspect of reproduction in particular, these findings stress that 
health professionals should pay attention to this evidence when treating and counseling those couples.  
About 30 to 70% of women with PCOS have to deal with overweight and obesity, which has a significant 
negative influence on the presence and severity of the PCOS symptomatology. The results of our study 
show that pre-pregnancy overweight in women with PCOS increases the risk of preterm birth and to 
give birth to a baby with a high birthweight. Although these findings are only applicable to singleton 
pregnancies, they suggest the importance of pre-pregnancy weight loss in overweight women with 
PCOS in order to reduce the risk of adverse delivery and neonatal outcomes. 
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Lifestyle modification is an effective strategy to lose weight. Moreover, weight loss through lifestyle 
modification has a positive effect on metabolic and hormonal parameters of women with PCOS. At 
present, there is an increased interest for the effectiveness of a treatment in terms of HRQoL. In our 
research, we observed a significant improvement of the HRQoL during an individualized 24-week 
lifestyle modification program (LMP), consisting of diet, exercise and cognitive behavioral therapy. 
Although, HRQoL improvement was significant over the total length of the LMP, this increase was 
primarily situated during the first part of the program. Based on these results, overweight women with 
PCOS should be encouraged to participate in a lifestyle modification program, and to maintain a 
healthy lifestyle.  
Subfertility is a consequence of PCOS present in 55 to 90% of those women. The first line 
pharmacological therapy in women with PCOS is the administration of clomiphene citrate (CC), but 15 
to 20% of those women are resistant for this drug. Then, a treatment with gonadotropins and a surgical 
ovarian drilling are effective alternatives, as confirmed by the results of our study. Based on real-life 
data, we showed that laparoscopic ovarian drilling (LOD) is the most cost-effective option for the 
patient and the health insurer in terms of cost per ongoing pregnancy. If the pre-, per- and postnatal 
period until 3 months postpartum are included, our results suggest that LOD is the most cost-effective 
options for the society. Since the latter includes the additional cost for a multiple pregnancy, women 
should be counseled towards LOD. However, since LOD is associated with a high absenteeism related 
cost, one shoul try to reduce this specific cost. 
This dissertation confirms that PCOS has an important impact on the life of the patient and her family. 
Additionally, the syndrome has financial consequences for the whole society. Therefore, health 
professionals should take these results into account when treating and counseling women with PCOS. 
Further, women with PCOS should be informed adequately so they can pariticpate in making joint 
clinical decisions. 
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Het polycystisch ovarium syndroom, kortweg PCOS, is een chronische aandoening die tot 10% van de 
vrouwen van reproductieve leeftijd treft. Het syndroom wordt gekenmerkt door een onregelmatige 
menstruele cyclus, een polycystisch beeld van één of beide ovaria, klinische en/of biochemische 
tekenen van hyperandrogenisme, overgewicht en subfertiliteit. Via deze kenmerken heeft het 
syndroom een belangrijke negatieve impact of het fysieke en psychologische welzijn van deze vrouwen. 
Ook hun familie (partner, kinderen) en de maatschappij worden door deze aandoening getroffen. 
Dit proefschrift heeft tot doel om onderzoek te doen naar psychologische, perinatale, lifestyle en 
gezondheids-economische aspecten van PCOS die belangrijk zijn voor de patiënt, haar familie en de 
maatschappij.  
PCOS heeft een belangrijke impact op de gezondheidsgerelateerde kwaliteit van leven (in het Engels: 
health-related quality of life [HRQoL]) van de getroffen vrouwen. Problemen met behoud van gewicht 
en gewichtsverlies, in geval van overgewicht, blijken hun grootste bezorgdheid. Dit wordt ook 
bevestigd door de resultaten van ons onderzoek. Daarenboven blijkt de aanwezigheid van acne bij 
volwassen vrouwen met PCOS een belangrijke negatieve impact te hebben op hun HRQoL. Aangezien 
HRQoL een belangrijke subjectieve parameter is voor het welzijn van de patiënt is het belangrijk om 
deze resultaten indachtig te zijn bij de behandeling en begeleiding van vrouwen met PCOS.  
Kenmerken van PCOS hebben ook een negatieve impact op verschillende aspecten van het seksuele 
leven van de vrouw. Zo voelen vrouwen met PCOS zich minder aantrekkelijk en ervaren zij een lagere 
seksuele tevredenheid in vergelijking met vrouwen zonder deze aandoening. Onderzoek hierover is 
echter nog zeer beperkt en resultaten zijn vaak ook tegenstrijdig. Ons onderzoek heeft zich toegespitst 
op het verband tussen enerzijds PCOS en anderzijds de graad van seksuele en relationele tevredenheid 
bij koppels die leven met deze aandoening. De resultaten tonen aan dat de graad van seksuele en 
relationele tevredenheid lager is bij vrouwen met PCOS in vergelijking met die van hun partners. Zowel 
de objectieve beoordeling van PCOS kenmerken (nl. pariteit, BMI van de vrouw en een actuele 
onvervulde kinderwens) als de subjectieve beoordeling van PCOS kenmerken (nl. de infertiliteit- en 
acne-gerelateerde bezorgdheid van de vrouw) wordt geassocieerd met de seksuele en relationele 
tevredenheid van één of beide partners. Hoewel geliefden in continue interactie leven met elkaar is 
de verscheidenheid van deze verbanden tussen de patiënten zelf en hun partners opvallend. Mede 
omdat de seksuele en relationele satisfactie integraal deel uitmaken van het leven van een koppel, 
benadrukken deze bevindingen dat hieraan voldoende aandacht moet worden besteed bij de 
begeleiding van deze koppels. En aangezien seksualiteit een essentieel aspect is van reproductie, blijkt 
dit vooral belangrijk in geval van een onvervulde kinderwens. 
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Ongeveer 30-70% van de vrouwen met PCOS heeft te kampen met overgewicht. Dit heeft een negatief 
effect op het voorkomen en de ernst van symptomen van deze aandoening. Uit de resultaten van ons 
onderzoek blijkt dat pre-conceptioneel overgewicht bij vrouwen met PCOS het risico op een preterme 
partus en de geboorte van een baby met een hoog geboortegewicht bevordert. Hoewel deze 
resultaten enkel van toepassing zijn op eenlingzwangerschappen, zijn dit belangrijke bevindingen op 
basis waarvan zwaarlijvige vrouwen met PCOS moeten worden geadviseerd om pre-conceptioneel 
gewicht te verliezen. 
Het aanpassen van de levensstijl blijkt een effectieve manier om gewicht te verliezen. Daarenboven 
blijkt gewichtsverlies door middel van een ‘lifestyle’ modificatie programma een positief effect te 
hebben op metabole en hormonale parameters van vrouwen met PCOS. Meer en meer wordt echter 
ook belang gehecht aan de effectiviteit van een behandeling in termen van HRQoL. Zo wordt in ons 
onderzoek een significante stijging van de HRQoL waargenomen tijdens een 24 weken durend ‘lifestyle’ 
modificatie programma, bestaande uit dieetadvies, een oefenprogramma en cognitieve 
gedragstherapie. Hoewel de stijging van de HRQoL significant was over de volledige duurtijd van het 
programma, was deze stijging het sterkst tijdens het eerste deel. Op basis van deze resultaten zouden 
zwaarlijvige vrouwen met PCOS moeten worden aangemoedigd om deel te nemen aan een ‘lifestyle’ 
modificatie programma, alsook om een gezonde levensstijl aan te houden.  
Subfertiliteit is een gevolg van PCOS dat voorkomt bij 55-90% van deze vrouwen. De medicamenteuze 
eerstelijns behandeling bij deze vrouwen is de toediening van clomifeen citraat (CC). Resistentie voor 
CC treedt echter op in 15-20% van de gevallen. Dan zijn twee andere behandelingen mogelijk: (a) een 
medicamenteuze behandeling met gonadotrofines, en (b) een chirurgische ovariële drilling. Beide 
behandelingen zijn effectieve alternatieven voor CC resistente patiënten, zo blijkt ook uit de resultaten 
van dit onderzoek. Op basis van ‘real-life’ data, hebben wij aangetoond dat een laparoscopische 
ovariële drilling (LOD) de meest kosteneffectieve optie is voor de patiënt en de zorgverzekeraar in 
termen van kost per doorgaande zwangerschap. Wanneer de kost van de zwangerschap, bevalling en 
postnatale periode mee in rekening wordt genomen, suggereren de resultaten van ons onderzoek dat 
LOD ook de meest kosteneffectieve optie is voor de maatschappij. Aangezien bij deze laatste 
berekening de extra kost voor een meerlingenzwangerschap in rekening wordt gebracht, zouden 
vrouwen moeten worden geadviseerd om te kiezen voor LOD. Anderzijds is deze chirurgische ingreep 
wel geassocieerd met een hoge kost voor ziekteverzuim dewelke men zou moeten proberen te 
drukken. 
Dit proefschrift bevestigt dat PCOS een belangrijke impact heeft op het leven van de patiënt en haar 
familie. Daarenboven heeft dit syndroom ook financiële gevolgen voor de volledige maatschappij. 
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Daarom moeten gezondheidswerkers de resultaten van dit onderzoek indachtig zijn bij de behandeling 
en begeleiding van vrouwen met PCOS. Patiënten moeten daarenboven ook adequaat worden 
geïnformeerd zodat zij kunnen participeren bij het maken van klinische beslissingen.
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Aan het einde van deze langdurende, maar niettemin leerrijke en noeste arbeid ben ik opgelucht en 
blij dat de bevalling van deze prachtige baby voorspoedig is verlopen. De steun van velen was hierbij 
onmisbaar. Daarom graag een woord van dank. 
Danken doet deugd ! Dankjewel … 
Petra, ik wil jou bedanken voor de kans die ik van jou kreeg om met dit project te starten. Bedankt 
voor de aangename en energieke samenwerking tijdens de voorbije jaren, jouw deskundige 
begeleiding, luisterend oor en begrip op persoonlijk moeilijke momenten, jouw geruststellende 
woorden als ik me weer eens druk maakte over een futiliteit. Jouw enthousiasme en geloof in dit 
project zijn voor mij mede een stimulans geweest om dit tot een goed einde te brengen.  
Lieven, ik wil jou bedanken voor jouw constructieve en deskundige begeleiding tijdens dit project. 
Bedankt om mij geduldig maar kritisch een stukje van de gezondheidseconomische wereld te laten 
ontdekken en mede de meerwaarde van een “retrospectieve” kosteneffectiviteitsanalyse te 
verdedigen. Het was voor mij een boeiende reis. 
Ik wil de leden van mijn begeleidingscommissie bedanken voor hun oprechte interesse in mijn werk. 
Jullie hebben mij elk vanuit jullie expertise geholpen om de “heterogene” inhoud van mijn proefschrift 
vorm te geven en ten gronde uit te werken. 
De leden van de examencommissie wil ik bedanken voor hun kritische vragen en constructieve 
feedback. Dit zette me nog eens extra aan tot nadenken over inhoudelijke en methodologische 
aspecten van mijn werk. 
Lesley, aan jou een speciaal woordje van dank. Jouw kennis en kunde, jouw kritische ingesteldheid en 
punctualiteit hebben me geholpen om enkele psychologische aspecten van PCOS te doorgronden, 
alsook om vaardiger te worden in het schrijven van een manuscript. Je hielp me om PCOS als “stressor” 
in het leven van veel vrouwen te lijf te gaan. Het was een plezier om met jou te mogen samenwerken. 
Ik heb veel van jou geleerd.  
Wat is een doctoraatsstudent zonder een portie statistische ondersteuning. Ellen, jij was in den 
beginne mijn statistische hulp en toeverlaat. Jouw bijkomende uitleg en jouw bevestigingen, gaven me 
het vertrouwen dat ik het toch allemaal wel wat snapte. Stijn, naast de pogingen die ik zelf ondernam 
om doorheen de meervoudige statistische analyses te worstelen, wil ik jou danken voor jouw 
deskundige uitleg en advies. Onze overlegmomenten waren voor mij steeds zeer waardevol. Jan en 
Tom, de statistici van de psychologie; dank voor het uitvoeren van de statistische analyses op een 
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beperkt aantal gegevens. Verwonderlijk welke mooie en (op heden) toch wel unieke resultaten hieruit 
zijn voortgekomen. Jullie hebben mij elk vanuit jullie expertise nieuwe statistische inzichten verschaft. 
Het team van het lifestyle programma, Isabelle, Veerle, Isabelle en Patrick; bedankt voor jullie oprechte 
interesse in dit project, de aangename en vriendschappelijke samenwerking en bovenal de grote 
flexibiliteit die jullie aan de dag hebben gelegd tijdens de uitvoering van het lifestyle programma. 
Collega’s van de Arteveldehogeschool en  het UZ Gent, dank voor de interesse in het verloop van mijn 
doctoraatsproject en het “succes” dat jullie me terloops toewensten. Dit gaf mij telkens een duwtje in 
de rug om de moed niet te laten zakken en verder te gaan. 
Dankbaarheid is het geheugen van het hart! Dankjewel … 
 
Graag ook een woord van dank en een grote ruiker bloemen voor mijn familie en vrienden: 
Ik vermoed dat jullie de PCOS-taal nog steeds niet machtig zijn maar toch toonden jullie oprechte 
interesse in mijn werk. Lieve familie en schoonfamilie, dank voor de emotionele en praktische steun 
die jullie ons in grote getale hebben geboden. Voor opvang van de kindjes konden wij ook altijd op 
jullie rekenen als ik me weer eens achter mijn computer verschool en Kristof met huishoudelijke taken 
werd opgezadeld. Lieve vrienden, waarschijnlijk vaak onbewust, maar jullie zorgden op tijd en stond 
voor de nodige afleiding. Onze uitjes en ons af en toe eens goed laten “gletchen” deden mij mezelf 
weer herkennen en beseffen dat er veel meer is dan werken alleen.  
Het sieraad van mijn leven zijn mijn familie en vrienden die er vertoeven! 
 
En last but not least een bijzonder dikke merci en een megadikke knuffel voor diegenen die mij het 
meest dierbaar zijn. De diamanten die mijn sieraad volmaakt maken.  
Maxime, lieve grote jongen; de vele knuffels, jouw guitige lach, maar ook jouw kritische ingesteldheid 
en gevatte uitspraken zoals “nu niet weer werken hé mama”, deden me deugd maar vooral ook 
zorgzaam toezien op een goed evenwicht tussen mijn werk en de zorg voor ons gezin. Anderzijds gaf 
jouw uitspraak “Als je goed werkt mama, dan krijg je van mij een prinsessendiploma” mij extra moed 
om deze eindmeet te bereiken. 
Jasmijn, lieve poppemie; al ben je nog zo klein, je brengt al ontzettend veel vreugde in mijn leven. Jouw 
schaterlachjes, jouw verwonderlijke blikken, jouw energieke en enthousiaste zelve doen me zoveel 
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deugd en komen mijn relativeringsvermogen alleen maar ten goede. Als ik zie hoeveel jij op één jaar 
tijd al hebt geleerd dan hink ik fel achterop. Enorm hoe snel en spontaan jij iets leert. Het zou fijn zijn 
om te weten hoe een kind als jij dit doet. We zouden er ongetwijfeld nog veel kunnen van leren. 
Kristof, lieve schat; bedankt voor het geduld dat je gedurende de voorbije jaren aan de dag hebt gelegd, 
jouw onvoorwaardelijke steun, oppeppende zinnetjes, er immer in blijven geloven. Zonder jouw steun 
was ik er nooit in geslaagd om dit project tot een goed einde te brengen. De quote “We did it” is hier 
dan ook meer dan op zijn plaats. Ontzettend bedankt daarvoor. Mijn dankbaarheid voor dit alles valt 
moeilijk in woorden uit te drukken. 
Dankuwel mijn lieve schatten! Ik hou van jullie! 
Jullie zijn de reden waarom mijn hart zo gelukkig is! 
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